

# THE INTERNATIONAL LIVER CONGRESS<sup>™</sup>

Savour science  
together again

22-26  
JUNE  
2022  
LONDON



# List of accepted abstracts

## Contents

Acute liver failure and drug induced liver injury.....	2
Alcoholic liver disease.....	4
Cirrhosis and its complications : Portal Hypertension .....	10
Cirrhosis and its complications: ACLF and Critical illness .....	16
Cirrhosis and its complications: Other clinical complications except ACLF and critical illness.....	20
Cirrhosis and its complications: Experimental and pathophysiology .....	26
Fibrosis .....	29
Gut microbiota and liver disease .....	36
Immune-mediated and cholestatic disease: Clinical aspects .....	37
Immune-mediated and cholestatic: Experimental and pathophysiology.....	44
Immunology .....	45
Liver development, physiology and regeneration .....	49
Liver transplantation and hepatobiliary surgery: Clinical aspects .....	51
Liver transplantation and hepatobiliary surgery: Experimental .....	58
Liver tumours: Clinical aspects except therapy .....	59
Liver tumours: Experimental and pathophysiology .....	64
Liver tumours: Therapy.....	69
Molecular and cellular biology.....	73
NAFLD: Clinical aspects except therapy .....	78
NAFLD: Diagnostics and non-invasive assessment .....	83
NAFLD: Experimental and pathophysiology .....	91
NAFLD: Therapy .....	99
Non-invasive assessment of liver disease except NAFLD .....	105
Public Health .....	108
Rare liver diseases (including paediatric and genetic).....	116
Viral Hepatitis A, B, C, D, E: Virology.....	122
Viral hepatitis A/E: Clinical aspects.....	127
Viral hepatitis B/D: Clinical aspects except therapy .....	127
Viral hepatitis B/D: therapy .....	134
Viral hepatitis C: Clinical aspects except therapy .....	145
Viral Hepatitis C: Post SVR and long term follow up.....	149

## Acute liver failure and drug induced liver injury

64

Obeticholic acid exacerbates the liver fibrosis of bile duct ligation model by inducing the liver expression of osteopontin

Poster Presentation

Presenter: Jie Wang

286

Prescription event monitoring of checkpoint inhibitor-induced liver injury and outcomes of rechallenge: a 10-year experience

Oral Presentation

Presenter: Edmond Atallah

350

The prognostic role of lysophosphatidylcholines and their immunomodulatory potential in acute liver failure

Oral Presentation

Presenter: FRANCESCA MARIA TROVATO

356

A report on the Australian Drug Induced Liver Injury Network: AusDILIN

Poster Presentation

Presenter: Beverly Nicoll

575

Incidence, phenotype and prognostic relevance of COVID-19-related liver injury across different age strata

Poster Presentation

Presenter: Lukas Hartl

577

Two different types of COVID-19 vaccines and serial liver biochemistries

Poster Presentation

Presenter: Grace Lai-Hung Wong

685

Role of liver biopsy in management of immune checkpoint inhibitors hepatitis: a single-center retrospective study

Poster Presentation

Presenter: Lucia Parlati

1035

Immune checkpoint inhibitors induced liver injury: an observational study



Poster Presentation

Presenter: Lucy Meunier

1052

Liver toxicities of immune checkpoints inhibitors for cancer: a multicenter retrospective study

Poster Presentation

Presenter: Lucia Parlati

1096

Acute severe presentation of autoimmune hepatitis: a 20-year retrospective review of the United States

Poster Presentation

Presenter: Thomas Enke

1309

Single-cell metabolic profiling of primary human hepatocytes shows heterogenous responses to drug metabolism

Poster Presentation

Presenter: Eva Sofía Boillet

1590

Management of severe, steroid-resistant and steroid-refractory hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy

Poster Presentation

Presenter: Morven Cunningham

1706

Activation marker CD69 differentiates non-alcoholic steatohepatitis from drug-induced liver injury

Poster Presentation

Presenter: Alberto Garcia Garcia

1728

Natural antibodies are required for necrotic cell debris clearance and liver repair during necrotic liver injury

Poster Presentation

Presenter: Matheus Mattos

1771

Human paracetamol hepatotoxicity is mitigated by the gut-liver axis in vitro

Poster Presentation

Presenter: Katie Morgan

2011

A new score to predict mortality at baseline in patients not fulfilling KCH criteria for non acetaminophen induced liver failure-The "SAFE" score(Severity of ALF in emergency)

Poster Presentation

Presenter: Harshvardhan Tevethia



2337

Ten-year single center experience in hepatotoxicity due to mushroom poisoning

Poster Presentation

Presenter: Ozan Sarikaya

2347

CCl4-induced acute liver injury in C57/BL mice model showed elevated expressions of Na<sup>+</sup> taurocholate cotransporting polypeptide on intestinal stellate cells

Poster Presentation

Presenter: Johnny Amer

2379

The association between chronic Colchicine use and incident decompensated cirrhosis

Poster Presentation

Presenter: Michal Carmiel

2455

Inhibition of C-C motif chemokine receptor 2 (CCR2) using a novel in silico designed peptide attenuates macrophage migration in vitro and intrahepatic monocyte recruitment in vivo

Poster Presentation

Presenter: Eline Geervliet

2548

Murine intrahepatic regulatory t cells modulate acute liver inflammation by promoting a protective and restorative microenvironment

Poster Presentation

Presenter: Ada Kurt

2596

Place of steroids and prognosis factors for grade =3 immune-checkpoint inhibitors induced hepatitis: a 6-year prospective study

Poster Presentation

Presenter: Eleonora De Martin

## Alcoholic liver disease

14

Heavy alcohol intake along with ALDH2 polymorphism increases the risk of hepatocellular carcinoma and mortality in hepatitis B virus-related cirrhosis

Poster Presentation

Presenter: Chih-Wen Lin

31

IL-1beta Signal Inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH)

Oral Presentation



Presenter: Nikhil Vergis

127

Biomarkers for prediction of alcohol-related liver cirrhosis in the Swedish general population

Poster Presentation

Presenter: gustav jakobsson

152

A history of bariatric surgery is independently associated with a younger age at onset of severe alcoholic hepatitis

Poster Presentation

Presenter: Lukas Van Melkebeke

166

Cyclophilin inhibitor CRV431 as a potential therapy for alcohol-related liver disease

Poster Presentation

Presenter: Elena Palma

244

Anti-fibrotic effect of rifaximin in early alcohol-related liver disease: a double-blind, randomised, placebo-controlled trial

Oral Presentation

Presenter: Mads Israelsen

259

Survival and liver recompensation after declined for early liver transplantation for severe alcohol-associated hepatitis

Oral Presentation

Presenter: Christine Hsu

289

UK national service evaluation of transplant assessments for patients with alcohol related liver disease

Poster Presentation

Presenter: Christopher Oldroyd

316

Fibroblast growth factor 21 is the main alcohol responsive peptide hormone in humans and individuals with alcohol use disorder exhibit increased plasma concentrations after alcohol intake

Poster Presentation

Presenter: Amalie Lanng

341

Tight junction damage and increased gut permeability in alcohol-related liver disease may be mediated by gut proteases

Poster Presentation

Presenter: Charlotte Skinner



405

Incident acute kidney injury in severe alcohol-related hepatitis is strongly associated with mortality and can be predicted using micro-RNAs and markers of systemic inflammation

Poster Presentation

Presenter: Luke D. Tyson

446

The impact of addiction team integration into the management of patients transplanted for alcohol-related liver disease: results from a multicenter comparative study

Poster Presentation

Presenter: Jules Daniel

502

Probiotic LGG-derived exosome-like nanoparticles inhibit ALD through intestinal FXR activation in mice: role of miR194 and bile acids

Type to be confirmed

Presenter: Wenke Feng

619

Risk of fractures and subsequent mortality in alcohol-related cirrhosis: a nationwide population-based cohort study

Poster Presentation

Presenter: Axel Wester

627

Use of statins among patients with cirrhosis due to alcohol-related liver disease - a danish nationwide cohort study

Poster Presentation

Presenter: Anna Marine Sølling Ramsing

707

Antibody response to gut microbiome bacteria in human alcoholic liver disease

Poster Presentation

Presenter: Antonella Putignano

798

Does screening for liver fibrosis change alcohol consumption, diet, and exercise? A prospective cohort study on the consequences of screening in 2,764 individuals

Oral Presentation

Presenter: Maria Kjærgaard

819

Socio-economic factors and healthcare setting are independently associated with medium and long-term outcomes from alcohol-related hepatitis

Poster Presentation

Presenter: Joshua Lambert

866



Sex-related differences in outcomes in alcohol-related cirrhosis following an episode of hepatic decompensation do not explain subsequent management inequalities

Poster Presentation

Presenter: Aaminah Mohammed

933

Influence of comorbidities and lifestyle factors on health-related quality of life in alcohol-related liver disease: a population-based survey

Poster Presentation

Presenter: Karen Dombestein Elde

1070

Patient and system-level factors underline offering and acceptance of alcohol use disorder therapy in veterans with cirrhosis

Poster Presentation

Presenter: Jasmohan S Bajaj

1071

24-Norursodeoxycholic acid ameliorates experimental alcoholic liver disease in both preventive and therapeutic settings

Poster Presentation

Presenter: Christoph Grander

1092

Impact of sex and recurrence in the prognosis of alcoholic hepatitis

Poster Presentation

Presenter: Jordi Gratacós-Gines

1260

Hepatocyte-derived biomarkers concentrations predict liver-related events within 2 years in patients with Child-Pugh class A alcohol-related cirrhosis

Poster Presentation

Presenter: Laure Elkrief

1264

Baseline plasma metabolic phenotype of patients with severe alcoholic hepatitis and its association with outcome

Oral Presentation

Presenter: Manisha Yadav

1274

Dynamic multiomics analysis characterizes circulating molecular determinants associated with poor outcome in patients with severe alcoholic hepatitis

Poster Presentation

Presenter: Jaswinder Maras

1310





Alcohol-induced changes of inflammatory markers in hepatic and systemic venous blood in early alcohol-related and non-alcoholic fatty liver disease

Poster Presentation

Presenter: Evelina Piper Hanley

1322

New treatment for alcohol-related liver disease: combinations of efficacy and treatment cost required for cost-effectiveness

Poster Presentation

Presenter: Davit Inia

1361

Active alcohol misuse is linked with lower short-chain fatty acid producing microbiota in a matched study of 450 patients with cirrhosis

Poster Presentation

Presenter: Jasmohan S Bajaj

1401

Role of macrophage-derived MLKL in alcohol-associated liver disease

Oral Presentation

Presenter: Xiaoqin Nagy

1470

Infections are common in patients with early alcohol-related liver disease and increases the risk of death

Poster Presentation

Presenter: Stine Johansen

1475

Abstinence is associated with better outcome in patients with hepatocellular carcinoma

Poster Presentation

Presenter: Astrid Marot

1488

In severe alcohol-related hepatitis, hepatocyte ballooning correlates with expression of p16 and components of a secretory phenotype that has been associated with cellular senescence

Poster Presentation

Presenter: Nikhil Vergis

1501

Targeting cyclin M4 as a new therapeutical approach to treat alcoholic liver disease

Poster Presentation

Presenter: Irene González-Recio

1575

Hepatic transcriptional signature of alcohol on genes involved in canonical retinoid metabolism

Poster Presentation

Presenter: Steven Trasino



1585

COVID-19 pandemic impact on alcoholic hepatitis healthcare utilisation

Poster Presentation

Presenter: Leya Nedumannil

1776

The role of integrated alcohol liver care in the management of patients with alcohol related liver disease in an acute hospital setting

Poster Presentation

Presenter: Naina Shah

1794

Untargeted lipidomics unveils a specific plasma signature of severe alcoholic hepatitis

Poster Presentation

Presenter: Florent Artru

1867

Toll-like receptor 2 activation in monocytes of alcohol use disorder patients contributes to systemic inflammation and alcohol-associated liver disease

Poster Presentation

Presenter: Luca Maccioni

1902

Improving NIAAA criteria for the diagnosis of alcoholic hepatitis, role of systemic inflammation

Poster Presentation

Presenter: Emma Avitabile

2071

Alcohol associated hepatitis in Latin America: results from the AH-LATIN study

Poster Presentation

Presenter: Jorge Arnold

2264

Prophylaxis of withdrawal syndrome decreases mortality in patients with alcohol-associated hepatitis

Poster Presentation

Presenter: David Marti-Aguado

2277

The use of pharmacotherapy in the treatment of alcohol use disorder

Poster Presentation

Presenter: Kathryn Allen

2289

Application of machine learning algorithms to classify steatohepatitis on liver biopsy

Poster Presentation

Presenter: Resham Ramkissoon

2498

Calorie-protein deficit and body mass index are the independent predictors of mortality in severe alcoholic hepatitis

Poster Presentation

Presenter: Harshita Tripathi

2618

Alcoholic foamy degeneration: a unique variant of ALD that shows a characteristic pattern of gene expression with upregulation of lipid metabolism and mitochondrial genes and downregulation of fibrosis genes

Poster Presentation

Presenter: Jordi Gratacós-Gines

## Cirrhosis and its complications : Portal Hypertension

174

TIPS insertion leads to partial reversal of systemic inflammation in patients with decompensated liver cirrhosis

Poster Presentation

Presenter: Lena Stockhoff

199

RWE evaluating patients with cirrhosis and features of portal hypertension reveals significant comorbidities

Poster Presentation

Presenter: Peter Greasley

234

Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)

Poster Presentation

Presenter: Alessandra Mangia

314

A simple model for predicting survival in cirrhotic patients undergoing portosystemic shunt embolization

Poster Presentation

Presenter: Won-Mook Choi

438

Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: relation to severity?

Poster Presentation

Presenter: Puria Nabilou

564



Gender affects the association between serum creatinine levels and clinical response to terlipressin in patients with hepatorenal syndrome type of acute kidney injury

Poster Presentation

Presenter: R. Todd Jamil

692

A novel cirrhotic ascites severity score predicts one-year mortality better than the classification into refractory or diuretic-responsive ascites

Poster Presentation

Presenter: Rasmus Hvidbjerg Gantzel

848

A network meta-analysis of numbers needed to treat to prevent an episode of overt hepatic encephalopathy in patients with cirrhosis treated for at least 6 months with lactulose alone, or lactulose plus rifaximin-alpha

Poster Presentation

Presenter: Eric Ngonga Kemadjou

943

Transjugular intrahepatic portosystemic shunt versus balloon-occluded transvenous obliteration for the management of ectopic varices

Poster Presentation

Presenter: Ranya Selim

975

Identification of potential new serum biomarkers for clinically significant portal hypertension by proteomic profiling of circulating extracellular vesicles

Poster Presentation

Presenter: Frane Pastrovic

1020

Factors influencing survival in cirrhotic patients with hepatic hydrothorax

Poster Presentation

Presenter: Sarah Romero

1051

Hepatic venous pressure gradient (HVPG) measured at events is lower in non-alcoholic fatty liver disease (NAFLD) associated cirrhosis as compared to alcoholic cirrhosis

Poster Presentation

Presenter: Lubomir Skladany

1087

Low subcutaneous adipose tissue is associated with mortality independently from portal hypertension in patients with cirrhosis

Poster Presentation

Presenter: Amine Benmassaoud

1088



The association between proton pump inhibitor exposure and key liver-related outcomes in patients with cirrhosis: a veterans affairs cohort study

Oral Presentation

Presenter: Nadim Mahmud

1142

Association of low mechano-energetic efficiency and prognosis in liver cirrhosis

Poster Presentation

Presenter: Sannia Sjöstedt

1161

Long term albumin administration is associated with reduced healthcare resource use in patients with uncomplicated cirrhotic ascites: results from a simulation model

Poster Presentation

Presenter: Elisabet Viayna

1219

Improved survival rates in hepatic encephalopathy after a decade of clinical practice with the addition of rifaximin-alpha to lactulose: a real-world data meta-analysis

Poster Presentation

Presenter: Juha Halonen

1224

Risk prediction of hepatic encephalopathy after molecular targeted therapy for hepatocellular carcinoma in patients with cirrhosis

Poster Presentation

Presenter: Kisako Fujiwara

1279

ABC: a novel algorithm to stratify decompensation risk in patients with cACLD (CHESS2102): an international, multicenter cohort study

Poster Presentation

Presenter: Chuan Liu

1301

Quantitative parameters of esophageal varices based on computed tomography may be used for predicting severe varices in patients with liver cirrhosis

Poster Presentation

Presenter: Shang Wan

1323

A cost-effectiveness evaluation of the GORE® VIATORR® TIPS Endoprosthesis versus large volume paracentesis in the management of portal hypertension complications in the Spanish healthcare system

Poster Presentation

Presenter: Mitesh Napoleone

1458



Factor VIII/protein C ratio does not reflect coagulation but is linked to pathophysiological mechanisms driving disease progression in patients with advanced chronic liver disease

Poster Presentation

Presenter: Lorenz Balcar

1479

Prognostic impact of variants in TM6SF2 and MBOAT7 in patients who have progressed to advanced chronic liver disease

Poster Presentation

Presenter: Lorenz Balcar

1487

Clinical course of cirrhotic patients developing ascites as the single first decompensation

Type to be confirmed

Presenter: Lorenz Balcar

1535

Hepatocellular carcinoma and number of elastic bands per session are strong predictors of bleeding after prophylactic endoscopic variceal bleeding

Poster Presentation

Presenter: Renato Medas

1563

Simultaneous large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: a randomized controlled trial

Oral Presentation

Presenter: Guohong Han

1576

TIPS with versus without variceal embolization for the prevention of variceal rebleeding: a randomized controlled trial

Oral Presentation

Presenter: Guohong Han

1589

Use of second-harmonic generation microscopy for automated detection of septa and nodules in needle liver biopsies of NASH cirrhosis

Poster Presentation

Presenter: Mazen Nouredin

1639

Hepcidin is higher in patients with more severe liver disease independent of portal hypertension

Poster Presentation

Presenter: Robin Greinert

1689

Effect of thrombocytopenia and platelet transfusion on outcomes of acute variceal bleeding: a real world experience



Poster Presentation

Presenter: Sagnik Biswas

1737

Personalized preemptive TIPS treatment for patients with Child-Pugh B cirrhosis and acute variceal bleeding by applying individualized prediction of treatment effect

Poster Presentation

Presenter: Guohong Han

1755

Real-world survival outcomes in patients with decompensated cirrhosis receiving long term human albumin infusions

Poster Presentation

Presenter: Nicholas Hannah

1831

Impact of non-selective beta-blockers on survival and liver-related complications after TIPS-Insertion

Poster Presentation

Presenter: Anja Tiede

1833

Real world validation of BAVENO-7 non-invasive diagnosis for clinically significant portal hypertension in compensated advanced chronic liver disease: international cohort study

Poster Presentation

Presenter: YU JUN WONG

1834

Derivation of machine learning histologic scores correlating with portal pressures and the development of varices in NASH patients with cirrhosis

Poster Presentation

Presenter: Mazen Nouredin

1883

Ruling out varices needing treatment with a non-invasive score in patients with compensated HBV cirrhosis

Poster Presentation

Presenter: Giacomo Emanuele Maria Rizzo

1908

Evaluation of clinically significant portal hypertension with a novel spleen-dedicated probe using transient elastography

Poster Presentation

Presenter: Aitor Odriozola Herrán

1914

Are psychometric tests helpful for the prediction of hepatic encephalopathy after TIPS insertion?

Poster Presentation

Presenter: Alena Friederike Ehrenbauer



1965

Stratified efficacy of first -line therapy to prevent first variceal bleeding according to previous decompensation of cirrhosis. A competing-risk meta-analyses of individual participant data  
Poster Presentation

Presenter: Càndid Villanueva

2121

Baseline plasma renin activity(PRA) predicts risk of AKI in patients with cirrhosis: a prospective observational study

Poster Presentation

Presenter: srinivasa reddy golamari

2153

Carvedilol plus Simvastatin modulates systemic inflammation in cirrhosis with portal hypertension and non-response to B-blockers: randomised double-blind study

Oral Presentation

Presenter: Edilmar Alvarado-Tapias

2160

Performance of spleen stiffness measured by point-shear wave elastography in esophageal varices screening

Poster Presentation

Presenter: Mauro Giuffrè

2212

Non-invasive diagnosis of clinically significant portal hypertension and treatment with non-selective beta-blockers: a new paradigm

Oral Presentation

Presenter: Elton Dajti

2219

Portal pressure decreasing effect of beta blockers in cirrhosis with clinically significant portal hypertension, according to the components of metabolic syndrome

Poster Presentation

Presenter: Anna Brujats

2270

Non-invasive tests for clinically significant portal hypertension after HCV-cure - individual patient data meta-analysis and validation

Oral Presentation

Presenter: Georg Semmler

2286

Transjugular, intra-hepatic portosystemic shunt (TIPS) in elderly patients: preliminary analysis of a multi center retrospective cohort

Poster Presentation

Presenter: Davide Roccarina





2392

Endoscopic glue injection v/s endoscopic human thrombin injection for bleeding gastric varics - a randomized controlled trial

Poster Presentation

Presenter: Ashok Jhaharia

2484

Updating target PPG value to reduce clinical events in patients receiving covered-TIPS for the prevention of variceal rebleeding

Poster Presentation

Presenter: Guohong Han

2619

Impact of alcohol abstinence in patients with alcohol-related cirrhosis and portal hypertension

Poster Presentation

Presenter: Benedikt Hofer

## Cirrhosis and its complications: ACLF and Critical illness

41

COVID-19 in patients with cirrhosis: insights from the multinational LEOSS registry

Poster Presentation

Presenter: Jonathan Frederik Brozat

216

Liver transplantation within 7-days of listing improves survival in ACLF-3

Oral Presentation

Presenter: Joseph Alukal

313

Serum metabolites on admission associate with the development of nosocomial infections in inpatients with cirrhosis

Poster Presentation

Presenter: Jasmohan S Bajaj

321

Association of impaired neutrophil migration with adverse outcomes in patients with liver cirrhosis

Poster Presentation

Presenter: Mona-May Langer

362

Renal and circulatory effects of terlipressin in patients with hepatorenal syndrome assessed by magnetic resonance imaging

Poster Presentation

Presenter: Karen Vagner Nabilou



434

SARS-CoV-2 infection in patients with underlying chronic liver disease is associated with significantly greater risks of inpatient hospitalization, intensive care unit admission, and overall mortality

Poster Presentation

Presenter: Robert Wong

593

Low FT3 levels are associated with acute decompensation and acute-on-chronic liver failure

Poster Presentation

Presenter: Mona-May Langer

640

Post hoc analyses of the ATTIRE trial suggest potential gender differences in response to albumin

Poster Presentation

Presenter: Alastair O'Brien

754

Can machines predict liver decompensation? Analysis of 1,415 patients with liver cirrhosis recruited at three German referral centers

Poster Presentation

Presenter: Sophie Elisabeth Müller

1123

LivR Well: a feasibility study for a home-based, multidisciplinary liver optimization program for the first 28 days after an admission for acute-on-chronic liver failure

Poster Presentation

Presenter: Natalie Ngu

1167

Neutrophil gelatinase-associated lipocalin predicts response to terlipressin and albumin in patients with hepatorenal syndrome

Oral Presentation

Presenter: Carmine Gabriele Gambino

1358

CLEARED Global consortium results highlight regional variation and need for equity in inpatient outcomes in hospitalized patients with Chronic Liver Disease

Oral Presentation

Presenter: Jasmohan S Bajaj

1417

Alcohol-associated hepatitis with acute-on-chronic liver failure in a diverse cohort: lung and circulatory organ failures along with MELD 35 are predictive of mortality

Poster Presentation

Presenter: Stephanie Rutledge

1561



Bilirubin and its dynamics are independently associated with mortality in patients with acute decompensation of cirrhosis

Poster Presentation

Presenter: Konstantin Kazankov

1610

Impact of predisposition and precipitants on the short-term prognosis among inpatients with chronic liver disease

Poster Presentation

Presenter: Yan Zhang

1663

A study evaluating outcomes of a virtual specialist liver cirrhosis clinic

Poster Presentation

Presenter: Claudia Moore-Gillon

1695

A novel metabolomics-based prognostic model shows superior diagnostic accuracy than MELD in chronic liver failure

Poster Presentation

Presenter: Rudolf E. Stauber

1724

Uncovering monocyte transcription, functional and metabolic signatures in recovery and non-recovery ACLF patients

Poster Presentation

Presenter: Rita Furtado Feio de Azevedo

1786

Predicting prognosis in large cohort of decompensated cirrhosis of liver (DCLD)- a machine learning (ML) approach

Type to be confirmed

Presenter: Ashok Choudhury

1901

Early initiation of continuous renal replacement therapy improves renal outcomes and survival in patients with acute on chronic liver failure - a prospective cohort study

Poster Presentation

Presenter: Rakhi Maiwall

1927

Different clinical courses of acutely decompensated cirrhosis in hepatitis B virus high-endemic area: data from Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study

Poster Presentation

Presenter: Tongyu Wang

1954



Characterization of energy and substrate metabolism in patients with spontaneously breathing and mechanically ventilated patients with liver cirrhosis: an indirect calorimeter based study

Poster Presentation

Presenter: Varsha Shasthry

1959

Extracorporeal membrane oxygenation, a valuable life-saving treatment in liver transplanted patients

Poster Presentation

Presenter: Benjamin Buchard

1974

Prevalence, profile and predictors of invasive fungal infections in acute on chronic liver failure (ACLF): analysis of APASL-ACLF research consortium database

Poster Presentation

Presenter: Pratibha Ramchandra Kale

2021

Maladaptive tubular repair is a harbinger of chronic kidney disease development in critically-ill cirrhosis patients admitted to intensive care unit - a prospective cohort study

Oral Presentation

Presenter: Rakhi Maiwall

2045

Outcomes in patients with cirrhosis and fungal infections: a systematic review and meta-analysis with machine learning

Poster Presentation

Presenter: Nipun Verma

2170

Impact of the presence of acute on chronic liver failure on morbidity - mortality after liver transplantation

Poster Presentation

Presenter: Jorge Arnold

2176

Hyperammonaemia defines the risk of acute-on-chronic liver failure in clinically stable outpatients with cirrhosis

Type to be confirmed

Presenter: María Pilar Ballester

2326

Comparative analysis of acute-on-chronic liver failure related to herbs and anti-tubercular drugs

Poster Presentation

Presenter: Ankur Jindal

2389

Untargeted lipidomics differentiate ACLF precipitated by severe alcoholic hepatitis

Poster Presentation



Presenter: Florent Artru

2396

Metabolomic analysis of organ failure marker compounds in blood samples of patients with decompensated liver cirrhosis after administration of the novel drug VS-01

Poster Presentation

Presenter: Wenyi Gu

2398

Metabolomic analysis of bacterial infection markers in blood samples of patients with decompensated liver cirrhosis infused with the novel drug VS-01

Poster Presentation

Presenter: Olaf Tyc

2414

Disturbances in sodium and chloride hemostasis predict outcome in stable and critically-ill patients with cirrhosis - not two sides of the same coin

Poster Presentation

Presenter: Georg Semmler

## Cirrhosis and its complications: Other clinical complications except ACLF and critical illness

47

Evaluation of Interleukin-6 for stepwise diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis

Poster Presentation

Presenter: Simon Johannes Gairing

93

Evaluation of statins as a new therapy to alleviate chronotropic dysfunction in cirrhotic rats

Poster Presentation

Presenter: Qamar Niaz

103

The effect of sarcopenia on survival of patients with cirrhosis: a systematic review and meta-analysis

Poster Presentation

Presenter: Xinxing Tantai

184

Effectiveness of probiotics in the secondary prevention of hepatic encephalopathy among cirrhotic patients

Type to be confirmed

Presenter: Muhammad Farooq Hanif

330



Sarcopenia as a predictor of mortality and complications in cirrhosis patients - A prospective cohort study

Poster Presentation

Presenter: NIDHIN DEVADAS

476

Diagnosis and pathophysiological analysis of sarcopenia using liver MR in chronic liver disease

Poster Presentation

Presenter: ATSUSHI NAKAMURA

500

Use of a cirrhosis database can positively impact patient care in United Kingdom practice

Poster Presentation

Presenter: Jessica Shearer

545

Psychomotor speed from minimal hepatic encephalopathy testing is associated with physical frailty in patients with end-stage liver disease

Poster Presentation

Presenter: Andres Duarte Rojo

618

A multistrain probiotic increases serum glutamine/glutamate ratio in patients with cirrhosis. A metabolomic analysis

Poster Presentation

Presenter: German Soriano

645

The composition of the bile acid pool is closely associated with fibrosis in the heart and liver of patients with cirrhosis

Poster Presentation

Presenter: Signe Wiese

663

SBP vs. non-SBP bacterial infections at admission have comparable outcomes in a multi-center cohort of inpatients with cirrhosis

Poster Presentation

Presenter: Jacqueline O'Leary

693

Natural history of Hepatic Encephalopathy (HE) in a tertiary referral centre for hepatology

Poster Presentation

Presenter: Chiara Mangini

744

Public knowledge and attitudes toward liver diseases and liver cancer in the Brazilian population

Poster Presentation

Presenter: Paulo Bittencourt



863

The negative impact of the pandemic on hospital admissions, morbidity and 30-day mortality for acute cirrhosis decompensation: a tertiary care perspective

Poster Presentation

Presenter: Kohilan Gananandan

869

Comparison of recommended daily energy intakes in people with cirrhosis, based on current guidelines, and their directly measured energy requirements: an individual patient data analysis

Poster Presentation

Presenter: Marsha Morgan

870

Rifaximin for the prevention and treatment of hepatic encephalopathy: a systematic review and meta-analysis of randomized clinical trials

Poster Presentation

Presenter: Harry D Morgan

890

Impact of cirrhotic cardiomyopathy and severity of liver cirrhosis on the development of acute kidney injury

Type to be confirmed

Presenter: Simona Bota

893

Influence of cirrhotic cardiomyopathy defined according to the new multidisciplinary diagnostic criteria on overall mortality among cirrhotic patients

Poster Presentation

Presenter: Simona Bota

942

Risk of herpes zoster infection in patients with cirrhosis: a nationwide population-based study in Korea

Poster Presentation

Presenter: Dongsu Jeon

984

Skeletal muscle pathological fat infiltration (myosteator) associates with higher mortality in patients with cirrhosis

Poster Presentation

Presenter: Maryam Ebadi

1015

Application of CT-contrast media is not associated with a higher risk for acute kidney injury in patients with decompensated liver cirrhosis

Poster Presentation

Presenter: Tammo Lambert Tergast



1066

Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event

Oral Presentation

Presenter: Marta Tonon

1151

Proton pump inhibitors are associated with higher mortality risk and higher risk of decompensation in patients with liver cirrhosis - A retrospective cohort study from the Amsterdam metropolitan area

Poster Presentation

Presenter: Koos de Wit

1211

Maintenance of sarcopenia and myosteatorsis after liver transplantation

Poster Presentation

Presenter: Franziska Recklies

1256

Clinical and prognostic characterization of the patterns of decompensation of liver cirrhosis

Poster Presentation

Presenter: Marta Tonon

1268

Safety, pharmacokinetics and pharmacodynamics of TNP-2092 capsule in chinese liver cirrhosis patients with hyperammonemia: a randomized, double-blind, placebo-controlled, dose-escalation phase Ib/IIa study

Poster Presentation

Presenter: Yanhua Ding

1296

Serological assessment of the collagen type III deposition predicts outcome in decompensated liver cirrhosis

Poster Presentation

Presenter: Mette Juul Nielsen

1321

Liver frailty index predicts poor outcomes in patients hospitalized for acute decompensation of cirrhosis

Poster Presentation

Presenter: Simone Trasino

1345

Urinary proteomics identifies oxidative stress and inflammation pathways as key factors differentiating acute-kidney injury-hepatorenal syndrome from acute tubular necrosis in patients with cirrhosis

Poster Presentation

Presenter: Laura Zhou





1359

Risk factors for short-term post discharge clinical outcomes in patients hospitalized with decompensated chronic liver disease: interim results from Global CLEARED study

Oral Presentation

Presenter: Ashok Choudhury

1468

Kidney transplant alone recipients with advanced liver disease have similar outcomes to those without advanced liver disease - a single center study of 150 patients

Poster Presentation

Presenter: Rohit Nathani

1618

Clinical features of exacerbation of portal vein thrombosis after discontinuation of anticoagulants

Poster Presentation

Presenter: Takayuki Kondo

1684

Systemic inflammatory response syndrome and renal resistive index as early predictors of treatment response to terlipressin in hepatorenal syndrome-acute kidney injury

Poster Presentation

Presenter: krishnadas devadas

1765

A prospective study of global myocardial function in decompensated cirrhosis using advanced echocardiographic techniques and its clinical significance

Poster Presentation

Presenter: Jeyamani Ramachandran

1856

Dyserythropoiesis is underrecognized and contributes to severe anemia in liver cirrhosis

Oral Presentation

Presenter: Chhagan Bihari

2002

Identification of overt hepatic encephalopathy precipitating factors: a pooled analysis of 3 clinical trials of rifaximin plus lactulose

Poster Presentation

Presenter: Jasmohan S Bajaj

2010

Dementia frequently co-exists with hepatic encephalopathy but not other cirrhosis complications in US veterans with cirrhosis

Poster Presentation

Presenter: Adeyinka Adejumo

2037



Bacterial infections as a predisposing factor for the development of portal vein thrombosis in cirrhotic patients: a prospective study

Poster Presentation

Presenter: Leonardo De Marco

2050

Impact of the COVID-19 pandemic on the incidence and type of infections in hospitalized patients with cirrhosis

Poster Presentation

Presenter: Berta Cuyas

2052

Increased expression of podoplanin, a marker of dilated lymphatic vessels in duodenal biopsies is an independent predictor of three-month mortality in patients with cirrhosis

Poster Presentation

Presenter: Savneet Kaur

2106

Provider perceptions of fresh frozen plasma transfusion in variceal bleeding lag behind current evidence and vary across clinical specialties

Poster Presentation

Presenter: Kelly Diaz

2107

Blood metabolomics unveils mitochondrial dysfunction as a potential key feature in the pathogenesis of hepatorenal syndrome

Poster Presentation

Presenter: Ann T Ma

2132

Hyperammonaemia is an independent biomarker of liver-related complications and mortality in clinically stable outpatients with cirrhosis

Poster Presentation

Presenter: Tom H Tranah

2222

Prospective evaluation of the EASL clinical guidelines algorithm of management of acute kidney injury in cirrhosis

Poster Presentation

Presenter: Ann T Ma

2312

MELD 3.0 accurately predicts short term survival of patients with end-stage liver disease

Poster Presentation

Presenter: Anna Vidovszky

2452



CyberLiver Animal Recognition Test (CL-ART): a novel remote monitoring tool to assess minimal hepatic encephalopathy

Poster Presentation

Presenter: Kohilan Gananandan

2503

Acute kidney injury during hospitalization in patients with liver cirrhosis is associated with increased mortality and chronic kidney disease on follow-up

Poster Presentation

Presenter: Anna Cederborg

2531

Ascites bacterial DNA and IL-6 are promising tools in the diagnosis of spontaneous bacterial peritonitis

Poster Presentation

Presenter: Niklas F Aehling

2558

Ascitic fluid mid-regional-pro-adrenomedullin (MR-pro-ADM): a novel rapid-assay sepsis biomarker to diagnose spontaneous bacterial peritonitis in cirrhotic patients

Poster Presentation

Presenter: Abderrahim Oussalah

2605

Effect of recruitment and selection policies on the volume of outcome of patients transplanted with ACLF-3

Oral Presentation

Presenter: Baptiste Michard

## Cirrhosis and its complications: Experimental and pathophysiology

204

Neurometabolic and gliovascular changes in murine hepatic encephalopathy

Type to be confirmed

Presenter: Wouter Claeys

305

Extracellular vesicles from mesenchymal stem cells reduce neuroinflammation in hippocampus and restore cognitive function in hyperammonemic rats

Oral Presentation

Presenter: Vicente Felipo

466

Increased platelet aggregation in decompensated cirrhosis indicates higher risk of further decompensation and liver-related mortality

Poster Presentation



Presenter: Alberto Zanetto

503

Lipidomics analyses of ATTIRE trial patients' plasma at day 1 demonstrates that reduced cholesterol esterification predicts development of hospital acquired infection

Oral Presentation

Presenter: Harriett Fuller

574

Renin/angiotensin system - coagulation - inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis

Poster Presentation

Presenter: Lukas Hartl

611

Effect of engineered poly(beta-amino ester) nanoparticles containing a nitric oxide donor on systemic and portal hemodynamics

Type to be confirmed

Presenter: Meritxell Perramón

745

Improvement of hepatic and extrahepatic functions and anti-inflammatory effects of nitazoxanide in disease models of LPS-induced systemic inflammation and acute-on-chronic liver failure

Poster Presentation

Presenter: Dean Hum

908

In silico characterization of the interactome of hepatic nonparenchymal cells reveals promising targets for antifibrotic therapy

Poster Presentation

Presenter: Oleksandr Petrenko

1157

Long-chain acylcarnitines promote leukocyte mitochondrial dysfunction: role in patients with acutely decompensated cirrhosis

Poster Presentation

Presenter: Ingrid Wei Zhang

1208

Reduced plasma extracellular vesicle CD5L content in patients with acute-on-chronic liver failure: interplay with specialized pro-resolving lipid mediators

Poster Presentation

Presenter: Joan Clària

1218

Peptidylglycine alpha-amidating monooxygenase and adrenomedullin measurements suggest cardio-circulatory dysfunction in advanced cirrhosis

Poster Presentation



Presenter: Søren Møller

1241

Combination of CCL4-induced decompensated cirrhosis with acute polymicrobial peritonitis as an optimized experimental model mimicking extrahepatic organ failures defined in ACLF

Poster Presentation

Presenter: Roger Flores-Costa

1328

Thrombin-induced platelet activation across distinct stages of portal hyperension and cirrhosis

Poster Presentation

Presenter: Ksenia Lumley

1340

Integrating single-cell RNA and spatial transcriptomic data defines altered cell state in human liver fibrosis

Oral Presentation

Presenter: Karen Piper Hanley

1480

Exploring metabolic space of advanced chronic liver disease regression

Poster Presentation

Presenter: Mojgan Masoodi

1499

Exacerbated response to patterned injury in the cirrhotic liver: potential susceptibility to ischemia

Poster Presentation

Presenter: Benjamin Leaker

1666

The regulatory protein and gene expression profile of skeletal muscle in chronic liver disease patients

Poster Presentation

Presenter: Sophie Allen

1690

Proteomic analysis of dysfunctional liver sinusoidal endothelial cells reveals substantial differences in the most common experimental models of chronic liver disease

Poster Presentation

Presenter: Mar Gil

1757

Long-term albumin administration improves survival, reduces TLR4 mediated hepatic inflammation and reduces gut translocation in models of cirrhosis

Poster Presentation

Presenter: Alexandra Phillips

1764



The prevalence and prognostic significance of vitamin C deficiency in patients with cirrhosis: a prospective observational cohort study

Poster Presentation

Presenter: declan connoley

1918

Wnt as activator of regeneration in cirrhosis of human liver: tissue collapse brings the Wnt source in hepatic veins to the site of the progenitor cell niche

Poster Presentation

Presenter: IanR Wanless

2020

The portal vein in patients with cirrhosis is not an extensively inflammatory or hypercoagulable vascular bed

Poster Presentation

Presenter: Ellen Driever

2061

Effect of liver stiffness on hepatocellular carcinoma phenotype in a biometric 3D model

Poster Presentation

Presenter: Jaafar Khaled

2122

Vascular endothelial growth factor C mediated restoration of mesenteric lymphatic vessels permeability and drainage improves gut immunity surveillance in experimental cirrhosis

Oral Presentation

Presenter: Pinky Juneja

2266

Can thymosin beta 4, 25(OH) vitamin D and sCD163 be used as biomarkers of prognosis in ACLF?

Poster Presentation

Presenter: Rahul Karna

## Fibrosis

109

Hepatic angiocrine HGF attenuates liver fibrogenesis via modulation of PDK1/AKT axis

Poster Presentation

Presenter: Jianye Wang

110

Bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages

Poster Presentation

Presenter: Leonard KAPS

125



Preclinical evaluation of the calpain inhibitor BLD-3051 as a therapeutic strategy for liver fibrosis  
Poster Presentation  
Presenter: Ravi Rajagopalan

168  
Experimental fibrosis alters matrix-bound vesicles cargo that do not revert after histologic recovery  
Poster Presentation  
Presenter: TOSHIFUMI SATO

409  
Hepatocyte cell-specific deletion of cathepsin D does not affect liver inflammation and fibrosis during cholestatic-induced liver fibrosis  
Poster Presentation  
Presenter: Maria Fernandez-Fernandez

499  
The therapeutic potential of alpha v integrins in liver fibrosis  
Poster Presentation  
Presenter: Syedia Rahman

535  
Dual inhibition of integrins alpha-v/beta-6 and alpha-v/beta-1 decreases portal pressure and liver fibrosis in rats with biliary cirrhosis  
Poster Presentation  
Presenter: Philipp Königshofer

607  
Dual roles of PSMP/MSMP in the progression of hepatic fibrosis and hepatocellular carcinoma  
Poster Presentation  
Presenter: Shaoping She

690  
NKT cells promote both type 1 and type 2 inflammatory responses in the non-obese diabetic inflammation and fibrosis (NIF) mouse model  
Poster Presentation  
Presenter: Sofia Mayans

783  
Using qFibrosis analysis to predict disease and survival outcome of patients with hepatocellular carcinoma after curative treatment  
Poster Presentation  
Presenter: Chih-Yang Tai

790  
Multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in animal model of NASH/fibrosis  
Poster Presentation  
Presenter: Jong Suk Lee



791

Direct anti-inflammatory and anti-fibrotic effects of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in thioacetamide-induced mouse model of liver injury and fibrosis

Poster Presentation

Presenter: Jung Kuk Kim

794

Loss of bile salt export pump (BSEP/ABCB11) protects mice from development of carbon tetrachloride (CCl<sub>4</sub>) induced hepatic fibrosis

Poster Presentation

Presenter: Claudia Fuchs

804

Large-scale multicenter study for the clinical utility of the non-invasive biomarkers Gas6 and soluble Axl in hepatocellular carcinoma, liver fibrosis and end-stage liver disease

Poster Presentation

Presenter: Wolfgang Mikulits

881

Multispectral analysis of liver biopsies from patients with chronic hepatitis C reveals unique macrophage phenotypes and spatial interactions associated with fibrosis progression

Poster Presentation

Presenter: Omar Saldarriaga

892

Neutrophil-specific NLRP3 activation triggers liver inflammation and fibrosis

Poster Presentation

Presenter: Benedikt Kaufmann

926

Imaging of fibrosis in metabolic associated liver disease by a radiolabeled affibody targeting PDGFRB

Poster Presentation

Presenter: Olivia Wegrzyniak

931

Liver complications in greek patients with sickle cell disease: a multicenter retrospective analysis from eight thalassemia and sickle cell units across Greece

Poster Presentation

Presenter: Konstantinos Manganas

1000

Hemodynamic, molecular, and histological characterization of a toxic liver fibrosis regression model

Poster Presentation

Presenter: Philipp Königshofer

1060





Peroxidasin deficiency re-programs macrophages toward pro-fibrosis function and promotes collagen resolution in liver

Oral Presentation

Presenter: Mozhdeh Sojoodi

1084

The upper limit of normal of alanine aminotransferase (ALT) in diagnosing liver disease and fibrosis by the Intelligent Liver Function Test (iLFT) system

Poster Presentation

Presenter: Jeremy Lee

1108

Inhibition of 11beta-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH

Poster Presentation

Presenter: Haeng Ran Seo

1144

Anti-fibrotic effects of microRNA-9-5p and microRNA-122

Poster Presentation

Presenter: Dana Eidelstein

1164

Higher daily Aramchol dose results in higher effect size in fibrosis improvement in the ARMOR study open label part

Poster Presentation

Presenter: Vlad Ratziu

1184

Development of a high precision liver biopsy method to improve the accuracy of fibrosis staging and collagen profiling

Poster Presentation

Presenter: Morten Christensen

1303

MAIT cell inhibition promotes liver fibrosis regression by reprogramming macrophage phenotype

Poster Presentation

Presenter: Morgane Mabire

1441

The LiverPRO score, a multivariable model for prediction of significant fibrosis in primary care: derivation, validation and comparison with FIB-4 and ELF-test in 5,000 study participants

Poster Presentation

Presenter: Katrine Prier Lindvig

1497

The protective effect of time-caloric restriction in liver fibrosis induced by nitrosamines in rat model

Poster Presentation



Presenter: christian Molina-Aguilar

1512

Macrophage MerTK promotes a profibrogenic cross-talk with hepatic stellate cells via soluble mediators

Poster Presentation

Presenter: Mirella Pastore

1518

Comparative fibrosis-reducing activities of farnesoid X receptor (FXR), peroxisome-proliferator activated receptor delta (PPAR) and thyroid hormone receptor (THR) agonists in the carbon tetrachloride mouse model

Poster Presentation

Presenter: Edward Cable

1594

A novel role for serine protease Kallikrein 8 in liver fibrosis through cleaving complement C3 and hepatic macrophage polarization

Poster Presentation

Presenter: Cichun Wu

1673

The modulation of NADPH oxidases by tyrosol-derived phenolic compounds prevents hepatic fibrogenesis

Poster Presentation

Presenter: Daniela Gabbia

1680

Exploring gender-related differences in liver fibrosis and regeneration through a new experimental carbon tetrachloride protocol in mice

Poster Presentation

Presenter: Katia Sayaf

1691

Multicenter external validation of FIB-6: a novel, machine-learning, simple bedside score to rule out severe liver fibrosis and cirrhosis in patients with MAFLD

Poster Presentation

Presenter: Gamal Shiha

1736

A bioengineered approach to re-create and study the extracellular matrix-immune cell crosstalk in normal and fibrotic liver

Poster Presentation

Presenter: Sara Campinoti

1872

Clinical and genetic factors associated with regression of fibrosis in ACLD after etiological therapy

Poster Presentation



Presenter: Yuly Mendoza

1882

Targeting the liver circadian clock by REV-ERB-alpha activation improves liver fibrosis by circadian gating of TGF-beta signaling

Oral Presentation

Presenter: Atish Mukherji

1911

The proteomic analysis of hepatic stellate cell differentiation from iPSCs identifies RORalpha as an antifibrogenic target

Oral Presentation

Presenter: Raquel A. Martinez Garcia de la Torre

1940

Stellate cell dynamics in progression and regression of hepatic fibrosis

Oral Presentation

Presenter: Laura Almale del Barrio

1960

Addressing the heterogeneity of fibrosis in liver biopsy specimens with qFibrosis -- a new paradigm for an old problem

Poster Presentation

Presenter: David E Kleiner

2017

Characterisation of the novel Galectin-3 inhibitor GB1107 on CCl4-induced liver fibrosis in mice

Poster Presentation

Presenter: Alison MacKinnon

2047

Quantitative digital pathology of 3D human NASH models establish continuous scores to evaluate the antifibrotic effects of Selonsertib, Firsocostat and Resmetiron

Poster Presentation

Presenter: Louis Petitjean

2126

Etiology-independent fibrosis severity scoring by quantitative digital pathology image analysis

Poster Presentation

Presenter: Adam Watson

2188

Liver stiffness and autoimmune profile in a cohort of patients with systemic sclerosis

Poster Presentation

Presenter: Davide Di Benedetto

2198



Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis

Poster Presentation

Presenter: Alexandru Popa

2202

Inhibition of tumour progression locus 2 (TPL2) halts the progression of liver fibrosis in a stringent long term choline deficient high-fat diet (CdHFD) rat model

Poster Presentation

Presenter: Milessa Silva Afonso

2204

Evaluation of the antifibrotic effects of naringenin, asiatic acid and icariin by using precision-cut liver slices of mouse and human

Poster Presentation

Presenter: Ke Luo

2272

Diagnostic efficacy of Mac-2 binding protein glycosylation isomer for predicting liver fibrosis in patients with metabolic associated fatty liver disease

Poster Presentation

Presenter: SE YOUNG JANG

2296

Multispectral imaging analysis of liver biopsies from patients with non-alcoholic steatohepatitis reveals enrichment of pathogenic macrophage phenotypes associated with disease progression

Type to be confirmed

Presenter: Joseph Gosnell

2317

Machine learning methods for detailed characterization of TGF-beta-induced signatures in a large iPSC-derived hepatic stellate cell cohort

Oral Presentation

Presenter: Panagiotis Stanitsas

2383

Diabetes, but not prediabetes, is associated with significant liver fibrosis

Poster Presentation

Presenter: Byung Ik Kim

2483

Lysophosphatidylserine may stimulate liver fibrosis

Poster Presentation

Presenter: Takako Nishikawa

2489

Quantitative assessment of liver fibrosis in NASH patients

Poster Presentation



Presenter: Tian Ruiz

## Gut microbiota and liver disease

111

Altered fecal microbiome and metabolome in hepatitis B related chronic liver diseases

Poster Presentation

Presenter: Yue Shen

358

Bacterial infections in cirrhosis are associated with reduction in gut microbial phage-bacterial interactions

Oral Presentation

Presenter: Jasmohan S Bajaj

458

The therapeutic effect of *Lactobacillus plantarum* on metabolic phenotypes in non-alcoholic fatty liver disease mice model

Poster Presentation

Presenter: DongYun Kim

530

Stool microbiota, compared to salivary microbiota, show more extensive correlations with plasma metabolites in decompensated cirrhosis in a multinational cirrhosis cohort

Poster Presentation

Presenter: I. Jane Cox

658

The gut virome in non-alcoholic fatty liver disease: distinct changes in Phagecoctavirus composition in a human microbiota associated animal model

Poster Presentation

Presenter: Hau-Tak Chau

1053

Altered gut microbiome, metabolome and bile acid composition in sarcopenia in liver cirrhosis

Oral Presentation

Presenter: Vanessa Stadlbauer

1327

Tissue-specific microbiome alterations in hepatocellular carcinoma

Poster Presentation

Presenter: Maria Nouredin

1453

Microbial produced ethanol: an underestimated burden on the liver

Oral Presentation



Presenter: Stijn Meijnikman

1797

Mitochondrial hyperactivation determines a transferable protective gut microbiota profile in metabolic-associated fatty liver disease development

Poster Presentation

Presenter: María Juárez-Fernández

2064

Fecal transplant-related reductions in Alcohol intake from human to mice are associated with alterations in the intestinal but not liver or prefrontal cortex transcriptome

Poster Presentation

Presenter: Jasmohan S Bajaj

2165

New insights from mapping of the mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation

Type to be confirmed

Presenter: Mikal Jacob Hole

2179

Designing a polymetabolic risk score for non-alcoholic steatohepatitis patients by differentiating their metabolic profiles from healthy controls

Poster Presentation

Presenter: Nadeen Habboub

2180

Intestinal hyperpermeability in cirrhosis is predictive for survival and associated with distinct microbiome changes

Poster Presentation

Presenter: Vanessa Stadlbauer

2304

Novel multi-technology meta-analysis identifies gut microbiome strains associated with clinical fibrosis in NAFLD patients

Poster Presentation

Presenter: Nicole Narayan

## Immune-mediated and cholestatic disease: Clinical aspects

280

Radiomics-based model for outcome prediction in primary sclerosing cholangitis

Type to be confirmed

Presenter: Laura Cristoferi

304



Outcomes of pregnancy in patients with autoimmune hepatitis in the Netherlands

Poster Presentation

Presenter: Susan Fischer

311

Cholangiopathy after severe COVID-19: what do we know so far?

Poster Presentation

Presenter: Helma Pinchemel Cotrim

393

Enhanced liver fibrosis score correlates with transient elastography in patients with treated autoimmune hepatitis

Poster Presentation

Presenter: Anna Stoelinga

396

Rationale for evaluation of PLN-74809 treatment in participants with primary sclerosing cholangitis in Phase 2a study INTEGRIS-PSC

Poster Presentation

Presenter: Eric Lefebvre

413

Quality of life outcomes in patients with primary biliary cholangitis treated with setanaxib: post-hoc results from a phase 2 randomised, placebo-controlled trial

Oral Presentation

Presenter: David Jones

439

Acute hepatitis after COVID-19 vaccine: case series by the International autoimmune hepatitis group (IAIHG) and the european reference network on hepatological diseases (ERN RARE-LIVER)

Poster Presentation

Presenter: Benedetta Terziroli Beretta-Piccoli

475

Scheduled endoscopic program for patients with primary sclerosing cholangitis improves transplant-free survival and enables early risk stratification

Poster Presentation

Presenter: Burcin Özdirik

517

Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosuppressive therapy, a prospective cohort study

Poster Presentation

Presenter: Kristin Jorgensen

520

Analyses of obeticholic acid treatment retention in UK patients based on medicine delivery data

Poster Presentation



Presenter: Carl Gibbons

542

Real-world prevalence of pruritus with obeticholic acid: a systematic literature review and meta-analysis

Poster Presentation

Presenter: Patrick Horne

588

Cognitive symptoms in non-cirrhotic primary biliary cholangitis

Poster Presentation

Presenter: Naw April Phaw

643

Screening and surveillance of biliary neoplasia based on brush cytology in primary sclerosing cholangitis (PSC): prevalence and outcomes

Type to be confirmed

Presenter: Martti Färkkilä

756

Impact of pruritus in primary sclerosing cholangitis (PSC): a multinational survey

Poster Presentation

Presenter: Kris Kowdley

900

A dynamic approach to modelling baseline disease status and ALT elevation over follow-up on clinical-event free survival in autoimmune hepatitis: a canadian multicentre cohort

Poster Presentation

Presenter: Christina Plagiannakos

934

Recurring intrahepatic cholestasis of pregnancy presents with distinct changes in the gut microbiota

Oral Presentation

Presenter: Hanns-Ulrich Marschall

956

Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study

Poster Presentation

Presenter: Marcus Mücke

1097

The efficacy of combined treatment of bezafibrate and ursodeoxycholic acid was reduced in patients with primary cholangitis at advanced stage

Poster Presentation

Presenter: Kosuke Matsumoto

1146

Extrahepatic autoimmune diseases in autoimmune hepatitis: effect on mortality





Poster Presentation

Presenter: Rasmine Birn-Rydder

1148

Confidence in treatment is contributing to quality of life in patients with autoimmune liver diseases.

The results of ERN-RARE Liver online survey

Poster Presentation

Presenter: Ewa Wunsch

1220

A pilot study of PBC symptom management with melatonin and fenofibrate: the PIMBLE study

Poster Presentation

Presenter: Beverly Nicoll

1306

Portal hypertension-associated clinical features in patients with primary biliary cholangitis are of distinct prognostic value

Poster Presentation

Presenter: Lukas Burghart

1313

The low incidence of HBV reactivation among anti-HBc+ subjects on immunotherapy reduces the impact of suboptimal screening rate

Poster Presentation

Presenter: Laia Feld

1348

The ABCB4 variant c.711 increases liver injury in PBC but not in PSC: prospective analysis with a median follow-up of 7 years in 331 patients

Poster Presentation

Presenter: Marcin Finkelmeier

1357

A multicentric study to estimate mortality and graft loss risk after liver transplantation (LT) in patients with recurrent primary biliary cholangitis (PBC)

Poster Presentation

Presenter: Aldo J Montano-Loza

1380

Associations between novel serum biomarkers chitinase-2-like protein (YKL-40), type IV collagen, and thrombospondin-2 (TSP-2) with fibrosis stage and clinical outcomes in patients with primary sclerosing cholangitis (PSC)

Poster Presentation

Presenter: Michael Trauner

1386

MRCP+TM - derived biliary metrics are associated with disease severity and clinical outcomes in patients with primary sclerosing cholangitis



Poster Presentation

Presenter: Nora Cazzagon

1405

Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)

Poster Presentation

Presenter: Cynthia Levy

1435

Association between patient-reported outcome measures and surrogate markers of liver fibrosis in large-duct primary sclerosing cholangitis

Poster Presentation

Presenter: Emmanuel Selvaraj

1451

Association between patient-reported outcome measures and severity of cholangiopathy in large-duct primary sclerosing cholangitis

Poster Presentation

Presenter: Emmanuel Selvaraj

1472

Ultrasound for the diagnosis of gallbladder polyps in PSC: polyps greater than 8 mm indicate malignancy

Poster Presentation

Presenter: Johannes Altenmüller

1474

Temporal changes in patient-reported outcome measures stratified by liver fibrosis severity in large-duct primary sclerosing cholangitis

Poster Presentation

Presenter: Emmanuel Selvaraj

1485

Temporal increase in interquartile range iron-corrected T1 in high-risk patients with large-duct primary sclerosing cholangitis

Poster Presentation

Presenter: Emmanuel Selvaraj

1529

Seladelpar treatment of patients with primary biliary cholangitis (PBC) for 2 years improves the GLOBE PBC score and predicts improved transplant-free survival

Poster Presentation

Presenter: Bettina Hansen

1541

Validation of a novel method of identifying patients with Primary Sclerosing Cholangitis (PSC) in a canadian population



Poster Presentation

Presenter: Harshil Patel

1546

The prevalence of primary biliary cholangitis (PBC) is on the rise: a canadian population-based study

Poster Presentation

Presenter: Bryce Tkachuk

1655

Rituximab is a safe and effective treatment for patients with autoimmune hepatitis: results from the Spanish registry for cholestatic and autoimmune hepatitis

Poster Presentation

Presenter: Mar Riveiro Barciela

1657

Autoimmune hepatitis diagnosed after COVID-19 vaccination. Results from the spanish registry for autoimmune and cholestatic hepatitis

Poster Presentation

Presenter: Ana Barreira

1699

A prospective trial of a gluten free diet in primary sclerosing cholangitis with associated colitis

Poster Presentation

Presenter: Timur Liwinski

1753

The international autoimmune hepatitis group retrospective registry: quality assessment and analysis of clinical characteristics and liver-related outcome

Poster Presentation

Presenter: Charlotte Slooter

1768

Liver inflammation activity in autoimmune hepatitis patients with normal ALT and IgG levels

Poster Presentation

Presenter: Jiacheng Liu

1824

Novel screening test for primary sclerosing cholangitis: the role of serology, liver function tests, histology and radiology

Poster Presentation

Presenter: Nina Barner-Rasmussen

1825

Low-dose IL-2 alleviates drug-induced primary biliary cholangitis in mice by improving Treg and Th17 balance

Oral Presentation

Presenter: Bo Feng



1916

More than just an itch: impact of cholestatic pruritus in primary biliary cholangitis (PBC) on health-related quality of life (HRQoL)

Poster Presentation

Presenter: Helen Smith

2024

Isolated IgG elevation is not associated with worse outcome in patients with autoimmune hepatitis

Poster Presentation

Presenter: ALVARO DIAZ GONZALEZ

2056

Linerixibat dose–response analysis of C4 concentrations as a quantitative approach to predict gastrointestinal tolerability

Poster Presentation

Presenter: Fernando Carreño

2062

Incidence and predictors of hepatocellular carcinoma development in patients with autoimmune hepatitis: a multicenter international study

Oral Presentation

Presenter: Francesca Colapietro

2248

Urinary sulfated progesterone metabolites are diagnostic markers for cholestatic pregnancy and markers of treatment response to ursodeoxycholic acid

Poster Presentation

Presenter: Luiza Borges Manna

2549

COVID-19 vaccine induced autoimmune hepatitis - a first case series from India

Poster Presentation

Presenter: Sowmya Iyengar

2566

Lymphoma in IgG4-related disease: should we be concerned?

Poster Presentation

Presenter: Arif Hussienbux

2578

Measurement properties of the PBC-10 in a dutch population

Poster Presentation

Presenter: Maria van Hooff

2592

Glucoregulatory disturbances in primary biliary cholangitis and non-alcoholic fatty liver disease compared with healthy individuals

Poster Presentation



Presenter: Anne-Sofie Houlberg Jensen

## Immune-mediated and cholestatic: Experimental and pathophysiology

193

Cholangiocytes cleave surface CD100 from biliary infiltrating T cells and mediate pathogenic Th17 differentiation

Oral Presentation

Presenter: Espen Melum

443

Over-responsiveness of the IL-6/STAT3 pathway in inflammatory CD4+ T cells of patients with primary sclerosing cholangitis

Poster Presentation

Presenter: Leona Dold

634

Dosing ileal bile acid transporter inhibitors in the fasted state minimizes gastrointestinal adverse effects while maintaining pharmacodynamic effect

Poster Presentation

Presenter: Cory Kostrub

1004

Magnesium accumulation by CNNM4 GalNAc-siRNA mediated silencing reduces cholestasis-associated liver fibrosis

Poster Presentation

Presenter: Marina Serrano-Macia

1116

Association of bile acids composition and synthetic pathway with therapeutic effect of bezafibrate in chronic cholestatic liver disease

Poster Presentation

Presenter: Manami Iida

1129

Reduced hepatic expression of PPAR alpha in primary biliary cirrhosis is modulated by miR-155

Poster Presentation

Presenter: Monika Adamowicz

1186

cholangiocytes-specific deletion of sphingosine-1-phospholipid receptor 1 attenuate cholestasis induced liver injury and fibrosis

Poster Presentation

Presenter: Yuan Zihang

1316



Pruriceptor activating compounds in the enterohepatic cycle in cholestatic itch

Poster Presentation

Presenter: Frank Alkhouri

1404

The spatial distribution and detailed composition of infiltrating immune cells define autoimmune- and checkpoint-therapy associated hepatitis

Oral Presentation

Presenter: Laurenz Krimmel

1787

Novel approach combining whole liver single-cell RNA sequencing and spatial gene profiling using Nanostring GEOMX enables identification of specific cell sub-populations and pathways regulated by CCL24

Type to be confirmed

Presenter: Michal Segal-Salto

2118

Characterising the early inflammatory landscape of primary sclerosing cholangitis

Poster Presentation

Presenter: Calli Dendrou

2225

Deep learning for automatic diagnosis and morphologic characterisation of malignant biliary strictures using digital cholangioscopy: a pilot study

Oral Presentation

Presenter: Miguel Mascarenhas

2232

Extrahepatic bile duct injury in MDR2 knockout mice can be repaired with L-NAC treatment

Type to be confirmed

Presenter: Orith Waisbourd-Zinman

## Immunology

76

Increased expression of programmed cell death ligand 1 and galectin 9 in transplant recipients who achieved tolerance after immunosuppression withdrawal

Poster Presentation

Presenter: Nguyen Hai Nam

88

Acidic microenvironment aggravates the severity of hepatic ischemia/reperfusion injury by modulating PPAR- $\gamma$  signal

Poster Presentation

Presenter: Yunjie Lu

153

Toll-like receptor 3 polymorphisms rs5743305 and rs3775291 affect innate immune responses in whole blood analyses

Poster Presentation

Presenter: Sophia Barkow

421

IL-15 boots HBV-specific CD8+ cell response by activated progenitor pool mitochondrial remodelling in on treatment e-Ag negative chronic hepatitis B

Poster Presentation

Presenter: Julia Peña Asensio

480

Mucosal-associated invariant T cells are rendered functionally exhausted within the tumour microenvironment in HCC in a cell-contact dependent manner

Poster Presentation

Presenter: Junika Pohl

516

Preclinical model for the study of immune responses specific for a hepatic-self-antigen

Poster Presentation

Presenter: Anaïs Cardon

533

Enforced cytotoxic signature of HBV pol455-specific CD8+ T cells in chronic HBV infection

Oral Presentation

Presenter: Kathrin Heim

600

CD8+ T cell acquisition of the LPS receptor within the hepatic stroma shapes anti-viral/anti-tumour potential

Oral Presentation

Presenter: Laura J Pallett

879

Proximity labelling reveals potential cis interactions of CD52 glycoprotein counter-receptors on circulating CD4+HLA-G+ regulatory T cells in acute decompensation of cirrhosis

Poster Presentation

Presenter: Tong Liu

948

Humoral and cellular immunity after vaccination against SARS-CoV-2 is reduced in patients with chronic liver disease

Poster Presentation

Presenter: Al-Dury Hamah Saed

999



Efficacy of branched-chain amino acid granules to restore innate immunity in cirrhosis-associated immune dysfunction: a randomized controlled trial

Poster Presentation

Presenter: NATTHAPAT RUJEERAPAIBOON

1012

A novel immunophenotyping of hepatocellular carcinoma based on amplified and mutated neoantigens for mRNA vaccine development

Oral Presentation

Presenter: He Jing

1023

The close correlation between sarcopenia and the phagocytic dysfunction in respond to bacterial pathogen Ecoli in cirrhotic patients

Poster Presentation

Presenter: NATTHAPAT RUJEERAPAIBOON

1039

Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis

Poster Presentation

Presenter: Apichat Kaewdech

1073

Predictive immune biomarkers to safely discontinue nucleos(t)ide analogue treatment in HBeAg negative chronic hepatitis B (NUC-B study)

Poster Presentation

Presenter: Sandra Phillips

1165

MAIT-cells in blood are associated with a higher risk of infection in patients with cirrhosis

Poster Presentation

Presenter: Bonnie Hagström

1192

Fatty acids directly limit mucosal-associated invariant T cell effector function in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Sebastian Deschler

1199

Multimodal single cell analysis reveals the basis for butyrate induction of TNF $\alpha$ -secreting regulatory T cells

Poster Presentation

Presenter: Mo Atif

1544

COVID-19 vaccination in liver cirrhosis: safety and immune and clinical responses





Poster Presentation

Presenter: Maria Ines Canha

1595

Building a case for pancreas and liver targeted interleukin-22 therapy in fatty liver disease

Poster Presentation

Presenter: Haresh Sajiir

1734

Patients with decompensated cirrhosis and liver transplant recipients demonstrate poor humoral and cellular immune response against COVID-19 vaccine

Poster Presentation

Presenter: Anand Kulkarni

1775

Presence of cirrhosis in chronic liver disease patients associates with a lower immune response to COVID-19 vaccines - a multicenter european study

Poster Presentation

Presenter: André L. Castro

1915

Heterogeneity of peripheral blood monocytes in patients with cirrhosis

Poster Presentation

Presenter: Anne Geng

1952

JAM-A is a multifaceted regulator in hepatic fibrogenesis, supporting LSEC integrity and stellate cell quiescence

Poster Presentation

Presenter: Jonathan Frederik Brozat

2048

Diminished function of cytotoxic T- and NK- cells in severe alcohol-associated hepatitis

Poster Presentation

Presenter: Adam Kim

2080

Multi-omics analysis of human livers reveals variation in intrahepatic inflammation across chronic hepatitis B infection phases

Poster Presentation

Presenter: Andre Boonstra

2102

Liver cirrhosis and cirrhosis etiology impacts the circulating immune mediators of early stage hepatocellular carcinoma

Poster Presentation

Presenter: Boris Beudeker



2124

Ebola virus infection promotes reduced gene expression of antigen presentation molecules in hepatic CD68+ macrophages in cynomolgus macaques

Poster Presentation

Presenter: Timothy Wanninger

2183

Differential changes in global and antigen-specific B cell frequencies and function associate with the outcome of HBV nucleos(t)ide analog treatment withdrawal

Oral Presentation

Presenter: Sabela Lens

2388

Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study

Oral Presentation

Presenter: Thomas Marjot

2397

Plasmalemma vesicle-associated protein expression is driven by senescent cell-endothelial crosstalk and shapes the immune landscape in chronic liver disease

Poster Presentation

Presenter: Alex Wilkinson

2594

Dysfunctional liver-resident CXCR6+ CD8 T cells during persistent viral liver infection

Type to be confirmed

Presenter: Miriam Bosch

## Liver development, physiology and regeneration

210

Three-dimensional conditions in a perfusion bioreactor to support maturation of human amnion epithelial stem cells into functional hepatocyte-like cells

Poster Presentation

Presenter: Sara Campinoti

315

Knockdown of Glyoxylate reductase/hydroxypyruvate reductase (GRHPR) accelerates liver regeneration and decreases chronic liver damage

Poster Presentation

Presenter: Viktoriia Iakovleva

484

Expression and function of axon guidance genes in the developing portal tract

Poster Presentation



Presenter: Catalina Gannoun

1002

Monoacylglycerol lipase inhibition specifically in macrophages compromises liver regeneration by inducing interferon type 1 that negatively impacts on hepatocyte proliferation

Oral Presentation

Presenter: Manon Allaire

1010

Patients with chronic liver diseases are at risk for diabetes even before development of cirrhosis

Poster Presentation

Presenter: Georgia Bale

1068

Characterization of bioengineered liver constructs using hepatoblast organoids (HBOs) and human liver extracellular matrix (ECM) 3D-platforms

Poster Presentation

Presenter: Margarita Papatheodoridi

1085

Novel avenue towards liver regeneration and treatment of acute and chronic liver diseases: safety and PK profile from a first-in human (FIH) clinical trial for HRX-0215 as first in class MKK4 inhibitor

Poster Presentation

Presenter: Wolfgang Albrecht

1460

Complete vascular tree reconstruction in rat decellularized liver scaffolds using differential recellularization pressures

Type to be confirmed

Presenter: Sandra Melitón Barbancho

1681

In vivo loss-of-function studies unravel protein tyrosine phosphatase delta as a regulator of liver regeneration during metabolic liver disease

Poster Presentation

Presenter: Armando Andres Roca Suarez

1981

Integrated proteomics and metabolomics analysis reveals canonical and novel regulatory pathways linked to liver regeneration in living donor liver transplant (LDLT) Donors

Poster Presentation

Presenter: Gaurav Tripathi

2035

Regulation of extracellular Nicotinamide adenine dinucleotide in patients with liver fibrosis: new insights into conventional hepatobiliary parameters

Poster Presentation

Presenter: Can Kamali



2300

Hyaluronan in the prenatal extrahepatic bile duct increases in response to injury

Poster Presentation

Presenter: Iris de Jong

2512

Embryogenesis of human fetal liver at various stages of gestation: a histomorphometric study

Poster Presentation

Presenter: Pooja Bhadoria

## Liver transplantation and hepatobiliary surgery: Clinical aspects

101

Outcomes of living liver donors are worse than those of matched healthy controls: nationwide cohort study

Poster Presentation

Presenter: Jong Man Kim

115

Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation

Oral Presentation

Presenter: Manuel Rodríguez-Perálvarez

159

Pretransplant changes in serum protein glycosylation relate to risk of HCC recurrence after liver transplantation and provide a potential prognostic biomarker: a proof-of-concept study

Poster Presentation

Presenter: Verhelst Xavier

310

Liver transplantation for complications of hepatoportal sclerosis

Poster Presentation

Presenter: Andrew Keaveny

382

Discordance in categorization of acute-on-chronic-liver-failure in the national transplant database

Poster Presentation

Presenter: Brian Lee

407

Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients

Poster Presentation

Presenter: Valentina Cossiga

432



A predictive model for mortality within one year of liver transplantation at the time of wait-listing for transplant: a novel approach using machine learning algorithms in a large US multi-ethnic cohort

Poster Presentation

Presenter: Sripriya Balasubramanian

445

Monitoring patients with anti HBs trough levels can minimise hepatitis B immune globulin therapy after liver transplant

Poster Presentation

Presenter: Erica Nicola Lynch

455

Formal referral networks optimise patient selection for liver transplantation

Poster Presentation

Presenter: Oliver Tavabie

528

Efficacy and safety of SARS-CoV-2 vaccination in liver transplant recipients

Poster Presentation

Presenter: Lucy Meunier

556

Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study

Poster Presentation

Presenter: Supachaya Sriphoosanaphan

573

Multidrug resistant bacterial infections after liver transplantation: prevalence, impact and associated risk factors

Oral Presentation

Presenter: Rosa Martin- Mateos

936

Impact of COVID-19 on the liver transplant activity in the US: variation by the region, etiology, and cirrhosis complications

Poster Presentation

Presenter: Ashwani Singal

965

Perinatal outcomes in liver transplant patients-possible positive effect of aspirin prophylaxis

Poster Presentation

Presenter: Marius Braun

972

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in liver transplant recipients

Poster Presentation



Presenter: Aitor Odriozola Herrán

1006

Early post liver transplant rescue treatment with sofosbuvir/velpatasvir/voxilaprevir in patients experienced to NS5A-inhibitors

Poster Presentation

Presenter: Margherita Saracco

1032

Inclusion of body composition parameters in MELD score leads to optimization of predictive performance in patients with cirrhosis

Poster Presentation

Presenter: Maryam Ebadi

1036

Long-lasting seropositivity after anti SARS-CoV-2 vaccination in pre liver transplant patients

Poster Presentation

Presenter: Alberto Calleri

1048

The outcome of living donor versus deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis

Poster Presentation

Presenter: Beshoy Effat Elkomos

1049

Impact of gender on survival of hepatocellular carcinoma

Poster Presentation

Presenter: Chaonan Jin

1090

Effectiveness of MRI methods in the assessment of hepatic steatosis in living liver donors

Poster Presentation

Presenter: Digidem Kuru Öz

1106

Long-term outcomes of donation after cardiac death and living donor liver transplant for primary sclerosing cholangitis

Poster Presentation

Presenter: Dilip Moonka

1112

Patients with acute-on-chronic liver failure have significantly greater healthcare resource utilization after liver transplantation

Poster Presentation

Presenter: Vinay Sundaram

1141



Use of statins after liver transplantation is associated with improved survival: results of a nationwide study

Poster Presentation

Presenter: Chiara Becchetti

1169

Liver transplantation for hepatocellular carcinoma with extended criteria: performance and applicability of the AFP score after official adoption by the French Organ Sharing Organization ABM: 5-year outcomes

Poster Presentation

Presenter: Christophe Duvoux

1207

Tacrolimus drug exposure level in the first year after liver transplantation is an independent risk factor for de novo malignancy in patients transplanted for alcohol-related liver disease

Poster Presentation

Presenter: Benedict Vanlerberghe

1234

SARS-CoV-2 vaccination in liver transplant recipients: factors affecting immune response and refusal to vaccine

Poster Presentation

Presenter: Maciej K. Janik

1248

The effect of clinicopathologic findings of hepatocellular carcinoma on posttransplant survival: a multicenter cohort from TAsL liver transplantation special interest group

Poster Presentation

Presenter: Murat Akyildiz

1249

Utility and prognostic value of diagnosing metabolic dysfunction-associated fatty liver disease in patients undergoing liver transplantation for alcohol-related liver disease

Poster Presentation

Presenter: Benedict Vanlerberghe

1349

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific cellular and humoral immunity in Coronavirus Disease-2019 (COVID-19) convalescence after liver transplantation - a prospective six month follow up

Poster Presentation

Presenter: Theresa Patel

1389

A third dose of the BNT162b2 mRNA vaccine significantly improved immune response among liver transplant recipients

Poster Presentation

Presenter: Yana Davidov



1412

Everolimus combined with low-dose tacrolimus controls histological graft injury and liver fibrosis as sufficiently as high-dose tacrolimus combined with mycophenolate after liver transplantation

Poster Presentation

Presenter: Fabian Dranicki

1484

The portrait of adult liver transplant recipients in the United States from 2002-2020

Poster Presentation

Presenter: Zobair Younossi

1502

Heterologous regimen viral-vector/mRNA produces significantly higher SARS-CoV-2 humoral response than homologous viral-vector and inactivated vaccines in liver transplant recipients

Poster Presentation

Presenter: Manuel Mendizabal

1539

Evolution of pretransplant cardiac risk factor burden and major adverse cardiovascular events in liver transplant recipients over time

Poster Presentation

Presenter: Claire Harrington

1714

Retransplantation (reLT) outcomes of patients who were initially transplanted for ACLF

Poster Presentation

Presenter: Gandhi Lanke

1779

The ratio of Activin A and Follistatin-related gene allows prediction of posthepatectomy liver failure and postoperative morbidity in patients prior to liver surgery

Poster Presentation

Presenter: Jonas Santol

1913

Derivation of a cardiac risk index for use in liver transplantation for non-alcoholic steatohepatitis

Poster Presentation

Presenter: Paul Levy

2023

The prognostic effect of adequate lymphadenectomy in clinically node-negative patients undergoing liver resection for intrahepatic cholangiocarcinoma

Poster Presentation

Presenter: Carlo Sposito

2067

Impact of MELD 3.0 versus MELD-Na in patients with renal dysfunction





Type to be confirmed

Presenter: Allison Kwong

2096

Sustainability of humoral immunity induced by the SARS-CoV-2 vaccine and response to booster dose among Liver Transplant recipients

Poster Presentation

Presenter: Liane Rabinowich

2099

Acute-on-chronic liver failure due to severe intrahepatic vaso-occlusion and recurrence of the initial disease: 2 major features in liver transplantation for severe sickle-cell-related hepatopathy

Poster Presentation

Presenter: Christophe Duvoux

2144

Post-operative complications and short-term survival in obese cirrhotic patients undergoing liver transplantation

Poster Presentation

Presenter: Carmen Alonso Martin

2147

Impact of comorbidities on liver transplantation: a prospective and multicentric study

Poster Presentation

Presenter: Magdalena Salcedo

2148

Liver transplant patients infection rate with SARS-CoV-2 is lower but depend upon the infection rate in the general population and have a better outcome

Poster Presentation

Presenter: Michal Issachar

2162

Sarcopenia predict complications after hepatic resection for primary hepatocellular carcinoma (HCC) in patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH)

Poster Presentation

Presenter: Federico Ravaioli

2192

A comparison of hispanic living liver donor candidates approved and denied at a high-volume urban transplant center

Poster Presentation

Presenter: Dana Toy

2217

Liver transplantation in HIV infected subjects: a long-term single center experience

Poster Presentation



Presenter: Noemi Gualandi

2230

SARS-CoV-2 infection in liver transplant recipients - a single center case series from Romania  
Poster Presentation

Presenter: Ioana-Alexandra Husar-Sburlan

2282

Liver transplantation for hepatocellular carcinoma: outcome and prognostic factors for recurrence  
Poster Presentation

Presenter: Veronica Paon

2292

The liver outcomes and equity (LOEq) index: neighborhood social determinants independently predict outcomes in liver transplantation

Poster Presentation

Presenter: Kali Zhou

2295

Prevalence, prognosis, clinical, biological and histological features of incidentally found hepatocellular carcinoma after liver transplantation

Poster Presentation

Presenter: Emilie delire

2351

Survival benefit from liver transplantation for patients with and without hepatocellular carcinoma  
Poster Presentation

Presenter: Ben Goudsmit

2353

Long-term outcomes of liver transplantation (LT) using grafts from donors with active and chronic hepatitis B virus (HBV) infection: multi-center cohort study

Poster Presentation

Presenter: Sujin Gang

2355

Safe use of hepatitis B surface antigen positive (HBsAg (+)) grafts in liver transplantation (LT): a nationwide study based on KOTRY (Korean Organ Transplantation Registry) data

Poster Presentation

Presenter: Sujin Gang

2465

A panel of three micro RNAs allows robust prediction of overall survival after liver resection

Poster Presentation

Presenter: David Pereyra

2473

Liver transplantation for primary sclerosing cholangitis and predictors of disease recurrence



Poster Presentation

Presenter: Julie Zhu

2561

Predictive factors of antibody response after anti-SARS-CoV-2 vaccine in liver transplant recipients

Poster Presentation

Presenter: Ilias Kounis

2591

Immunotherapy before solid organ transplantation: an international transplant community-focused survey

Poster Presentation

Presenter: Tommy Ivanics

2597

Evaluating the predictive performance and transferability of machine learning-based prediction models using national liver transplant data registries

Poster Presentation

Presenter: Tommy Ivanics

2607

Liver transplant recipients have a higher incidence of lung cancer than general population

Poster Presentation

Presenter: Jose Ignacio Herrero

## Liver transplantation and hepatobiliary surgery: Experimental

519

Immune responses before and after liver transplantation: a cohort study of the induced immune response

Poster Presentation

Presenter: Dina Leth Møller

1200

Bile duct on a chip: engineering a microfluidic platform for studying biliary epithelium in a dish

Oral Presentation

Presenter: Jorke Willemse

1478

Andrographolide can potentially rescue unusable liver grafts by reducing fat content, enhancing mitochondrial function, and inhibiting Th1/Th17 immunity

Poster Presentation

Presenter: Zhenlin Huang

1871

Trends and causes of etiology in adult liver transplant patients: multicenter study



Poster Presentation

Presenter: Mesut Akarsu

2273

Modeling ischemic cholangiopathy in human cholangiocyte organoid for screening of novel cholangio-protective agents

Oral Presentation

Presenter: Shaojun Shi

2456

A new avatar mouse model to predict the liver immune homeostasis and histologic inflammation of liver transplant patients

Poster Presentation

Presenter: Soon Kyu Lee

## Liver tumours: Clinical aspects except therapy

163

Validation of a glycomics-based test associated with risk of HCC development in cirrhosis

Poster Presentation

Presenter: Verhelst Xavier

225

Benefits of tailored HCC surveillance programs on case-fatality rate and cancer-specific mortality using a modelling approach

Poster Presentation

Presenter: Massih Ningarhari

274

T cell receptor sequencing reveals HCC diversity according to BCLC stages within liver tissue and peripjeral blood

Poster Presentation

Presenter: Yijin Wang

437

NanoView EV Chip-based profiling in liver cancer differentiation - HCC from intrahepatic CCA - small EVs vs large EVs

Poster Presentation

Presenter: Bingduo Wang

511

Radiomic model based on contrast-enhanced CT imaging to predict early recurrence for patients with hepatocellular carcinoma after radical resection

Oral Presentation

Presenter: Liying Ren

591

Myosteatosi and excessive visceral adipose tissue as prognostic factors in patients with hepatocellular carcinoma treated with sorafenib

Poster Presentation

Presenter: Min Kyu Kang

624

Long term imaging outcomes of liver imaging reporting and data system categories in a prospective hepatocellular carcinoma surveillance cohort

Poster Presentation

Presenter: Sang Hyun Choi

650

Diagnostic accuracy of protein-induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) among caucasian cirrhotic patients with or without diagnostic serum a-fetoprotein (AFP) levels

Poster Presentation

Presenter: antonia syriha

799

Circulating vesicles hold etiology-related protein biomarkers of cholangiocarcinoma risk, early diagnosis and prognosis mirroring tumour cells

Oral Presentation

Presenter: Ainhua Lapitz

875

An easy to use score to predict survival in patients with hepatocellular carcinoma before the first transarterial chemoembolization session: AFP-DIAM score

Poster Presentation

Presenter: Estelle Rebillard

884

Measurement of protease activity using novel plasma biosensors can accurately detect hepatocellular carcinoma

Poster Presentation

Presenter: Tram Tran

960

On treatment alpha-fetoprotein reductions predict immunotherapy efficiency in patients with hepatocellular carcinoma

Poster Presentation

Presenter: Bernhard Scheiner

991

Gender differences in hepatocellular carcinoma : is it all due to adherence to surveillance? A study of 1,716 patients over 3 decades

Poster Presentation

Presenter: Wei-Lun Liou



1008

Non-alcoholic fatty liver disease and increased risk of incident primary liver tumours: a meta-analysis of observational cohort studies

Poster Presentation

Presenter: Andrea Dalbeni

1009

Characterization of gut microbiota and exploration of potential predictive model for hepatocellular carcinoma microvascular invasion

Poster Presentation

Presenter: Ningning Zhang

1046

Evaluation of the effectiveness of surveillance according to the ultrasound liver imaging reporting and data system (US LI-RADS) visualization score in patients with chronic hepatitis B

Oral Presentation

Presenter: Min Kyung Park

1122

Training, validation and testing of a multiscale three-dimensional deep learning algorithm in accurately diagnosing hepatocellular carcinoma on computed tomography

Oral Presentation

Presenter: Wai-Kay Seto

1223

Machine learning algorithm based on dual screening for hepatocellular carcinoma using circulating cell-free DNA and cfDHCC scoring system

Poster Presentation

Presenter: HYUK SOO EUN

1227

Sarcopenia impairs survival and treatment efficacy in patients with hepatocellular carcinoma undergoing immunotherapy

Poster Presentation

Presenter: Bernhard Scheiner

1284

Comparable efficacy between on-going vs. initiation of antiviral therapy at the time of curative treatment for hepatitis B virus-related hepatocellular carcinoma

Poster Presentation

Presenter: Mi Na Kim

1342

Immune-related adverse events and clinical outcomes in unresectable hepatocellular carcinoma: a single-institute retrospective analysis

Poster Presentation

Presenter: Antonella Issachar



1411

Multistage epigenome-wide association study identifies highly accurate epigenomic signatures in association with hepatocellular carcinoma: the HCC Epigenome Score

Type to be confirmed

Presenter: Abderrahim Oussalah

1523

Interleukin-6 as a new marker for advanced sarcopenic HCC patients with different cirrhotic aetiology

Poster Presentation

Presenter: Andrea Dalbeni

1559

Time-trends in cholangiocarcinoma incidence - a danish nationwide cohort study

Poster Presentation

Presenter: Morten Daniel Jensen

1564

A novel hierarchical fusion strategy of deep learning networks to detect hepatocellular carcinoma from dynamic computed tomography images

Poster Presentation

Presenter: I-Cheng Lee

1569

Prospective randomized controlled trial of biomarkers for early detection of hepatocellular carcinoma

Oral Presentation

Presenter: Hooman Farhang Zangneh

1625

Changing global epidemiology of liver cancer from 1990-2019: NASH is the fastest growing cause of liver cancer

Poster Presentation

Presenter: Daniel Huang

1707

Liver resection for single large hepatocellular carcinoma: a prognostic factors study

Poster Presentation

Presenter: Giuliana Amaddeo

1962

Characterization and clinical correlation of the immune contexture in intrahepatic cholangiocarcinoma using multiplex immunohistochemistry

Poster Presentation

Presenter: Charlotte Hoffmann

2041

Deep view on HCC gene signatures and their comparison with other cancers



Poster Presentation

Presenter: Yuquan Qian

2095

Lifestyle factors and population attributable risk of hepatocellular carcinoma in lean vs non-lean populations

Type to be confirmed

Presenter: Kali Zhou

2139

Causes of death after Intrahepatic cholangiocarcinoma diagnosis : a population-based study

Poster Presentation

Presenter: Ahmed Jalal

2149

Genes modulating liver fat accumulation and lipogenesis predict development of hepatocellular carcinoma among direct antiviral agents treated cirrhotics C with and without viral clearance

Poster Presentation

Presenter: Antonio Acquaviva

2181

Potential role of soluble triggering receptor expressed on myeloid cells 2 in risk stratification of patients with hepatocellular carcinoma

Poster Presentation

Presenter: Francesca Baorda

2186

Bone mineral density is a predictor of mortality in female patients with cholangiocarcinoma undergoing palliative treatment

Poster Presentation

Presenter: Markus Jördens

2233

Multiparametric ultrasound approach using a tree based decision classifier for the inconclusive focal liver lesions evaluated by contrast enhanced ultrasound

Poster Presentation

Presenter: Tudor-Voicu Moga

2238

Adherence to hepatocellular carcinoma screening in patients with hepatitis C cirrhosis treated with direct-acting antivirals against hepatitis C

Poster Presentation

Presenter: Elisaul Suarez Zambrano

2308

Closely monitored alpha-fetoprotein allows early detection of hepatocellular carcinoma recurrence after orthotopic liver transplantation

Poster Presentation





Presenter: Magdalena Hahn

2310

Predictors of survival of patients with hepatocellular carcinoma in best supportive care

Poster Presentation

Presenter: Claudia Campani

2390

Serum exosomal miRNA-720 as a diagnostic marker for hepatocellular carcinoma

Poster Presentation

Presenter: Jeong Won Jang

2530

Prospective evaluation of combining three biomarkers and image tools for early detection of hepatocellular carcinoma: an interim analysis

Poster Presentation

Presenter: Hyung Joon Yim

## Liver tumours: Experimental and pathophysiology

57

Mixed HCC-CCA originates from hepatic progenitor cells, is dependent on IL6 signaling and is ablated by senolytic agents

Oral Presentation

Presenter: Nofar Rosenberg

277

Cancer-associated fibroblasts nurture LGR5 marked liver tumour-initiating cells and promote their metastasis

Poster Presentation

Presenter: Qiuwei Pan

328

Molecular insights into the tumour suppressor role of Protein Phosphatase 2A B56 delta complex in human liver, and its clinically relevant inhibition by cancerous inhibitor of PP2A

Poster Presentation

Presenter: Judit Domenech Omella

336

Identification of new dominant neoantigens in hepatocellular carcinoma based on a single plasmid system with co-expressing patient's HLA and antigen

Poster Presentation

Presenter: Pu Chen

457



Polypeptide N-acetylgalactosaminyltransferase 14 mediated O-glycosylation on prohibitin-2 serine 161 modulates cell growth, migration and drug susceptibility in hepatocellular carcinoma

Poster Presentation

Presenter: Chau-Ting Yeh

532

Gut bacteria modulate anti-tumour immunity in patients with hepatocellular carcinoma

Poster Presentation

Presenter: Dhruvi Devshi

553

Lack of the E3-ubiquitin ligase TRIM21 promotes higher emergence of hepatocellular carcinoma nodules in diabetic mice with non-alcoholic steatohepatitis

Poster Presentation

Presenter: Ghania Kara-Ali

609

Role of autophagy-mediated neuropilin-1 degradation on lenvatinib efficacy in human hepatocarcinoma

Poster Presentation

Presenter: Paula Fernández-Palanca

628

Different acylcarnitines tissue profiles as metabolomics signatures of human hepatocellular carcinoma in non-alcoholic fatty liver disease according to fibrosis level

Poster Presentation

Presenter: Benjamin Buchard

641

Hepatocellular carcinoma alters granulopoiesis to produce neutrophils with an immature phenotype

Poster Presentation

Presenter: Daniel Geh

711

Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumour-stroma crosstalk in experimental models

Oral Presentation

Presenter: Paula Olaizola

731

Hippo inactivation drives BMI1-associated proliferative hepatocarcinogenesis in chronic hepatitis B virus infection

Poster Presentation

Presenter: Ruth Broering

788

RNA-Seq based transcriptome analysis revealed inhibiting methionine aminopeptidase 2 prevented hepatocellular carcinoma with inhibited angiogenesis



Poster Presentation

Presenter: Yongtao Wang

844

Proteomic analysis of bile in the rat thioacetamide model reveals new mechanisms in human cholangiocarcinogenesis

Poster Presentation

Presenter: Leticia Colyn

855

Expression of hepatitis B surface antigen in vivo and in vitro induces endoplasmic reticulum stress, impairs autophagy and promotes proliferation

Poster Presentation

Presenter: Ruth Broering

857

Induction of branching morphogenesis in cholangiocarcinoma organoids in vitro improves similarity with the original tumour

Oral Presentation

Presenter: Gilles van Tienderen

861

Cross-talk between cholangiocarcinoma cells and extracellular microenvironment drives desmoplastic matrix deposition

Poster Presentation

Presenter: Gilles van Tienderen

877

DNA methylation regulates lncRNAs compromising hepatic identity during hepatocarcinogenesis

Poster Presentation

Presenter: Miriam Recalde

895

Inhibiting IRE1a-endonuclease activity potentiates the effect of doxorubicin in hepatocellular carcinoma

Poster Presentation

Presenter: MARIA KOPSIDA

918

Genetic ablation of miR-22 fosters hepatic carcinogenesis in mice

Poster Presentation

Presenter: Monika Gjorgjieva

938

Focal nodular hyperplasia: a response to portal vein thrombosis followed by a sequence of arterio-portal shunting, hyperperfusion, focal retrograde sinusoidal blood and Wnt flow, and Wnt-induced activation of the bud maturation sequence

Poster Presentation



Presenter: IanR Wanless

1017

Hepatocellular carcinoma and neutrophils - towards understanding positive and negative impacts on treatments and progression

Poster Presentation

Presenter: Helen Louise Reeves

1179

Dynamic organotypic culture of primary liver cancer as a personalised immunocompetent drug screening platform for immuno-oncology

Poster Presentation

Presenter: Ravi Jagatia

1187

High plasma level of osteopontin, a potential biomarker in hepatocellular carcinoma, is associated with weakened anti-tumour immunity

Poster Presentation

Presenter: Tengfei Si

1209

The uptake of extracellular lipids promotes cholangiocarcinoma progression

Poster Presentation

Presenter: Mikel Ruiz de Gauna

1269

Peroxiredoxin 2 is a target for hepatocellular carcinoma chemoprevention

Poster Presentation

Presenter: Eugénie Schaeffer

1287

Loss of Actin-Binding LIM protein (ABLIM) plays a potential role in migratory cholangiocyte transformation

Poster Presentation

Presenter: Lea Duwe

1398

Modulation of the cholangiocarcinoma stem-like compartment by monounsaturated fatty acids

Type to be confirmed

Presenter: Giulia Lori

1560

Cyclophilin D knockout promotes cell death pathways in preventing HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH

Poster Presentation

Presenter: Winston Stauffer

1746



Ribosomal protein encoding genes: potential drivers of primary sclerosing cholangitis associated cholangiocarcinoma

Poster Presentation

Presenter: Megan Illingworth

1774

Stemness features during cholangiocarcinoma progression in vivo: characterization of primary and metastatic stem-like cells

Poster Presentation

Presenter: Margherita Raggi

1840

miR34a-5p is a target of E2F2 transcription factor in MAFLD-related HCC

Poster Presentation

Presenter: Maider Apodaka-Biguri

1975

TIA1 in fatty liver disease and hepatocellular carcinoma

Poster Presentation

Presenter: Dobrochna Dolicka

2083

Mitochondrial damage, revealed as key factor in cabozantinib efficacy against hepatocellular carcinoma, is potentiated by the BH3-mimetic navitoclax

Poster Presentation

Presenter: Anna Tutusaus

2207

PMEPA1: an oncogene in hepatocellular carcinoma linked to TGF-beta signaling

Oral Presentation

Presenter: Carmen Andreu-Oller

2228

Mutations in BAP1 drive tumour sensitivity to programmed cell death in patient-derived cholangiocarcinoma organoids

Poster Presentation

Presenter: Shaojun Shi

2267

Integrative clustering of multiple genomic data using organoid model with application to subtype analysis in intrahepatic cholangiocarcinoma

Poster Presentation

Presenter: Hee Seung Lee

2349

Role of soluble adenylyl cyclase in the formation and growth of liver tumours

Poster Presentation

Presenter: Jung-Chin Chang



2417

A targeted screen identifies Dmbt1 as an oncogene in cholangiocarcinoma

Poster Presentation

Presenter: Pooya Shokoohi

2418

ACSL4-dependent ferroptosis promotes HCC progression

Poster Presentation

Presenter: Julia Piche

2497

Identification of risk factors for HBV-derived HCC using HLA-DPB1 genotype and HBV peptides for genome medicine

Poster Presentation

Presenter: Masaya Sugiyama

2506

Early Kupffer cell depletion does not affect hepatocellular carcinoma progression in mice

Poster Presentation

Presenter: Bart Vanderborght

2508

RELB activation drives tumour aggressiveness and predicts prognosis in hepatocellular carcinoma

Poster Presentation

Presenter: Luisa Nader

2571

Cross-talk between MerTK-expressing stromal cells and cholangiocarcinoma

Oral Presentation

Presenter: Mirella Pastore

## Liver tumours: Therapy

307

Yttrium-90 radioembolization versus drug-eluting beads chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase 2 randomized controlled trial

Oral Presentation

Presenter: Elisabeth Dhondt

380

Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

Oral Presentation

Presenter: Laura Izquierdo-Sánchez



598

Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma

Poster Presentation

Presenter: Elia Gigante

625

The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma

Poster Presentation

Presenter: Claudia Fulgenzi

671

Combination of cracity score with alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Poster Presentation

Presenter: Wei Teng

811

Survival of patients with advanced hepatocellular carcinoma treated with sorafenib in France during 2009-2018: analysis of the French hospital and claim database

Poster Presentation

Presenter: Jean-Pierre Bronowicki

1042

Textbook outcome after major hepatectomy for perihilar cholangiocarcinoma - definitions and influencing factors

Poster Presentation

Presenter: Christian Benzing

1043

A preferable signature of gut microbiota and bile acids predicted better outcomes of unresectable hepatocellular carcinoma to immune checkpoint inhibitors

Type to be confirmed

Presenter: Pei-Chang Lee

1047

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Poster Presentation

Presenter: Mathew Vithayathil

1120

Outcome predictors of gemcitabine-based or fluoropyrimidine-based chemotherapy for unresectable intrahepatic cholangiocarcinoma

Poster Presentation

Presenter: Chen-Ta Chi



1210

Transcatheter arterial chemoembolization (TACE) followed by conformal radiotherapy versus TACE alone for hepatocellular carcinoma: a western controlled trial

Oral Presentation

Presenter: Cyrille Feray

1276

Transarterial radioembolisation in non resectable hepatocellular carcinoma in curative strategies: a single centre experience

Poster Presentation

Presenter: Helene Regnault

1286

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study

Poster Presentation

Presenter: Antonio D'Alessio

1356

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Oral Presentation

Presenter: Antonio D'Alessio

1579

Comparative effectiveness of treatment for early-stage intrahepatic cholangiocarcinoma

Poster Presentation

Presenter: Yi-Te Lee

1632

Twenty-year trends in radiofrequency ablation for treatment-naive hepatocellular carcinoma within the Milan criteria

Poster Presentation

Presenter: SE YOUNG JANG

1672

Incidence of hepatocellular carcinoma reduced in chronic hepatitis B patients treated with entecavir plus Biejia-Ruangan: extended follow-up of a multicenter, randomised, double-blinded, placebo-controlled trial

Poster Presentation

Presenter: Dong Ji

1687

In vitro and in vivo preclinical efficacy of PD-L1-targeted liposomal doxorubicin as a combined therapy for the treatment of hepatocellular carcinoma

Type to be confirmed

Presenter: Daniela Gabbia





1815

LiMAx facilitates patient selection prior radioembolization for patients with hepatocellular carcinoma in liver cirrhosis

Poster Presentation

Presenter: Catherine Leyh

1829

The efficacy of molecular targeted therapies after atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC) in Japan

Poster Presentation

Presenter: Kaoru Tsuchiya

1894

The LiMAx level before transarterial chemoembolization or radioembolization is a predictor for short-time survival in patients with early stage HCC

Poster Presentation

Presenter: Janett Fischer

1923

Implementation of a new prognostic scoring system after major hepatectomy in curative intent for perihilar cholangiocarcinoma

Poster Presentation

Presenter: Christian Benzing

1986

The effect of discordance between preoperative imaging and postoperative pathology on the prognosis of hepatocellular carcinoma

Poster Presentation

Presenter: Woo Sun Rou

2112

Early Nivolumab addition to Regorafenib in patients with hepatocellular carcinoma progressing under 1st line therapy (GOING trial). Interim analysis and safety profile

Poster Presentation

Presenter: Marco Sanduzzi Zamparelli

2274

Impact of endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy

Poster Presentation

Presenter: Christian Möhring

2314

Interleukin 10 and Interferon Gamma levels are elevated in patients with hepatocellular carcinoma showing response to treatment with atezolizumab and bevacizumab

Poster Presentation

Presenter: Sabine Lieb



2381

Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma: a real-world analysis

Poster Presentation

Presenter: Benedetta Stefanini

2407

Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study

Poster Presentation

Presenter: David J. Pinato

2444

Efficacy and safety of atezolizumab and bevacizumab in real-world treatment of advanced hepatocellular carcinoma

Poster Presentation

Presenter: Fabian Finkelmeier

2480

GALAD score correlates with therapy response for transarterial and systemic therapies in patients with hepatocellular carcinoma

Poster Presentation

Presenter: Anne Olbrich

2621

Liver transplantation for patients with fibrolamellar hepatocellular carcinoma: a comprehensive multicenter analysis to support future decision making

Oral Presentation

Presenter: Marco Claasen

## Molecular and cellular biology

249

Role of Monocyte chemoattractant protein-induced protein 1 in liver fibrosis and activation of hepatic stellate cells

Poster Presentation

Presenter: Natalia Pydyn

436

The genomic landscape of IDH1 mutant intrahepatic cholangiocarcinoma: a multicentre comprehensive analysis

Poster Presentation

Presenter: Margherita Rimini

536

Isolation of hepatocytes from various liver tissues by a novel, semi-automated perfusion technology



Poster Presentation

Presenter: Ralf Weiskirchen

612

Human amnion-derived mesenchymal stem cells pre-conditioning inhibits inflammation and apoptosis of immune and parenchymal cells in an in vitro model of liver ischemia/reperfusion

Poster Presentation

Presenter: Giovanni Zito

700

NFATc1 drives progressive liver inflammation and fibrosis by regulating pro-apoptotic stress responses

Oral Presentation

Presenter: Muhammad Umair latif

705

Ptpn1 deletion protects oval vells against lipoapoptosis by favoring lipid droplet formation and dynamics

Poster Presentation

Presenter: Pilar Valdecantos

712

Accurate detection of HBV splice variant DNA by using long-read sequencing

Poster Presentation

Presenter: Sanne Hulspas

820

Primary cilia in biliary regeneration - a potential approach to improve outcomes in liver transplantation

Oral Presentation

Presenter: Hannah Esser

831

The identification and characterization of novel bile acid-derived Farnesoid X Receptor agonists

Poster Presentation

Presenter: Dannielle Kydd-Sinclair

1064

Human antigen R (HuR) is a master regulator of hepatic glucose metabolism

Oral Presentation

Presenter: Sofia Lachiondo-Ortega

1130

MiR-122, the regulator of the immune privileged liver

Type to be confirmed

Presenter: Maytal Gefen

1182



SARS-CoV-2 induces pericyte procoagulant response associated with portal vein microthrombosis and intrapulmonary vascular dilations in fatal COVID-19

Poster Presentation

Presenter: Massimiliano Cadamuro

1238

Dual ileal/renal-liver bile acid transporter inhibitors with different transporter selectivity in vitro differentially increase faecal and urinary bile acid excretion in organic anion transporting polypeptide 1a/1b knockout mice in vivo

Poster Presentation

Presenter: Ellen Strängberg

1239

Integrated bile lipidome and meta-proteome analysis classifies lipid species and microbial peptides predictive of carcinoma of the gall bladder

Poster Presentation

Presenter: Nupur Sharma

1270

Novel anti-cholestatic treatment strategies by combining inhibition of the Apical sodium-dependent bile acid transporter with stimulation of urinary bile salt excretion or lowering bile salt synthesis

Oral Presentation

Presenter: Roni Kunst

1290

The effects of apurimic/apirimidinic endonuclease 1 as a sensitizer to sorafenib in hepatocellular carcinoma

Poster Presentation

Presenter: Mahzeiar Rohr-Udilova

1293

The type III collagen degradome: establishment of tissue formation and degradation epitopes reflecting fibrosis resolution or fibrogenesis

Poster Presentation

Presenter: Mette Juul Nielsen

1354

Soluble guanylyl cyclase expression and signaling in different types of liver fibrosis

Poster Presentation

Presenter: Ksenia Nader

1408

Impact of maternal obesity on liver disease in the offspring: a comprehensive transcriptomic analysis and validation of results

Poster Presentation

Presenter: Beat Moeckli

1515



Liver directed in utero AAV gene therapy for maple syrup urine disease in a neonatal lethal murine model

Poster Presentation

Presenter: Kate Mullany

1612

Patient-derived hepatocellular carcinoma organoids as predictors of Treatment Response

Poster Presentation

Presenter: Kyung Joo Cho

1637

Dissecting A-to-I RNA editome of liver macrophages in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Achilleas Fardellas

1702

The role of OFD1 and loss of primary cilia in cholangiocarcinoma: a novel promising therapeutic target

Oral Presentation

Presenter: Pietro Carotenuto

1711

Restoring bone marrow hematopoietic stem cells (BM-HSC) reserve augments regression of fibrosis and regeneration in animal model of cirrhosis

Type to be confirmed

Presenter: Nidhi Nautiyal

1738

Human resident liver macrophages protect against metabolic stress in obesity

Poster Presentation

Presenter: Emelie Barreby

1741

Reversal of epithelial-mesenchymal transition in a cholangiocarcinoma cell line by genetic targeting of sulfatide synthesis

Poster Presentation

Presenter: Gloria Álvarez-Sola

1760

Unravelling the circadian transcriptome and epigenome of the human liver

Poster Presentation

Presenter: Atish Mukherji

1796

Single-cell dynamics of interacting mesenchymal and leukocyte populations in advanced NASH

Poster Presentation

Presenter: Kim Ravnskjaer



1802

Dysregulated glutamine metabolism in intrahepatic cholangiocarcinoma: a perspective for targeted therapy

Poster Presentation

Presenter: Michela Anna Polidoro

1849

Microfluidic 3-dimensional bioprinting and 2-dimensional micropatterns as tools to bioengineer biliary ducts

Poster Presentation

Presenter: Pascale Dupuis-Williams

1863

Mcpip1 fl/fl LysM Cre mice as an animal model of TNF $\alpha$ -dependent liver endothelial cell dysfunction in humans with chronic inflammation

Poster Presentation

Presenter: Jerzy Kotlinowski

1906

Peroxisome proliferator activated receptor gamma regulates patatin-like phospholipase domain-containing protein 3 in adipocytes in vitro and in vivo in a mouse model of nonalcoholic steatohepatitis

Poster Presentation

Presenter: Emmanuel Dauda Dixon

1948

Animal variants of sodium-taurocholate co-transporting polypeptide permitting hepatitis B virus infection

Poster Presentation

Presenter: Fuwang Chen

2007

Cholangiocarcinoma-on-chip: a platform for 3D liver tumour model

Poster Presentation

Presenter: Michela Anna Polidoro

2279

Regulation of cholangiocyte ciliogenesis by soluble adenylyl cyclase

Poster Presentation

Presenter: Hang Lam Li

2316

CRISPR perturbation in iPSC-derived hepatic stellate cells reveals role for TNF-driven interferon response in chronic liver disease

Poster Presentation

Presenter: Kelly Haston



## NAFLD: Clinical aspects except therapy

62

The prevalence of non-alcoholic fatty liver disease in the United Kingdom: a systematic review and meta-analysis

Poster Presentation

Presenter: Yusef Alenezi

162

Hepatic steatosis is not associated with increased mortality in the elderly - time for a paradigm shift?

Type to be confirmed

Presenter: Laurens van Kleef

214

Health-related quality of life is impaired in people living with HIV and hepatic steatosis

Poster Presentation

Presenter: Maurice Michel

299

Moderate alcohol consumption is associated with significant fibrosis progression in non-alcoholic fatty liver disease - a cohort study with over 17 years of follow-up

Poster Presentation

Presenter: Julia Blomdahl

324

Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: korean military population-based cross-sectional study

Poster Presentation

Presenter: Jaejun Lee

388

Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis

Poster Presentation

Presenter: James Thomas

468

Association of non-alcoholic fatty liver disease and fibrosis with incident dementia and cognitive function: the Rotterdam Study

Poster Presentation

Presenter: Laurens van Kleef

497

High meat consumption is prospectively associated with non alcoholic fatty liver disease and liver fibrosis markers

Poster Presentation

Presenter: Dana Ivancovsky Wajcman



568

Relevance of diabetes medication on recruitment criteria for clinical studies in patients with nonalcoholic fatty disease and type 2 diabetes mellitus

Poster Presentation

Presenter: Michael Holzhey

651

The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective study using UK Biobank data

Type to be confirmed

Presenter: Theresa Hydes

743

Comorbidity severity scores and cardiovascular comorbidities in patients with non-alcoholic steatohepatitis (NASH), with and without cirrhosis, in a real-world setting

Poster Presentation

Presenter: Jeffrey Lazarus

767

NAFLD association with renal impairment in type 2 diabetes patients

Poster Presentation

Presenter: Jesús Rivera

779

The impact of liver fibrosis on the immune response to SARS-CoV-2 vaccination in metabolic associated fatty liver disease patients

Poster Presentation

Presenter: Marta Freitas

803

Non-alcoholic steatohepatitis is also becoming a major liver transplant indication in Spain, a historically low risk area

Poster Presentation

Presenter: Laura Martínez-Arenas

853

Total healthcare cost and characteristics associated with higher change in cost in patients with non-alcoholic steatohepatitis

Poster Presentation

Presenter: Zobair Younossi

864

Nonalcoholic fatty liver disease (NAFLD) / nonalcoholic steatohepatitis (NASH) is associated with worse outcomes in patients hospitalised for COVID-19: a real-world analysis of a large population from the premier healthcare database

Poster Presentation

Presenter: Frank Tacke





914

Estimating the prevalence of advanced fibrosis due to nonalcoholic fatty liver disease in the United States population

Poster Presentation

Presenter: Naim Alkhouri

920

Non-alcoholic fatty liver disease associated liver fibrosis is linked with the severity of coronary artery disease mediated by systemic inflammation

Poster Presentation

Presenter: Xianbin Cai

954

Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease related cirrhosis: a meta-analysis of observational studies

Poster Presentation

Presenter: Roberta Stupia

1058

Real-world prevalence of metabolic associated fatty liver disease (MAFLD) and fibrotic-non-alcoholic steatohepatitis (NASH) in patients with obesity (PwO) in an outpatient specialist clinic in Italy

Poster Presentation

Presenter: Federico Ravaioli

1099

Young-onset diabetes mellitus increases the risk of liver-related events in patients with non-alcoholic fatty liver disease

Oral Presentation

Presenter: Xinrong Zhang

1162

Postprandial dysfunction in metabolic associated fatty liver disease (MAFLD)

Poster Presentation

Presenter: Josephine Grandt

1387

Lean non-alcoholic fatty liver disease patients from the global NASH registry

Poster Presentation

Presenter: Zobair Younossi

1394

Burden of hepatocellular cancer in patients with type-2 diabetes mellitus: a 2011-2020, french, longitudinal, retrospective, national, cohort study

Oral Presentation

Presenter: Lucia Parlati

1400



Automated FIB-4 calculator and targeted provider education improved referral of at-risk fibrotic NAFLD patients

Poster Presentation

Presenter: Cindy Piao

1425

Long term outcomes of non-alcoholic fatty liver disease (NAFLD) and metabolic associated fatty liver disease (MAFLD)

Poster Presentation

Presenter: Zobair Younossi

1429

MARC1 and HSD17B13 variants have protective effects on liver injury in the obese: results from a prospective cohort of patients undergoing bariatric surgery

Poster Presentation

Presenter: Marcin Krawczyk

1432

The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease (NAFLD): data from national health and nutrition examination survey (NHANES) 2005-2018

Poster Presentation

Presenter: Zobair Younossi

1820

Non-alcoholic fatty liver disease patients have worse health-related quality of life compared to the general population irrespective of their fibrosis stage: results from a prospective multicenter UK study

Oral Presentation

Presenter: Margarita Papatheodoridi

1837

Metabolic dysfunction-associated fatty liver disease increases cardiovascular risk regardless of classical risk factors

Poster Presentation

Presenter: María Del Barrio Azaceta

1861

Changes in hepatic fat fraction as assessed by MRI-PDFF are correlated with changes in markers of hepatic inflammation, disease activity and fibrosis in biopsy-proven non-cirrhotic NASH with fibrosis

Poster Presentation

Presenter: Samuel Daniels

1870

The metabolic dysfunction-associated fatty liver disease definition, regardless of its clinical subclassification, identifies patients at high risk for liver disease progression

Poster Presentation

Presenter: María Del Barrio Azaceta



2036

Assessment of the prevalence of nonalcoholic fatty liver disease, its severity, and comorbidities in lean americans: national health and nutrition examination surveys (NHANES) with transient elastography assessment from 2017 to 2018

Poster Presentation

Presenter: Emily Truong

2044

Coagulation imbalance is associated with hepatic fibrosis and vascular complications in patients with type2 diabetes and NAFLD

Poster Presentation

Presenter: Francesca Lombardi

2070

Presence of two or more metabolic risks regardless of fatty liver is a risk factor for significant hepatic fibrosis

Poster Presentation

Presenter: Huiyul Park

2140

Pregnancy as a unique opportunity to identify NAFLD in women: a prospective assessment

Poster Presentation

Presenter: Tatyana Kushner

2467

N-terminal propeptide of type III collagen (PRO-C3) based risk for liver fibrosis predict cardiovascular events in nonalcoholic fatty liver disease

Poster Presentation

Presenter: Francesco Baratta

2470

Genetic risk of fatty liver disease and mortality in the general population

Poster Presentation

Presenter: Helene Gellert-Kristensen

2541

Role of NAFLD-associated genetic variants on renal function in patients with nonalcoholic fatty liver disease

Poster Presentation

Presenter: Laura D'Erasmus

2543

The association between nonalcoholic fatty liver disease and insulin resistance within normal glucose level population

Poster Presentation

Presenter: chun-yi Wang

2616



Chronic pruritus represents a major burden in non-cholestatic hepatobiliary disorders

Poster Presentation

Presenter: Andreas E Kremer

## NAFLD: Diagnostics and non-invasive assessment

11

Identifying advanced liver disease in asymptomatic patients in primary care: an evaluation of patient outcomes 24 months after implementing a primary care liver pathway and community liver service

Poster Presentation

Presenter: Tina Reinson

30

Predictive survival-time modelling of Non-Alcoholic Steatohepatitis (NASH) fast progressors using real-world evidence

Poster Presentation

Presenter: Nils Svängård

92

Impact of type 2 diabetes on the accuracy of non-invasive tests of liver fibrosis: a comprehensive analysis of 1,051 biopsy proven NAFLD patients showing clinical implications

Oral Presentation

Presenter: Jerome Boursier

121

Online education significantly improved gastroenterologists' knowledge of the diagnostic and monitoring techniques used in liver fibrosis

Poster Presentation

Presenter: James White

156

Health outcomes and risk assessment in chronic liver disease (HERALD): a large Swedish research platform

Poster Presentation

Presenter: Emilie Toresson Grip

181

Impact of alcohol use on the diagnostic performance of serum-based indices for fatty liver disease

Poster Presentation

Presenter: Oscar Danielsson

201

Liver stiffness on magnetic resonance elastography and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants

Poster Presentation

Presenter: Veeral Ajmera



245

Utilising features of metabolic syndrome to cost-effectively improve metabolic dysfunction-associated fatty liver disease diagnosis rates

Poster Presentation

Presenter: Cassandra Baiano

325

Machine learning algorithms identify novel biomarker combinations for NAFLD

Oral Presentation

Presenter: Jenny Lee

345

Non-invasive assessment of type VII collagen degradation is related to NAFLD activity but not fibrosis stage

Poster Presentation

Presenter: Mette Juul Nielsen

374

Reliability of histologic disease activity measures in non-alcoholic fatty liver disease (NAFLD) and development of an expanded NAFLD activity score

Poster Presentation

Presenter: Rohit Loomba

488

Evaluating future risk of NAFLD fibrosis in adolescents: prediction and decision curve analysis

Poster Presentation

Presenter: Kushala Abeysekera

547

Fibroscan-AST (FAST) score predicts liver-related outcomes in 1683 HIV-infected patients at risk for NAFLD

Type to be confirmed

Presenter: Giada Sebastiani

561

Quantification of hepatic steatosis in patients with non-alcoholic fatty liver disease: comparison of sound speed, attenuation coefficient and continuous CAP measurements with MRI-PDFF

Poster Presentation

Presenter: Rémi Collin

679

Community NAFLD screening programme in patients with type 2 diabetes mellitus indicates high burden of undiagnosed liver disease

Poster Presentation

Presenter: Emma McCormick

695



Non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus in Greenland  
Poster Presentation

Presenter: Rasmus Hvidbjerg Gantzel

785

A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640: results from the FASCINATE-1 study

Poster Presentation

Presenter: Rohit Loomba

801

Enhanced Liver Fibrosis test in predicting severe liver-related outcomes in the general population

Poster Presentation

Presenter: Kustaa Saarinen

812

Radiowater perfusion PET of the liver, and its value as a biomarker to discriminate between NAFLD and NASH, and activity and fibrosis grade

Poster Presentation

Presenter: Olof Johansson

903

The combination of the ELF and FIB-4 scores have high predictive performance for significant fibrosis in patients with NAFLD

Poster Presentation

Presenter: Zobair Younossi

923

Association of the biological age and the level of global deoxyribonucleic acid methylation with metabolic parameters in patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Anastasiia Radchenko

951

LEARN algorithm: a novel option for predicting non-alcoholic steatohepatitis

Poster Presentation

Presenter: Gang Li

959

Head to head comparison between MEFIB versus MAST for identification of high-risk patients with NAFLD

Poster Presentation

Presenter: Beom Kyung Kim

993

MRI assessment (cT1) with LiverMultiScan following VCTE improves the diagnostic yield for high-risk NASH

Poster Presentation



Presenter: Naim Alkhouri

1143

The PNPLA3 (rs738409) G/G-genotype is associated with presence of NASH and increased long-term risk of cirrhosis in NAFLD

Poster Presentation

Presenter: Magnus Hagström

1149

Hepatic expression of secreted calcium-binding protein 2 by hepatic stellate cells is associated with human non-alcoholic fatty liver disease progression

Poster Presentation

Presenter: Frederik Larsen

1154

Clinicians' perspectives on barriers and facilitators for the adoption of non-invasive liver tests: a mixed-method study

Poster Presentation

Presenter: Yasaman Vali

1252

Decreases in liver cT1 accurately reflect histological improvement induced by therapies in NASH with enhanced sensitivity to fibrosis change: a multi-centre pooled cohort analysis

Type to be confirmed

Presenter: Mazen Nouredin

1315

Validation of the new 2021 EASL algorithm for the non-invasive diagnosis of advanced liver fibrosis in non-alcoholic fatty liver disease

Oral Presentation

Presenter: Clémence M Sarowar

1335

Ectopic fat deposition in the liver and pancreas and the presence of excess visceral adipose tissue significantly increase hospitalisation risk following COVID-19

Poster Presentation

Presenter: Tom Gualandi

1365

Genomic and metabolomic profiles and their correlations with preclinical signs of endothelial dysfunction measured by peripheral arterial tonometry in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Mario Masarone

1367

Determinants of liver stiffness measurements in patients with NAFLD - an individual patient data meta-analysis

Poster Presentation



Presenter: Ferenc Mozes

1385

Knowledge of liver fibrosis stage among adults with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis improves adherence to life style changes

Poster Presentation

Presenter: Carrieri Lazarus

1403

The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH

Poster Presentation

Presenter: Mazen Nouredin

1420

Independent determinants of CAP values in healthy individuals with dysmetabolism

Poster Presentation

Presenter: Cristiana Bianco

1471

Performance of liver-related clinical scores in the SAPHIR study

Poster Presentation

Presenter: Lorenz Balcar

1481

Correlations of 2D-Shear wave and transient elastography liver stiffness measurements in patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Dimitrios Karagiannakis

1498

Utility of FIB-4 thresholds to identify patients with at-risk F2-F3 NASH based on screening data from a 2000 patient biopsy confirmed cohort of resmetirom Phase 3 clinical trial, MAESTRO-NASH

Oral Presentation

Presenter: Jörn Schattenberg

1500

Performance of the Enhanced Liver Fibrosis (ELF) test in real world practice versus clinical trials of non-alcoholic steatohepatitis

Poster Presentation

Presenter: Zobair Younossi

1506

Machine learning using simple non-invasive tests of fibrosis and B-mode ultrasound for the prediction of adverse liver-related outcomes in NAFLD

Poster Presentation

Presenter: Heather M Kosick





1548

Incorporating a two-tiered liver fibrosis assessment into annual diabetes review in primary care - 3 year follow up study

Poster Presentation

Presenter: Dina Mansour

1549

New scoring system using MRI with AST for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis

Poster Presentation

Presenter: Kento Imajo

1599

Impact of artificial intelligence assistive tool on the histopathologic review of fibrosis in non-alcoholic steatohepatitis patients

Poster Presentation

Presenter: aileen Chng

1601

PRO-C3 based sequential algorithm can screen high-risk NASH and severe fibrosis in asian NAFLD population

Poster Presentation

Presenter: Liang-Jie Tang

1603

Real-world use of the FIB-4 calculator in primary care workflows to screen for advanced non-alcoholic fatty liver disease in a large US health system

Poster Presentation

Presenter: George Therapondos

1719

In silico identification and validation of plasma Ficolin-2 (FCN-2) as non-invasive biomarker of fibrosis in Non-alcoholic Fatty Liver Disease (NAFLD)

Poster Presentation

Presenter: Noel Salvoza

1721

A lower cut-off of liver stiffness measurement (8/13) kPa performs better than Baveno 6 criteria for advanced chronic liver disease in patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Sagnik Biswas

1735

High prevalence of multi-organ steatosis and fibroinflammation, identified by multi-parametric magnetic resonance imaging, in people with type 2 diabetes

Poster Presentation

Presenter: Nicole Eichert



1805

Plasma TREM2, a novel non-invasive biomarker for diagnosis of NASH in NAFLD patients with elevated liver stiffness

Poster Presentation

Presenter: Charlotte Wernberg

1813

Unbiased clustering of exhaled breath profiles in metabolic dysfunction-associated fatty liver disease identifies a patient phenotype at higher risk of disease progression

Poster Presentation

Presenter: Rohit Sinha

1822

The pericellular basement of the hepatocytes is highly affected by bariatric surgery in obese patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Ida Lønsmann Lønsmann

1855

A re-appraisal of the diagnostic performance of ultrasonography for fatty liver disease

Poster Presentation

Presenter: Chul-min Lee

1886

Cost utility analysis for screening for fibrotic NASH in the type 2 population from European countries

Poster Presentation

Presenter: Mazen Nouredin

1890

Free Light Chains as a potential biomarker of inflammation and fibrosis in non-alcoholic steatohepatitis

Poster Presentation

Presenter: Antonio Liguori

1893

12-week very low calorie diet in NAFLD induces rapid improvements in biomarkers of necro-apoptosis and fibrogenesis of a magnitude comparable to those seen in phase 2 drug trials

Poster Presentation

Presenter: Jadine Scragg

1907

Signature of circulating hepatic proteins detects fibrosing-steatohepatitis in progressive non-alcoholic fatty liver disease

Poster Presentation

Presenter: Olivier Govaere

1968



Peripheral blood mononuclear cells mitochondrial copy number and adenosine triphosphate inhibition test in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Eileen Yoon

1989

Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era

Poster Presentation

Presenter: Dae Won JUN

1990

Assessing the applicability of non-invasive diagnostic tests (NITs) in non-alcoholic fatty liver disease: an international qualitative study

Poster Presentation

Presenter: Maja Thiele

2012

Evaluation of the performance of a novel digital pathology method for the continuous quantification of steatosis, ballooning and inflammation in liver biopsies and its correlation with NASH-CRN scores in patients with NASH

Poster Presentation

Presenter: Louis Petitjean

2029

Can combination of M2BPGi and APRI help endocrinologists refer patients with advanced hepatic fibrosis to hepatologists?

Poster Presentation

Presenter: Mi Mi Kim

2090

The relationship between foetal head circumference growth trajectories and nonalcoholic fatty liver disease in adolescents

Poster Presentation

Presenter: Jeffrey Lee

2152

Liver stiffness assessed by transient elastography predicts clinical events in patients with T2DM and NAFLD

Poster Presentation

Presenter: Jesús Rivera

2226

Repeated noninvasive liver biopsy surrogate LIVERFASt correlates with BMI and liver enzyme improvements

Poster Presentation

Presenter: Victor de Lédighen



2290

Increased liver stiffness on vibration controlled transient elastography (Fibroscan) as a predictor of all-cause mortality in people with fatty liver disease

Poster Presentation

Presenter: Michael Braude

2298

Magnetic resonance imaging-based biomarker accurately identifies patients with nonalcoholic steatohepatitis and significant liver fibrosis: a multicentre, international, validation study

Poster Presentation

Presenter: David Marti-Aguado

2475

Diagnostic accuracy of MRE for staging hepatic fibrosis in patients with NAFLD

Poster Presentation

Presenter: Manuel Romero Gomez

2482

Aldafermin quantitatively improves inflammation in a 24-week clinical trial in patients with nonalcoholic steatohepatitis

Poster Presentation

Presenter: Tian Lan

2528

Clinical and economic evaluation of community-based preventative screening strategies for non-alcoholic fatty liver disease in people with Type-2 diabetes mellitus

Poster Presentation

Presenter: Roberta Forlano

2529

Confounding factors in diagnostic performance of magnetic resonance elastography for staging liver fibrosis in patients with non-alcoholic fatty liver disease: an individual patient data meta-analysis

Poster Presentation

Presenter: Manuel Romero Gomez

2567

Is it possible to identify nonalcoholic steatohepatitis and the associated degree of fibrosis by noninvasive methods in patients with MAFLD?

Poster Presentation

Presenter: José Casado

## NAFLD: Experimental and pathophysiology

185

The DNA damage response is involved in the metabolic dysregulation of MAFLD patients via inefficient fatty acid oxidation



Poster Presentation

Presenter: Beatriz Gómez Santos

206

Hepatic miR-144 drives fumarase activity preventing NRF2 activation during obesity

Poster Presentation

Presenter: Valerio Azzimato

209

TNFR1 inhibition reduces lipogenesis and improves insulin resistance and fibrosis in NAFLD

Poster Presentation

Presenter: Heike Bantel

478

Obesity alters the partitioning of glycerol metabolism pathways in NAFLD

Poster Presentation

Presenter: Jack Carruthers

495

Human induced pluripotent stem cell-derived mesenchymal stem cells ameliorates mitochondrial oxidative dysfunction in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Min Kyung Park

683

Skeletal muscle-derived myokine affects insulin sensitivity and lipogenesis in a human hepatocyte spheroid model

Poster Presentation

Presenter: Jean-Baptiste Potier

728

Patient-derived liver organoids to reveal PNPLA3 I148M role in Non-Alcoholic Fatty Liver Disease

Poster Presentation

Presenter: Elia Casirati

747

Transcriptomic analysis confirms that PNPLA3 I148M variant is associated with impaired mitochondrial function and antioxidant response in 3D cultured human hepatic stellate cells and liver tissue of patients with NAFLD

Poster Presentation

Presenter: Elisabetta Caon

749

Unravelling the role of Protein Kinase D2 in the control of hepatic insulin sensitivity

Type to be confirmed

Presenter: Patricia Rada

769



HTD1801 (berberbine ursodeoxycholate), a unique single molecule with multiple beneficial effects in metabolic and liver diseases

Poster Presentation

Presenter: Leigh MacConell

842

Metabolic, biochemical, histopathological and transcriptomic effects of long-acting FGF21 analogue in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH

Poster Presentation

Presenter: Malte H. Nielsen

939

NAFLD-induced encephalopathy is associated with low-grade brain tissue hypoxia and inflammation, as well as cerebrovascular, glial, metabolic and behavioural alterations

Poster Presentation

Presenter: Anna Hadjihambi

974

The inhibition of the epigenetic effectors DNMT1 and G9a as a potential therapeutic strategy against the nonalcoholic fatty liver development

Oral Presentation

Presenter: José María Herranz

1019

The presence of interferon alters the progression of non-alcoholic fatty liver disease

Poster Presentation

Presenter: Michelle Møhlenberg

1125

Targeted metabolomics reveals alterations in one-carbon metabolism in NAFLD patients

Poster Presentation

Presenter: Mikkel Werge

1132

Metabolic NAFLD subtypes align with cardiovascular and genetic risk factors

Poster Presentation

Presenter: José M. Mato

1170

Deletion of ATR in hepatocytes improves NAFLD features by increasing mitochondrial function

Poster Presentation

Presenter: Maeva Saroul

1189

The AXL inhibitor bemcentinib reduces inflammation and fibrosis by inducing a dynamic change in macrophages and CD8+T cells subsets during experimental NASH

Poster Presentation

Presenter: Sturla M Groendal



1206

Human Liver Organoids with myeloid lineages model the multi-cellular crosstalk in Non-Alcoholic Steatohepatitis

Poster Presentation

Presenter: Milad Rezvani

1215

Senescence, hand in hand with hepatic iron overload during the progression of NAFLD

Poster Presentation

Presenter: Miren Bravo

1216

Increased liver content of omega-3-derived lipid mediators associates with enhanced mitochondrial oxidative phosphorylation, fatty acid oxidation and metabolic efficiency

Poster Presentation

Presenter: Cristina López-Vicario

1240

Factors associated with increased gut permeability and severity of liver disease in diabetic patients with NAFLD

Poster Presentation

Presenter: Roberta Forlano

1319

Increased burden of inherited IRF3 rare genetic variants in Europeans with severe Non-alcoholic fatty liver disease

Poster Presentation

Presenter: Luigi Chhatwal

1332

Sex-dependent hepatoprotective role of IL-22 in NAFLD-related fibrosis

Poster Presentation

Presenter: Mohamed Sanduzzi Zamparelli

1341

Identification of novel targets in adipose tissue involved in non-alcoholic fatty liver disease progression

Poster Presentation

Presenter: Jose M Lee

1346

Isoleucine and valine correct hepatic lipid processing, reduce liver steatosis and suppress inflammation in obese mice with manifest NASH

Poster Presentation

Presenter: Eveline Narayan

1355



Butyrate protects against diet-induced NASH and liver fibrosis and suppresses specific non-canonical TGFB signaling pathways in human hepatic stellate cells

Poster Presentation

Presenter: Eveline Gunn

1426

Experimental non-alcoholic fatty liver disease causes regional liver functional deficits while total metabolic liver function is preserved

Poster Presentation

Presenter: Peter Lykke Eriksen

1449

Hepatic lipid fingerprint reveals sex-dependent lipid droplet composition in metabolic associated fatty liver disease

Poster Presentation

Presenter: Elisabet Rodríguez-Tomàs

1493

Lipidomics and proteomics reveal mitochondrial dysfunction in liver and visceral adipose tissue from patients with nonalcoholic steatohepatitis

Poster Presentation

Presenter: Helena Castañé

1557

Machine learning assessment of liver biopsy images enabled the identification of metallothionein genes as determinants of fibrosis regression in NASH

Oral Presentation

Presenter: Michael D. Bereket

1643

Targeting liver glutaminase 1 modulates hepatic ammonia in experimental Non-Alcoholic Steatohepatitis

Poster Presentation

Presenter: Maria Mercado-Gómez

1645

Clinical relevance of an animal model of nonalcoholic steatohepatitis (NASH) and digital pathology with artificial intelligence (DP-AI) analyses of hepatic fibrosis

Poster Presentation

Presenter: Deming Xu

1682

Small changes in the metabolism of bile acids by the gut microbiota are associated to NASH pathogenesis

Poster Presentation

Presenter: Justine Gillard

1685





Unravelling the landscape of adipose tissue macrophages in human non-alcoholic fatty liver disease  
Poster Presentation

Presenter: Markus Boesch

1698

Atorvastatin attenuates diet-induced non-alcoholic steatohepatitis in ApoE\*3-Leiden mice by reducing hepatic inflammation

Poster Presentation

Presenter: José A. Inia

1762

Carnitine signature in liver corelates with nonalcoholic fatty liver disease progression

Poster Presentation

Presenter: Andrea Jiménez Franco

1773

Type 2 diabetes and religious fasting: effects on metabolism and liver steatosis

Poster Presentation

Presenter: Svenja Sydor

1783

The I48M PNPLA3 variant mitigates Niacin beneficial effects: how the genetic screening in non-alcoholic fatty liver disease (NAFLD) patients gains value

Poster Presentation

Presenter: Erika Paolini

1785

The co-presence of PNPLA3, MBOAT7 and TM6SF2 loss-of-functions impairs mitochondrial morphology and number in severe NAFLD patients

Poster Presentation

Presenter: Miriam Longo

1812

The association of spleen volume with sex, age, type 2-diabetes, and non-alcoholic fatty liver disease - initial results from more than 35,000 UK Biobank participants

Poster Presentation

Presenter: Samuel Johansson

1835

Targeting adipose tissue macrophages ameliorates hepatic injury in a murine model of NAFLD

Poster Presentation

Presenter: Celia Martínez Sánchez

1836

Multiplex immunostaining and transcriptomic profiling identify novel immune cell markers for non-alcoholic steatohepatitis and primary sclerosing cholangitis

Poster Presentation

Presenter: Adrien Guillot



1845

Phospholipid fingerprints reveal sex differences in the adipose tissue phospholipid composition from morbidly obese patients

Poster Presentation

Presenter: Gerard Baiges

1865

Ubiquitination of GSDMD regulated by NEDD4 is involved in hepatocyte pyroptosis of nonalcoholic steatohepatitis

Poster Presentation

Presenter: Rui Jin

1935

Unraveling the transcriptional dynamics of NASH pathogenesis affecting atherosclerosis development

Poster Presentation

Presenter: Anita M. Stokman

1978

Repeated weight cycling in obese mice improves hepatic inflammation

Poster Presentation

Presenter: Anita M. Stokman

1996

The functional roles of BMP10 in the pathogenesis of nonalcoholic fatty liver disease

Poster Presentation

Presenter: Wenjun Zhang

1998

Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with severe hepatic impairment

Poster Presentation

Presenter: Giridhar Tiruchera

2009

Amino acid glycine suppresses steatohepatitis and tumorigenesis in hepatocyte-specific phosphatase and tensin homolog knockout mice

Poster Presentation

Presenter: Kazuyoshi Kon

2054

Advanced quantitative phenotypic fibrosis and steatosis scoring is more superior to histology-based conventional staging in NASH animal models

Poster Presentation

Presenter: Li Chen

2068



Molecular characterization of metabolic associated fatty liver disease as an immune-mediated inflammatory disease: IMID associated fatty liver disease

Type to be confirmed

Presenter: Enrique García-Nieto

2074

Chemical suppression of adipose triglyceride lipase improves nonalcoholic steatohepatitis in a diabetic and hyperlipidemic mouse model

Poster Presentation

Presenter: Emmanuel Dauda Dixon

2077

Methionine adenosyltransferase 1a antisense oligonucleotides induce the fibroblast growth factor 21-driven recovery from obesity and associated hepatoesteatosis

Poster Presentation

Presenter: Xabier Buque

2113

NLRP3 inflammasome dependent cell death in myeloid cells drives liver inflammation and fibrosis in murine steatohepatitis

Poster Presentation

Presenter: Benedikt Kaufmann

2346

Two diseases, one model - assessing the suitability of FOZ mice to examine CVD in NAFLD

Poster Presentation

Presenter: Sebastian Bott

2350

Oleic acid-induced acute lung injury in Ob/Ob mice fed with high-fat-diet exacerbate bile acid uptake and liver injury that was reversed by antagonizing their entry

Poster Presentation

Presenter: Johnny Amer

2352

The ubiquitin-like modifier FAT10 is upregulated during NASH and impairs PPAR-alpha activity

Poster Presentation

Presenter: Ludivine Clavreul

2395

TNF-alpha knockout mice are protected from diet-induced NAFLD in a model of non-obese NAFLD

Poster Presentation

Presenter: Katharina Burger

2481

Low dose thyroid hormone improves hepatic mitochondrial fatty acid oxidation and rescues nonalcoholic fatty liver disease in mice

Poster Presentation



Presenter: Raghu Ramanathan

2527

Three-dimensional imaging of cleared human liver tissues reveals extensive fibrosis heterogeneity in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Buket Alpdogan

2551

In vivo functional genetic screen with a pooled-shRNA library for therapeutic targets of non-alcoholic fatty liver disease

Poster Presentation

Presenter: Yong-An Lee

2585

Hepatic insulin resistance is the basis of bile acid dysmetabolism in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Sami Qadri

2604

Heterogeneity of phosphatidylcholine metabolism in non-alcoholic fatty liver disease

Oral Presentation

Presenter: Sami Qadri

## NAFLD: Therapy

10

The effect of glucagon on rates of hepatic mitochondrial oxidation and pyruvate carboxylase flux in man assessed by positional isotopomer tracer analysis (PINTA)

Poster Presentation

Presenter: Kitt Falk Petersen

130

Identification of biomarkers of histological response in patients with non-cirrhotic NASH treated with Lanifibranor

Poster Presentation

Presenter: Jerome Boursier

133

TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in nonalcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study

Poster Presentation

Presenter: Kris Kowdley

136



Favorable lipid and pruritus profile of liver-distributed farnesoid X receptor agonist TERN-101 at clinically efficacious doses in nonalcoholic steatohepatitis phase 2a LIFT study

Poster Presentation

Presenter: Kris Kowdley

137

Liver-distributed farnesoid X receptor agonist TERN-101 demonstrates potent target engagement with a favorable exposure-response profile in nonalcoholic steatohepatitis patients

Poster Presentation

Presenter: Cara H. Nelson

194

EDP-297: a novel, highly potent, farnesoid X receptor agonist, results of a phase 1 study in healthy subjects

Poster Presentation

Presenter: Alaa Ahmad

258

Weight loss with semaglutide treatment or time-restricted feeding differentially improves non-alcoholic steatohepatitis in diet-induced obese insulin resistant mice

Poster Presentation

Presenter: Francois Briand

276

ECC4703, a full thyroid hormone receptor beta (THRb) agonist, demonstrated excellent selectivity and liver targeting properties and improvement of plasma lipid, NAFLD activity score and fibrosis in NASH animal model

Poster Presentation

Presenter: Jianfeng Xu

300

LIVRQNAc increases fatty acid oxidation in a primary human hepatocyte model of non-alcoholic steatohepatitis

Poster Presentation

Presenter: Matthew Russell

430

Assessment of therapeutic effect of liraglutide in newly established cell culture model of nonalcoholic and drug-induced fatty liver disease

Poster Presentation

Presenter: Tea Omanovic Kolaric

460

Efx treatment improved histopathology and noninvasive markers of liver injury and fibrogenesis to a similar extent in NASH patients with high-risk PNPLA3 genotypes, compared to those with lowest genetic risk: a post-hoc analysis of balanced study

Poster Presentation

Presenter: Erik Tillman



566

Oxygen-nutrient mismatch: a novel concept to explain how Obeticholic acid benefits NASH treatment

Poster Presentation

Presenter: Gerond Lake-Bakaar

653

Metabolomic changes in NASH phenotype liver-on-a-chip caused by INI-678, a small molecule HSD17B13 inhibitor, supports a role for HSD17B13 in inflammation and fibrosis

Oral Presentation

Presenter: Heather Hsu

742

Sustained reduction of triglyceride and LDL cholesterol from single administration of the novel long-acting FGF21 analogue 0499

Poster Presentation

Presenter: Kirsten Dahl

758

Combination of an Acetyl-CoA carboxylase inhibitor and obeticholic acid reduced lipids and bile acids and altered lipid and amino acid metabolism in the liver of humanized mice

Poster Presentation

Presenter: Wen-Wei Tsai

816

Magnesium modulation by CNNM4 silencing in DIAMOND mice via GalNAc-siRNA therapy: a new and effective therapeutic approach against MAFLD

Type to be confirmed

Presenter: Jorge Simón

856

Identification of a fibrosis endotype in NAFLD patients more prone to interventions aimed at reducing fibrogenesis

Poster Presentation

Presenter: Ida Villesen

910

The pan-PPAR agonist lanifibranor improves markers of cardiometabolic health in patients with NASH independent of weight change

Poster Presentation

Presenter: Michael Cooreman

912

Lanifibranor therapy reduces the FibroScan-aspartate aminotransferase (FAST) score associated with histological 'NASH resolution and improvement of fibrosis' and biomarker response

Poster Presentation

Presenter: Michael Cooreman



935

Dissecting the effects and mechanism-of-action of statin use on fatty liver disease: a multidimensional study

Oral Presentation

Presenter: Ibrahim Ayada

945

Effect of smartphone-assisted lifestyle intervention in patients with metabolic-associated fatty liver disease (MAFLD): a preliminary analysis of a randomized controlled trial

Poster Presentation

Presenter: Suraphon Assawasuwannakit

1100

Efficacy and mechanism of time-restricted fasting in non-alcoholic liver disease

Poster Presentation

Presenter: Jiang Deng

1119

Functionalizing novel cancer related genes in liver disease and liver regeneration

Poster Presentation

Presenter: Nooshin Nourbakhsh

1121

Safety, pharmacokinetics and efficacy of the novel pan-phosphodiesterase inhibitor ZSP1601 in 36 NASH patients: a double-blinded, placebo-controlled, multiple-dose escalation phase Ib study

Oral Presentation

Presenter: Yue Ding

1134

Effect of long-term dietary intervention on liver pathology and markers of hepatocellular senescence in the GAN diet-induced obese mouse model of NASH

Poster Presentation

Presenter: Kristoffer Voldum-Clausen

1202

Fecal microbiota transplant using endoscopic-placement hydrogel reduces liver fibrosis with no changes in steatosis in a rat model of steatohepatitis with fibrosis

Poster Presentation

Presenter: Ramon Bartolí

1236

Reversing diet-induced steatohepatitis and CCl<sub>4</sub> induced fibrosis with AN1284 treatment

Poster Presentation

Presenter: Rinat Abramovitch

1251



A non-calorie restricted low carbohydrate high fat diet improves nonalcoholic fatty liver disease (NAFLD) activity score (NAS) and HbA1c in type 2 diabetes: a six-month randomised controlled trial  
Oral Presentation

Presenter: Camilla Dalby Hansen

1281

Spontaneous and drug-induced histological changes in nonalcoholic steatohepatitis: an assessment by meta-analysis of trials

Poster Presentation

Presenter: Grazia Pennisi

1391

Synergistic activity of GLP-1 peptide analog XW003 and the long-lasting GIP receptor agonist XW017 in a diet induced obese mouse model

Poster Presentation

Presenter: Martijn Fenaux

1399

Preclinical pharmacology of low molecular weight GLP-1 receptor agonist XW014

Poster Presentation

Presenter: Martijn Fenaux

1419

Multiple doses of thyroid hormone receptor-beta agonist TERN-501 were well-tolerated and resulted in significant dose-dependent changes in serum lipids and sex hormone binding globulin in a first-in-human clinical study

Type to be confirmed

Presenter: Cara H. Nelson

1428

Integrated transcriptomics of CRV431 treatment in a Phase 2a NASH trial confirms anti-fibrotic effect of pan-cyclophilin inhibition and identifies CRV431-specific biomarkers

Poster Presentation

Presenter: Patrick Mayo

1442

Biomarkers, imaging and safety in a well-compensated NASH cirrhotic cohort treated with resmetirom, a thyroid hormone receptor beta agonist, for 52 weeks

Oral Presentation

Presenter: Stephen Harrison

1520

Pharmacokinetic (PK) and pharmacodynamics (PD) of BIO89-100, a novel glycoPEGylated FGF21, in nonalcoholic steatohepatitis (NASH) patients with compensated cirrhosis

Poster Presentation

Presenter: Naim Alkhouri

1542





Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, achieves rapid and potent reductions in body weight and liver fat: results of a placebo-controlled, double-blind, first-in-human (FIH) clinical trial

Oral Presentation

Presenter: Stephen Harrison

1709

HEC96719, a novel tricyclic farnesoid X receptor agonist for treatment of non-alcoholic steatohepatitis: results of preclinical study and phase I trial

Poster Presentation

Presenter: Yan Wang

1903

Effect of saroglitazar in reducing liver enzymes and liver stiffness in non-alcoholic fatty liver disease: a single arm prospective study

Poster Presentation

Presenter: krishnadas devadas

1946

Intrahepatic microcirculation disorders and hyperammonemia and their correction at nonalcoholic steatohepatitis patients with initial stages of liver fibrosis

Poster Presentation

Presenter: Tatiana Ermolova

2082

Ticagrelor, but not clopidogrel, attenuated hepatic steatosis in a model of non-alcoholic fatty liver disease

Poster Presentation

Presenter: Hyunwoo Oh

2111

Lemon balm extract ALS-L1023, an angiogenesis inhibitor, inhibits liver fibrosis in a non-alcoholic fatty liver disease model

Poster Presentation

Presenter: Hyo Young Lee

2250

Hepatocyte-specific JNK signaling is protective during progression of NASH

Poster Presentation

Presenter: Ines Volkert

2583

Semaglutide use in adjunct to multidisciplinary lifestyle interventions improves weight and body composition in NAFLD patients

Poster Presentation

Presenter: Rochelle Wong

## Non-invasive assessment of liver disease except NAFLD

18

Use of the enhanced liver fibrosis test to risk stratify patients in the intelligent liver function test pathway: ruling out cirrhosis and advanced fibrosis

Poster Presentation

Presenter: Madeline Pearson

263

Comparison of CT, blood test, elastometry and their combination for non-invasive staging of liver fibrosis

Poster Presentation

Presenter: Paul Cales

264

Reliability criteria of non-invasive tests for liver fibrosis

Poster Presentation

Presenter: Paul Cales

306

Metabolomic profiling of capillary dry blood samples for the differential diagnoses of hepatocellular carcinoma and liver diseases

Poster Presentation

Presenter: Philipp Brunnbauer

597

Stable rates of cirrhosis diagnosed by Fibroscan despite changing trends in liver disease epidemiology: a single centre retrospective cohort study

Poster Presentation

Presenter: Joan Ericka Flores

659

Comparative assessment of noninvasive methods (NIMs)- LIVERFAST, liver stiffness measurement (LSM) with transient elastography (TE, Fibroscan) ELF and FiB-4 - in a prospective cohort with chronic liver diseases (CLD) from a tertiary liver center

Poster Presentation

Presenter: Wattana Sukepaisarnjaroen

689

Diagnostic accuracy of non-invasive imaging modalities for the diagnosis of liver cirrhosis compared to histological assessment in a clinical setting

Poster Presentation

Presenter: Liv Thing

755

Use of Fibrosis-4 (FIB-4) in liver fibrosis screening: which thresholds to choose?

Poster Presentation



Presenter: Denis Ouzan

880

Plasma cell-free DNA methylation as biomarker for hepatocellular carcinoma

Poster Presentation

Presenter: María Gárate-Rascón

1034

A derivation and validation study of paired liver and plasma proteomics in 659 individuals reveals circulating biomarkers for alcohol-related liver disease

Poster Presentation

Presenter: Maja Thiele

1114

Development and validation of a hepatic vascular geometrical model for noninvasive diagnosis of clinically significant portal hypertension in cirrhosis (CHESS1802)

Poster Presentation

Presenter: Chengyan Wang

1172

Development and validation of a machine learning-based model for varices screening in compensated cirrhosis (CHESS2001): an international multicenter study

Oral Presentation

Presenter: Yifei Huang

1190

The diagnostic accuracy of ElastQ 2-D shear wave elastography for liver fibrosis risk assessment in a mixed etiology, multinational cohort

Poster Presentation

Presenter: David JM Bauer

1191

Machine learning models for prediction of severe portal hypertension in patients with compensated cirrhosis

Poster Presentation

Presenter: Oleksandr Petrenko

1235

Reproducibility and applicability of spleen stiffness measurement by vibration controlled transient elastography in patients with and without chronic liver disease

Poster Presentation

Presenter: Cristina Manfredi

1307

Association of long term methotrexate therapy with liver fibrosis markers: a multi-centre prospective case-control study

Oral Presentation

Presenter: Edmond Atallah



1708

Diagnostic performance of non-invasive liver fibrosis biomarkers: a bayesian individual patient data meta-analysis of hepatitis B cohorts in sub-saharan Africa (HEPSANET)

Oral Presentation

Presenter: Alexander Stockdale

1726

Validation of the continuous controlled attenuation parameter (CAPc) using the MRI-PDFF as reference

Poster Presentation

Presenter: Edouard Bardou-Jacquet

1866

A novel non-invasive index for the prediction of liver fibrosis in chronic hepatitis B patients with concurrent nonalcoholic fatty liver disease

Poster Presentation

Presenter: Jie Li

1891

Comparison between two 2D-SWE techniques using transient elastography as a reference method for liver stiffness assessment

Poster Presentation

Presenter: Alina Popescu

2042

Shear wave elastography is a useful and accurate tool to triage patients with acute liver failure syndromes

Poster Presentation

Presenter: FRANCESCA MARIA TROVATO

2206

A novel simple and reliable 2D-shear wave elastography (SWE) and ultrasound-guided coefficient attenuation parameter (SCAP) technique for patients with chronic liver disease

Poster Presentation

Presenter: Christiane Stern

2260

ADAPT, a score incorporating PRO-C3, for the early detection of liver fibrosis in a large population-based study

Oral Presentation

Presenter: Ann T Ma

2419

Gadoxetic acid-enhanced MRI-derived Functional Liver Imaging Score (FLIS) and spleen diameter provide complementary information for risk stratification in ACLD

Type to be confirmed

Presenter: Mattias Mandorfer



2533

Artificial intelligence-assisted jaundice detection by smartphone images

Poster Presentation

Presenter: Tung-Hung Su

## Public Health

122

Testing coverage and strategy required to sustain Hepatitis C elimination in an injecting network of people who inject drugs: a network-based model

Poster Presentation

Presenter: Ryan Buchanan

145

Hepatocellular carcinoma screening trends in individuals with cirrhosis in North Carolina

Poster Presentation

Presenter: Christine Hsu

212

Smoking, alcohol consumption and combined association risk for developing liver cancer in chronic hepatitis B: a prospective study

Oral Presentation

Presenter: cao maomao

243

Cost- effectiveness evaluation of the hepatitis C elimination strategy in Cyprus in the era of affordable direct-acting antivirals

Poster Presentation

Presenter: Ilias Gountas

297

Rethinking the management of chronic hepatitis B in the context of rural sub-saharan Africa: results from a social justice mixed methods study in rural Senegal (the AmBASS-PeCSen study)

Poster Presentation

Presenter: Marion Coste

318

Incidence, prevalence and mortality of chronic liver diseases in Sweden between 2005 and 2019

Oral Presentation

Presenter: Hannes Hagström

470

Randomized controlled trial of home-based hepatitis C self-testing for key populations in Malaysia

Oral Presentation

Presenter: Xiaohui Sem



512

Global survey of healthcare workers' attitudes to treatment of chronic hepatitis C infection in children and adolescents

Poster Presentation

Presenter: Farihah Malik

655

Impact of community-based campaign in United States to increase hepatitis B virus screening and linkage to care among Asian immigrants from high endemic countries

Poster Presentation

Presenter: Sung Kwon

666

The prognostic implications of liver function test abnormalities in patients admitted to hospital with COVID-19

Poster Presentation

Presenter: Raza Malik

667

A novel prognostic model including liver function parameters accurately predicts 30-day mortality in patients admitted with COVID-19

Poster Presentation

Presenter: Raza Malik

668

Low health literacy is associated with higher healthcare service utilisation and costs among patients with cirrhosis

Poster Presentation

Presenter: Elizabeth Powell

688

A modelling approach to estimate alcohol-related liver morbidity and mortality in France

Poster Presentation

Presenter: Claire Delacôte

694

A model to predict drinking population at-risk of liver disease in France: a tool for decision-making public health policies

Poster Presentation

Presenter: Claire Delacôte

770

Blood donors in Europe have substantially higher risk of exposure to HEV than in North America: results from a systematic review and meta-analysis

Poster Presentation

Presenter: Annika Wolski



771

Abdominal obesity is key when evaluating interactions between alcohol use and obesity for liver disease

Oral Presentation

Presenter: Fredrik Åberg

898

A population based-study of rates and trends of hepatitis C in immigrants and the Canadian-born in Quebec, Canada, 1998-2018

Poster Presentation

Presenter: Ana Maria Passos-Castilho

976

HBV screening in west african migrant community and faith-based organizations increases HBV vaccination among this high-risk population in greater Barcelona, Spain

Poster Presentation

Presenter: Camila Picchio

979

Community-based HBV testing among west african migrants in greater Barcelona, Spain increases linkage to specialist care and vaccination: the HBV-COMSAVA model

Poster Presentation

Presenter: Camila Picchio

989

The impact of COVID-19 pandemic control measures on HCV treatment initiation in British Columbia, Canada

Poster Presentation

Presenter: Naveed Janjua

1076

Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease

Poster Presentation

Presenter: Zobair Younossi

1110

Associations of food insecurity and fast-food consumption with diet quality in adults with nonalcoholic fatty liver disease in a large population-based U.S. cohort

Poster Presentation

Presenter: Ani Kardashian

1126

Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy

Poster Presentation

Presenter: Roberta D'Ambrosio



1198

Structured early detection of compensated advanced chronic liver disease - results of the SEAL program

Oral Presentation

Presenter: Anita Arslanow

1230

Real life pooling of plasma samples for hepatitis C RNA detection as a screening strategy of hepatitis C active chronic infection

Poster Presentation

Presenter: Federico Garcia Garcia

1237

Epidemiology of hepatocellular carcinoma in Portugal

Poster Presentation

Presenter: Mario Jorge Silva

1261

"Zero C" hospital project: an innovative screening and referral model in hospitalized patients at different divisions

Poster Presentation

Presenter: VALERIO ROSATO

1325

LINK-B: a hepatitis B program to test and link to care patients lost of follow up

Poster Presentation

Presenter: Ana lai

1368

Testing for liver disease in primary case: fibrosis first

Poster Presentation

Presenter: Ian Rowe

1395

Hepatitis C care cascade analysis among adult women in Georgia

Poster Presentation

Presenter: Ketevan Stvilia

1476

Progress in HCV screening in the national hepatitis C elimination program in Georgia during the COVID-19 pandemic, 2019-2021

Poster Presentation

Presenter: Amiran Gamkrelidze

1547

Could a multi-target blood test make hepatocellular carcinoma surveillance programs more effective? A modelling-based virtual trial

Poster Presentation





Presenter: Jagpreet Chhatwal

1581

Evaluation of immune response and disease flares in metabolic-associated fatty liver disease patients following SARS-CoV-2 vaccination: a prospective cohort study

Poster Presentation

Presenter: Qianru Zhu

1609

A model, screen test and treat hepatitis C elimination project among under-served communities in Islamabad-the federal capital of Pakistan

Poster Presentation

Presenter: Huma Qureshi

1619

The HCV care cascade for children and young people in British Columbia, Canada: a large, linked administrative population-based cohort study

Oral Presentation

Presenter: Dahn Jeong

1622

The disease burden of hepatitis B and hepatitis C from 2015 to 2030: the long and winding road

Oral Presentation

Presenter: Devin Razavi-Shearer

1634

Hepatitis B and hepatitis C testing practices and seroconversions among dialysis facilities in Georgia

Poster Presentation

Presenter: Maia Butsashvili

1660

Innovative linkage model to re-engage loss-to-follow-up individuals in the national hepatitis C elimination program of Georgia

Poster Presentation

Presenter: Amiran Gamkrelidze

1675

Clinical impact and cost-effectiveness of hepatitis C testing in an emergency department in Barcelona, Spain

Oral Presentation

Presenter: Jordi Llaneras

1722

Combined COVID-19 vaccination and HIV and hepatitis C virus screening intervention for high-risk populations at a mobile testing unit in Madrid, Spain

Poster Presentation

Presenter: Jeffrey Lazarus



1730

A model to eradicate HCV in undocumented migrants and low-income refugees in Italy

Type to be confirmed

Presenter: mariantonietta pisaturo

1754

Enhancing the cascade of hepatitis C care in community-recruited high-risk people who inject drugs during the COVID-19 pandemic: the Alexandros program

Poster Presentation

Presenter: Vana Hatzakis

1789

SVR4 and SVR12 monitoring by using dried blood spot test: is it the best alternative for people who use drugs?

Poster Presentation

Presenter: Jeffrey Lazarus

1795

Genetics of liver fat and volume associate with altered metabolism and whole body magnetic resonance imaging

Oral Presentation

Presenter: Shafqat Ahmad

1880

Collateral benefit of Georgia national hepatitis C elimination program - improving blood transfusion safety in the country of Georgia

Poster Presentation

Presenter: Maia Alkhazashvili

1896

Outcomes of a community led comprehensive HCV and HBV care provision model, including same-day "test and treat" to facilitate micro-elimination of HCV among people who inject drugs in Manipur, India

Poster Presentation

Poster Presentation

Presenter: Rajkumar Nalinikanta

1905

A novel hepatitis C intervention in Denmark to test and treat people who inject drugs

Poster Presentation

Presenter: Jeffrey Lazarus

1910

Peer-led hepatitis C services reach poorly served populations at scale: a model for tackling health inequalities

Poster Presentation

Presenter: Leila Reid

1943



Cost-effectiveness of integrated treatment for hepatitis C virus among people who inject drugs in Norway: an economic evaluation of the INTRO-HCV trial

Poster Presentation

Presenter: Aaron G. Lim

1985

Characterization of HCV recent infections and re-infections among high-risk population from Georgia using global hepatitis outbreak and surveillance technology

Poster Presentation

Presenter: Adam Kotorashvili

2016

Prevalence and predictors of significant liver fibrosis : a population-based cross-sectional study

Poster Presentation

Presenter: Aayushi Rastogi

2053

Association between liver cirrhosis and cardiovascular events in a large german cohort - a population based study

Type to be confirmed

Presenter: Kabbani Abdul-Rahman

2098

Prognostic value of liver function test for COVID-19 hospitalized patients with respiratory disease

Poster Presentation

Presenter: CARLOS ALVENTOSA MATEU

2109

Effectiveness of COVID-19 viral vector vaccine Ad.26.COVS.2 vaccine and comparison with mRNA vaccines in patients with cirrhosis

Poster Presentation

Presenter: Binu John

2116

Humoral, cellular, clinical responses and safety to SARS-CoV-2 messenger RNA vaccines in patients with compensated and decompensated cirrhosis: a long-term single center prospective study

Poster Presentation

Presenter: Massimo Iavarone

2133

The protective role of dairy protein on sarcopenic obesity in middle-aged and older women: a community-based, 12-year, prospective cohort study

Poster Presentation

Presenter: Jun-Hyuk Lee

2166

Detection of microplastics in cirrhotic liver tissue

Poster Presentation



Presenter: Thomas Horvatits

2175

Patient Navigators: an innovative approach to improve hepatitis c case finding leveraging existing human immunodeficiency virus service delivery models to reach last mile patients in Nasarawa State, Nigeria

Poster Presentation

Presenter: Chukwuemeka Agwuocha

2205

The Community Pop-Up Clinic (CPC): a unique strategy to achieve HCV elimination in the inner city

Poster Presentation

Presenter: Brian Conway

2216

The number of public health policies reduces the burden and mortality of alcohol-associated liver disease worldwide: a call for action

Oral Presentation

Presenter: Luis Antonio Diaz

2247

The global burden of liver cancer (LC) and chronic liver diseases (CLD) is driven by non-alcoholic steatohepatitis (NASH) and alcohol liver disease (ALD)

Oral Presentation

Presenter: Zobair Younossi

2252

Age, gender and region-specific HBsAg and anti-HCV seroprevalence in Ghana: a nationwide hospital based cross-sectional study

Poster Presentation

Presenter: Yvonne Nartey

2253

The elimination of hepatitis C in the Cherokee Nation: the impact of harm reduction

Poster Presentation

Presenter: Jorge Razavi-Shearer

2297

Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variant

Poster Presentation

Presenter: Binu John

2365

Epidemiology and management of hepatitis B and C in primary care in the Netherlands - data from the Rijnmond primary care database

Poster Presentation

Presenter: Sylvia Brakenhoff



2369

Point of care testing for hepatitis C in the priority settings of mental health, prisons and drug and alcohol facilities

Poster Presentation

Presenter: Catherine Ferguson

2378

Association of novel lifestyle- and whole foods base inflammation scores with metabolic dysfunction-associated fatty liver disease: a population-based study among iranian adults

Poster Presentation

Presenter: Ehsaneh Taheri

2440

Assessment of COVID-19 impact and response on hepatitis B virus and hepatitis C virus prevention and treatment from nationwide survey in Japan

Poster Presentation

Presenter: Md Razeen Ashraf Hussain

2450

Knowledge, attitude and practice regarding COVID-19 vaccination among HCV infected patients in Georgia

Poster Presentation

Presenter: Lasha Gulbiani

2522

CRIVALVIR-FOCUS: low HIV and chronic Hepatitis B and C infection prevalence among women in reproductive and sexual health services in Valencia, Spain

Poster Presentation

Presenter: Miguel Garcia-Deltoro

2601

mRNA COVID-19 vaccine effectiveness in liver transplant patients

Poster Presentation

Presenter: Muhammad Khan

## Rare liver diseases (including paediatric and genetic)

95

A pilot study of biliary atresia newborn screening using dried blood spot matrix metalloproteinase-7

Poster Presentation

Presenter: Chee Seng Lee

339

In vitro rescue of nonsense variations by drug-induced readthrough of premature termination codons in progressive familial intrahepatic cholestasis type 2



Poster Presentation

Presenter: Martine Gonzalès

366

Search for biomarkers and prognostic indicators of liver degeneration in glycogen storage disease type Ia

Poster Presentation

Presenter: Roberta Resaz

401

ACOX2 deficiency-induced liver fragility (ADILF), a not-so-rare inborn error in bile acid metabolism that responds to ursodeoxycholic acid treatment

Oral Presentation

Presenter: Marta Alonso-Peña

543

Alpha-1 antitrypsin (AAT) augmentation therapy and liver phenotype in individuals with homozygous Pi\*Z AAT mutation (Pi\*ZZ genotype)

Poster Presentation

Presenter: Malin Fromme

571

Impact of acute hepatic porphyria attack frequency on patient-reported outcomes: results from the porphyria worldwide patient experience research (POWER) study

Poster Presentation

Presenter: Amy Dickey

580

Efficacy and safety of givosiran in patients with acute hepatic porphyria: 36-month results of the phase 3 ENVISION randomised clinical trial

Oral Presentation

Presenter: Manish Thapar

719

Large-scale, multi-centric prospective validation of the polycystic liver disease complaint-specific assessment (POLCA)

Poster Presentation

Presenter: Antoon Billiet

763

Improvements in quality of life in odevixibat responders and nonresponders: an analysis of pooled data from the PEDFIC 1 and PEDFIC 2 studies

Poster Presentation

Presenter: Cara L. Mack

847

Total, primary, and secondary serum bile acid changes and pruritus improvement during odevixibat treatment in patients with progressive familial intrahepatic cholestasis



Poster Presentation

Presenter: Henkjan J. Verkade

850

Changes in hepatic parameters, growth, sleep, and biochemical markers with odevixibat treatment across patients with various types of progressive familial intrahepatic cholestasis

Poster Presentation

Presenter: Lorenzo D'Antiga

865

Analysis of quality of life, hepatic biochemical markers, and sleep in patients with progressive familial intrahepatic cholestasis who had a pruritus response with odevixibat treatment

Poster Presentation

Presenter: Girish Gupte

1081

Longitudinal follow-up data on adults with classic, severe alpha-1 antitrypsin deficiency (Pi\*ZZ genotype)

Poster Presentation

Presenter: Malin Fromme

1101

In vivo CRISPR/Cas9 editing of the TTR gene with NTLA-2001 in patients with transthyretin amyloidosis- dose selection considerations

Oral Presentation

Presenter: Edward J Gane

1158

Gender dependent neurological and hepatic improvement in Wilson disease patients treated with Trientine dihydrochloride: post hoc results from a prospective study

Poster Presentation

Presenter: Karl Heinz Weiss

1197

Efficacy and safety of odevixibat over 72 weeks of treatment in patients with progressive familial intrahepatic cholestasis

Poster Presentation

Presenter: Richard J. Thompson

1204

In vitro rescue of the bile acid transport function of some ABCB11 variants by CFTR potentiators: a targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2

Poster Presentation

Presenter: Emmanuel Gonzalès

1246

Plasma-based proteomics profiling of patients with Wilson's disease

Poster Presentation



Presenter: Jie Su

1329

Management of hepatic sarcoidosis - multicentric approach

Poster Presentation

Presenter: Janina Guerra Veloz

1360

Plasma proteomics identifies hepatic steatosis and sex differences in 2,147 children and adolescents

Poster Presentation

Presenter: Lili Niu

1388

Pregnancy outcomes in women with Budd Chiari syndrome: a single center experience

Poster Presentation

Presenter: Sagnik Biswas

1415

High-risk Thrombophilia predict early thrombosis recurrence in acute non-cirrhotic portal vein thrombosis related to local factors: LOCAPORT

Oral Presentation

Presenter: Louise Lebedel

1463

New cases of Budd-Chiari syndrome and splanchnic vein thrombosis after COVID-19 vaccination - a vascular liver disease group (VALDIG) initiative

Poster Presentation

Presenter: Rael Maan

1653

Abdominal wall hernia is a frequent complication of polycystic liver disease and associated with hepatomegaly

Poster Presentation

Presenter: Thijs Barten

1658

MR-derived metrics have utility in identifying paediatric patients with stable autoimmune hepatitis

Poster Presentation

Presenter: Piotr Pawliszak

1710

Development and validation of a novel ICP-MS method to quantify different copper species in human plasma from patients with Wilson disease

Poster Presentation

Presenter: Mark Ma

1745





Quantitative magnetic resonance cholangiopancreatography identifies features of ductal disease change in primary sclerosing cholangitis: a prospective observational cohort study

Type to be confirmed

Presenter: Palak Trivedi

1806

Quantitative magnetic resonance cholangiopancreatography outperforms Mayo risk score in predicting clinical outcomes in primary sclerosing cholangitis

Oral Presentation

Presenter: Raj Vuppalanchi

1816

Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial

Oral Presentation

Presenter: Karl Heinz Weiss

1847

Age at diagnosis is associated with mortality in patients with hereditary hemochromatosis

Poster Presentation

Presenter: Clare Foley

1854

Development of Hepatoblastoma organoids as a patient-derived ex-vivo system

Poster Presentation

Presenter: Laura Zanatto

1955

High rates of histological findings compatible with porto-sinusoidal vascular disease in patients with constantly elevated gamma-glutamyl transferase levels undergoing a liver biopsy

Poster Presentation

Presenter: Nicola Pugliese

2019

Plasma metabolomics and machine learning characterizes metabolite signature capable of segregating patients with poor outcome in pediatric cirrhosis

Poster Presentation

Presenter: Babu Mathew

2022

Clinical utility of non-ceruloplasmin copper determined by copper speciation for monitoring Wilson disease therapy: comparative data analysis with 24-hour urinary copper excretion from the CHELATE trial

Type to be confirmed

Presenter: C.Omar Kamlin

2063



Experience of cholestatic pruritus emphasized by patients with PBC: results from the PBC Foundation app survey

Poster Presentation

Presenter: Chris Mitchell

2191

Cancer risk in acute hepatic porphyria: a nationwide matched cohort study in 1,245 individuals

Poster Presentation

Presenter: Mattias Hagström

2220

Innovative approach using clinical metagenomics for the diagnosis of non-elucidated liver disease

Poster Presentation

Presenter: Anna Sessa

2237

Accumulation of molybdenum in major organs following chronic oral administration of bis-choline tetrathiomolybdate in Sprague Dawley rats

Poster Presentation

Presenter: Kharmen Billimoria

2254

Bile duct injury in a toxic model of biliary atresia may be reversible

Poster Presentation

Presenter: Orith Waisbourd-Zinman

2255

Liver fibrosis and fat by transient elastography in patients with Alpha-1 antitrypsin deficiency

Poster Presentation

Presenter: Hassaan Yousuf

2283

Novel imaging feature in patients with porto-sinusoidal vascular disorder (PSVD) - radiological evaluation guiding diagnosis

Poster Presentation

Presenter: Georg Semmler

2303

Liver involvement in systemic light chain amyloidosis : is the heart guilty?

Poster Presentation

Presenter: Vincent Leroy

2408

The role of the mechanistic target of rapamycin (mTOR) in Alpha-1 Antitrypsin Deficiency

Poster Presentation

Presenter: Lisa Bewersdorf

2443



Cerebrotendinous xanthomatosis: long-term course in 5 patients and first description of a successful pregnancy management during therapy with chenodesoxycholic acid (CDCA)

Poster Presentation

Presenter: Jan Köhler

2472

A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population

Poster Presentation

Presenter: Anne-Sofie Seidelin

## Viral Hepatitis A, B, C, D, E: Virology

29

Liver-resident T cell PD-1 correlates with intrahepatic HBV-DNA and is reduced following prolonged antiviral therapy

Oral Presentation

Presenter: Mireia García-López

228

Hepatitis E Virus Capsid Antigen (HEV-Ag): a practical diagnostic biomarker in the HEV outbreak scenerio

Poster Presentation

Presenter: Simon Lytton

241

Bulevirtide is broadly active against all HDV genotypes expressing envelopes from HBV genotypes A-H and a large panel of clinical isolates

Poster Presentation

Presenter: Savrina Manhas

275

Identification of cyclin L1 as a hepatitis B virus host factor regulating viral transcription

Oral Presentation

Presenter: Collins Oduor Owino

291

Novel ultra-potent capsid assembly modulators prevent abnormal accumulation of empty capsids and associated T-cell mediated liver injury in a mouse model of hepatitis B virus infection

Oral Presentation

Presenter: Luca Guidotti

309

A persistent HBV infection features spontaneous cccDNA loss and new rounds of infection

Poster Presentation

Presenter: Yong-Yuan Zhang



369

A genome-wide CRISPR/Cas9 screen identifies Rab5A as host factor of the hepatitis E virus life cycle

Oral Presentation

Presenter: Noémie Oechslin

482

Functionnal and mitochondrial dynamics alterations in patients with chronic hepatitis B and advanced fibrosis

Poster Presentation

Presenter: Dimitri Loureiro

487

Dual antiviral activity of farnesyl transferase inhibitor on hepatitis D virus infection revealed by RT-ddPCR

Poster Presentation

Presenter: Eloi Verrier

710

Characterization of circulating hepatitis B Virus RNAs in vitro and chronic hepatitis B patients

Poster Presentation

Presenter: Doohyun Kim

720

Identification of shuttle protein hnRNPA1 as a modulating factor of circulating hepatitis B Virus RNAs release in chronic hepatitis B patients

Poster Presentation

Presenter: Hyoseon Tak

752

Long-read sequencing of HCC samples reveals complete architecture of HBV integrations and chimeric mRNA isoforms associated with oncogenes

Poster Presentation

Presenter: Cameron Soulette

911

Polymorphic analysis of bulevirtide sequence in PreS1 of large HBsAg across HBV genotypes A-H

Poster Presentation

Presenter: Roberto Mateo

916

RIPK1 plays a survival role in the liver of mice with active HDV replication

Poster Presentation

Presenter: Gracian Camps

941

Limited value of HBV-RNA levels for the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in HBe antigen negative chronic hepatitis B patients



Poster Presentation

Presenter: Valerie Ohlendorf

1024

A versatile small animal immunocompromised model for chronic hepatitis E

Poster Presentation

Presenter: Siddharth Sridhar

1185

Phospho-proteomic analysis of HBV infection revealed novel mechanisms for the regulation of viral transcription and pro-fibrotic stellate cell activation

Oral Presentation

Presenter: Alessia Virzi

1195

Acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg stability and secretion and promotes cell survival

Poster Presentation

Presenter: Lorenzo Piermatteo

1337

PAGE-B and FIB-4 predict the occurrence of hepatocellular carcinoma in HBV patients: a french nationwide cohort study

Poster Presentation

Presenter: Gautier Boillet

1375

High tolerance of hepatitis E virus towards alcohol-based disinfectants

Poster Presentation

Presenter: Patrick BEHRENDT

1384

Multicentre performance evaluation of the Elecsys HCV Duo immunoassay

Poster Presentation

Presenter: Michael Voitenleitner

1418

Intrahepatic transcriptional profiling demonstrates preclinical models of chronic hepatitis B resemble different stages of natural history in humans

Poster Presentation

Presenter: Ricardo Ramirez

1566

Hepatitis B virus splice variants are associated with reduced likelihood of functional cure and differ across phases of chronic hepatitis B infection

Poster Presentation

Presenter: Peter Revall



1606

Understanding acute HCV infection kinetics in humanized mice via an agent-based modeling approach

Poster Presentation

Presenter: Harel Dahari

1630

Presence of sodium taurocholate co-transporting polypeptide and hepatitis B replication markers on placenta: another home for the virus?

Type to be confirmed

Presenter: Ashish Kumar Vyas

1648

Exploring dynamic changes in HBcrAg and HBV RNA in e-Antigen negative HBV/HIV patients on antiretroviral therapy: still evidence of integrated activity after 5 years of treatment

Poster Presentation

Presenter: Ruth Byrne

1651

Next-generation sequencing of Swiss HEV isolates allows for reconstitution of functional clones

Poster Presentation

Presenter: Jérôme Gouttenoire

1696

HEC96719, a novel FXR agonist, inhibits HBV infection in vitro and in vivo

Poster Presentation

Presenter: Pu Wang

1731

Combined effect of Vonafexor and Interferon-alpha on HBV replication in primary human hepatocytes

Poster Presentation

Presenter: David Durantel

1791

Hepatitis Delta virus quasispecies conservation and variability in ribozyme region

Poster Presentation

Presenter: Beatriz Pacín Ruiz

1887

Exosomal cargo as a key player of the immune response after direct-acting antiviral treatment in chronic hepatitis C patients

Poster Presentation

Presenter: Ioannis-Georgios Koskinas

1889

Therapeutic suppression of HBV transcripts promotes reappearance of the SMC5/6 complex and cccDNA silencing in vivo without affecting posttranslational modifications of cccDNA-bound histones



Poster Presentation

Presenter: Lena Allweiss

1930

Updated national prevalence estimates of chronic hepatitis B virus infection in countries within the European (EU) and European Economic Area (EEA): a systematic review

Poster Presentation

Presenter: Sandra Bivegete

1958

Relevance of HEV detection in ejaculate of chronically infected patients

Poster Presentation

Presenter: Mathias Schemmerer

2065

HDV-mediated inhibition of HBV in superinfection mouse model: the role of type I Interferon

Poster Presentation

Presenter: Beatriz Pacín Ruiz

2088

Assessment of Myrcludex or heparin antiviral activity on HBV infection using a 3-dimensional primary human hepatocyte culture system

Poster Presentation

Presenter: Juliette Besombes

2380

Concordance of the Xpert hepatitis B viral load test and conventional quantitative PCR in detecting and quantifying viremia using stored plasma and dried blood spot samples in West Africa

Poster Presentation

Presenter: Gibril Ndow

2409

A high-throughput viral integration sequencing method reveals that mitochondrial DNA is frequently targeted by HBV integration

Poster Presentation

Presenter: Teresa Pollicino

2446

Enhanced T cell responses in patients and mouse model of hepatitis B and comorbid non-alcoholic fatty liver disease

Poster Presentation

Presenter: Nishi Patel

2496

Hepatitis B virus sero-prevalence and genotype distribution among pregnant women in Siem Reap, Cambodia

Poster Presentation

Presenter: Bunthen E



2509

Genotype distribution and mutations associated with hepatocellular carcinoma risk among hepatitis B carriers in Goto Islands, Japan

Poster Presentation

Presenter: Serge Ouoba

2579

Comprehensive analysis of the different phases of chronic hepatitis B virus infection

Poster Presentation

Presenter: Michael Basic

## Viral hepatitis A/E: Clinical aspects

308

Detection of highly variable RNA-containing viral particles on CNT-based electrochemical impedimetric DNA-nanosensors

Poster Presentation

Presenter: Victor Hryharovich

469

Hepatitis B Delta: assesment of knowledge and practices of French non academic hepato-gastroenterologists

Poster Presentation

Presenter: Jean-François David Cadranel

1089

Hepatitis E seroprevalence in solid organ transplant recipients in Croatia

Poster Presentation

Presenter: Petra Mrzljak

## Viral hepatitis B/D: Clinical aspects except therapy

119

Detection of notable hepatitis B virus serologic activity after hepatitis B surface antigen seroclearance

Poster Presentation

Presenter: Danny Ka-Ho Wong

176

Comparison of on-treatment ALT or FIB-4 as an on-treatment biomarker of hepatitis B treatment for liver cirrhosis patients

Poster Presentation

Presenter: JOO HYUN OH





301

Liver fibrosis burden determines risk of hepatocellular carcinoma among patients with hepatitis B surface antigen seroclearance

Poster Presentation

Presenter: Lung Yi Loey Mak

334

Estimating the prevalence of hepatitis delta infection among foreign-born adults with chronic hepatitis B in the United States

Poster Presentation

Presenter: Robert Wong

459

Secular trend of the accuracy of hepatocellular carcinoma risk scores in treated chronic hepatitis B patients in 2005-2020: a territory-wide study of 48,706 subjects

Poster Presentation

Presenter: Terry Cheuk-Fung Yip

510

Risk prediction of hepatocellular carcinoma in chronic hepatitis B patients outside current treatment criteria

Poster Presentation

Presenter: Gi-Ae Kim

534

Suboptimal glycemic control is associated with adverse clinical outcomes in patients with chronic hepatitis B and diabetes mellitus

Poster Presentation

Presenter: Lung Yi Loey Mak

661

Statin use and surface antigen loss in patients with chronic hepatitis B

Poster Presentation

Presenter: Shahed Iqbal

662

The discriminatory power of risk scores for hepatocellular carcinoma in treated chronic hepatitis B patients with and without diabetes: a territory-wide study of 48,706 subjects

Oral Presentation

Presenter: Terry Cheuk-Fung Yip

818

Patient engagement in hepatitis B clinical trials: 'HBV cure' is a motivation for participation in all ethnically diverse patients

Poster Presentation

Presenter: Almuthana Mohamed

827



Anti-HDV reflex testing increases the number of hepatitis D cases diagnosed in both academic and community centers

Poster Presentation

Presenter: Adriana Palom

867

HBVoice: a framework to enhance advocacy for patients and communities affected by hepatitis B virus infection

Poster Presentation

Presenter: Philippa Matthews

982

HBeAg-positive patients with HBsAg<135IU/mL or HBcrAg<3.6logU/mL have more chance to be HBsAg loss after nucleos(t)ide analogue cessation

Poster Presentation

Presenter: Yandi Xie

1037

Serum markers of cccDNA transcriptional activity (HBcrAg and pre-genomic HBV RNA) and large HBsAg (LHBs) protein are predicting response to pegylated interferon in HDV infection

Poster Presentation

Presenter: Ivana Carey

1271

A decision-making model for prediction of a stable disease course in chronic hepatitis B patients

Poster Presentation

Presenter: Imri Ofri

1326

Healthcare resource utilization and costs of hepatitis delta in the United States: an analysis of all-payer claims database

Poster Presentation

Presenter: Joseph Shah

1347

Validation of an internal hepatitis D virus DNA quantitative assay: developing assay suitable for global clinical application and clinical trials assessment

Poster Presentation

Presenter: Natalie Chang

1370

Early increase in HBcrAg levels after peginterferon withdrawal predicts subsequent ALT flares

Poster Presentation

Presenter: Sylvia Brakenhoff

1371

Hepatitis B pre-genomic RNA differentiates HBeAg-negative disease from infection: time to refine disease stages with new biomarkers?



Poster Presentation

Presenter: Bo Wang

1416

Long term persistence of anti-HBs antibodies after vaccination with a 3-antigen HBV vaccine compared to a single-antigen HBV vaccine

Oral Presentation

Presenter: Timo Vesikari

1423

Fatty liver index as a risk factor for all-cause and liver related mortality in patients under therapy for chronic hepatitis B (ANRS CO22 Hepather cohort study)

Oral Presentation

Presenter: Paul Hermabessiere

1436

Evaluating hepatitis delta virus disease prevalence and patient characteristics among adults in the United States: an analysis of all-payer claims database

Poster Presentation

Presenter: Robert G. Gish

1524

Hepatitis delta in Northern Portugal - a long-term follow-up study

Poster Presentation

Presenter: Isabel Garrido

1540

Impact of hepatitis B virus infection on liver-related death among people tested for HBV in British Columbia: results from a large longitudinal population-based cohort study

Poster Presentation

Presenter: Makuza Jean Damascene

1571

Comparable risk of hepatocellular carcinoma between immune-tolerant and active phase in hepatitis B e antigen-positive patients

Poster Presentation

Presenter: Han Ah Lee

1587

Metabolic dysfunction-associated fatty liver disease subgroups and risk of hepatocellular carcinoma and mortality in patients with chronic viral hepatitis

Oral Presentation

Presenter: Mi Na Kim

1646

Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the setting of HBeAg positive infection

Poster Presentation



Presenter: Romina Salpini

1700

In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy

Poster Presentation

Presenter: Stefano D'Anna

1712

Absence of hepatitis B virus (HBV) in at-risk infants receiving early antiretroviral therapy in a cohort of HIV-transmitting mothers in KwaZulu-Natal, South Africa

Poster Presentation

Presenter: Anna McNaughton

1758

Rising clinical and economic burden among hepatitis D patients who attended Spanish hospitals

Poster Presentation

Presenter: Maria Buti

1769

Analysis from national hospital discharge records database in Spain : increased baseline comorbidity burden including liver severity among HDV coinfection versus HBV mono-infection patients

Poster Presentation

Presenter: Maria Buti

1788

Value of intrahepatic HBV markers in virologically suppressed HBV and HDV infected patients

Poster Presentation

Presenter: Ester García-Pras

1793

Hepatitis Delta virus infection in patients with chronic hepatitis B is associated with greater risk of liver disease progression and liver-related mortality: a systematic review and meta-analysis

Poster Presentation

Presenter: Robert G. Gish

1818

The serum markers of cccDNA transcriptional activity have a role in predicting long-term outcomes in children with perinatally acquired HBV infection

Poster Presentation

Presenter: Christiana Moigboi

1875

Presence of liver inflammation and fibrosis in Asian patients with chronic hepatitis B in the grey zone  
Type to be confirmed

Presenter: Jiacheng Liu



1879

Characteristics and renal function in patients with chronic hepatitis B virus infection: baseline data from the phase 2b B-Clear study

Poster Presentation

Presenter: Jennifer Cremer

1994

Characterisation of baseline complement values in patients with chronic hepatitis B virus infection in the phase IIb B-clear study

Poster Presentation

Presenter: Jennifer Cremer

2073

Estimations of the global prevalence and clinical burden of occult hepatitis B infection (OBI): a systematic review and meta-analysis

Poster Presentation

Presenter: Yu Ri Im

2110

Time for universal screening for hepatitis D? A study describing screening patterns, characteristics and outcomes of hepatitis D virus infection

Poster Presentation

Presenter: Rohit Nathani

2127

Distribution of patients by guideline-defined disease phase and/or grey zones in B-Clear, an international multicentre clinical trial

Poster Presentation

Presenter: Jennifer Cremer

2185

Benign course of HBV reactivations during DAAs in untreated ENI with HBV-HCV co-infections correlates with different HBsAg kinetics compared to NAs treated CHB patients

Poster Presentation

Presenter: Piero Colombatto

2239

Predictors of advanced liver fibrosis in chronic hepatitis B patients in the daily clinical practice

Poster Presentation

Presenter: Fadi Abu Baker

2257

Metabolic associated fatty liver disease is associated with appendicular lean soft tissue abnormalities in patients with chronic hepatitis B

Poster Presentation

Presenter: Luciana Diniz Silva

2259



The course of COVID-19 infection in patients with chronic hepatitis B and Delta

Poster Presentation

Presenter: Onur Keskin

2301

Serum soluble program cell death-1 is predictive of hepatocellular carcinoma in untreated chronic hepatitis B patients

Poster Presentation

Presenter: Rachel Wen-Juei Jeng

2306

Parameters related to ALT elevation in patients with HBeAg negative chronic infection

Poster Presentation

Presenter: Ulus Akarca

2331

Clinical evidence for unconventional hepatitis delta virus infections in endemic countries

Poster Presentation

Presenter: Mary Rodgers

2402

Rapid point-of-care test for hepatitis B core-related antigen (HBcrAg) to identify HBV-infected patients eligible for antiviral therapy

Poster Presentation

Presenter: Yusuke Shimakawa

2449

Prevalence of HBV infection and receiving antiviral treatment for eligible patients in blood relatives from clustering families of HBV infection with unfavorable prognoses and cascading of care linked to treatment in West China

Poster Presentation

Presenter: yuan yang

2534

Liver inflammation in asian chronic hepatitis B patients with detectable HBV-DNA and normal alanine aminotransferase according to diverse upper limits of normal

Poster Presentation

Presenter: Rui Huang

2546

Diversity of circulating HBV genomes and impact on viral infection

Poster Presentation

Presenter: jules sotty

2612

Chronic hepatitis delta with normal ALT and hepatitis D viremia

Poster Presentation

Presenter: SENA ARICI



## Viral hepatitis B/D: therapy

220

Safety, tolerability and pharmacokinetics of single ascending doses of ALG-020572, a GalNAc-conjugated antisense oligonucleotide, in healthy subjects

Poster Presentation

Presenter: Edward J Gane

253

Predictors of HBsAg loss after cessation of nucleo(s)tide analogue therapy in asian patients with low HBsAg levels

Poster Presentation

Presenter: Milan Sonneveld

296

Sustained 12 week off treatment antiviral efficacy of ATI-2173, a novel active site polymerase inhibitor nucleotide, combined with tenofovir disoproxil fumarate in chronic hepatitis B patients, a phase 2a clinical trial

Type to be confirmed

Presenter: Douglas Mayers

298

Improvement of liver-stiffness after 6 months of therapy: real-life data for HBV/HDV co-infected patients treated with bulevirtide

Poster Presentation

Presenter: Alexander Killer

406

Role of plasmatic and urinary TDF and TAF concentration in a cohort of HBV chronic hepatitis patients

Poster Presentation

Presenter: Giacomo Stroffolini

420

Model to predict on-treatment restoration of functional HBV-specific CD8+ cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B

Poster Presentation

Presenter: Julia Peña Asensio

424

Antiviral treatment cessation in HBeAg negative chronic hepatitis B: clinical outcome is associated with increase in specific pro-inflammatory cytokines

Poster Presentation

Presenter: Marte Holmberg



435

Tenofovir alafenamide for pregnant chinese women with active chronic hepatitis B: a multicenter, prospective, real-world study

Poster Presentation

Presenter: Qing-Lei Zeng

462

Suboptimal virological response to antiviral therapy in chronic hepatitis B as an independent predictor for occurrence of HCC and development of severe liver events

Poster Presentation

Presenter: Chau-Ting Yeh

509

Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary endpoint results from a phase 3 randomized, multicenter, parallel design study

Oral Presentation

Presenter: Heiner Wedemeyer

557

Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta

Poster Presentation

Presenter: Pietro Lampertico

567

Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta

Poster Presentation

Presenter: Pietro Lampertico

583

Virologic response to bulevirtide is delayed in cirrhotic HDV patients with clinically significant portal hypertension

Poster Presentation

Presenter: Mathias Jachs

587

Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide - Results of a "real world study"

Poster Presentation

Presenter: Mathias Jachs

636

HBV RNA levels are associated with virological response to treatment with pegylated interferon alpha in patients with chronic hepatitis D virus infection

Poster Presentation

Presenter: Lisa Sandmann





639

Management of chronic hepatitis B virus infection within a large integrated health care setting: treatment patterns among kaiser permanente members in southern california, 2008 - 2019

Poster Presentation

Presenter: Deborah Malden

644

Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection

Oral Presentation

Presenter: Young-Suk Lim

654

Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody

Poster Presentation

Presenter: Kosh Agarwal

660

Quantification of HBV hepatocyte burden using novel multiplex immunofluorescence staining and image analysis reveals substantial reduction in HBV liver burden with anti-viral treatment

Poster Presentation

Presenter: Pamela Odorizzi

664

GST-HG141 inhibits de novo HBV cccDNA formation in cultured primary human hepatocytes

Poster Presentation

Presenter: Vadim Bichko

674

Predictive factors of virological response at one year in patients with chronic HBV/HDV co-infected treated with Bulevirtide

Poster Presentation

Presenter: Victor de Lédighen

681

Impact of baseline viral load on hepatocellular carcinoma risk during antiviral treatment in non-cirrhotic patients with HBeAg-positive chronic hepatitis B

Poster Presentation

Presenter: Won-Mook Choi

723

Therapeutic vaccination with CLB-3000 in a mouse model of chronic hepatitis B induces anti-HBs responses associated with functional cure

Poster Presentation

Presenter: Aileen Rubio



775

Therapeutic vaccine JNJ-0535 induces a strong HBV-specific T-cell response in healthy adults and a modest response in chronic HBV-infected patients

Type to be confirmed

Presenter: An De Creus

776

Evaluation of the disposition and mass balance recovery of vebicorvir, a first generation hepatitis B core inhibitor, in rats and humans

Poster Presentation

Presenter: Katie Zomorodi

778

Effect of tenofovir disoproxil fumarate treatment on intrahepatic viral burden and liver immune microenvironment in chronic hepatitis B patients with minimally elevated serum alanine aminotransferase

Poster Presentation

Presenter: Abhishek Aggarwal

782

Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B

Poster Presentation

Presenter: Man-Fung Yuen

784

Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B

Poster Presentation

Presenter: Mark S Sulkowski

797

Safety, tolerability, pharmacokinetics, and preliminary antiviral activity of the capsid assembly modulator (CAM) ZM-H1505R after multiple escalating oral doses in patients with chronic hepatitis B virus (CHB) infection

Poster Presentation

Presenter: Jijia Mai

805

ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PD-L1 Ab ASC22 (Envafolelimab) plus nucleos(t)ide analogs

Oral Presentation

Presenter: Guiqiang Wang

832



Evaluation of renal and bone safety at 4 years in post-liver transplant patients with chronic kidney disease receiving Tenofovir Alafenamide for HBV prophylaxis

Poster Presentation

Presenter: Edward J Gane

868

Functional cure based on pegylated interferon alpha therapy in nucleoside analog-suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest Project in China) - 3.5 years data update

Poster Presentation

Presenter: Chan Xie

888

Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study

Oral Presentation

Presenter: Kosh Agarwal

891

Understanding the dynamics of HBsAg decline through model-informed drug development (MIDD) of JNJ-3989 and JNJ-6379 for the treatment of chronic hepatitis B virus infection (CHB)

Poster Presentation

Presenter: Huybrecht T'jollyn

902

Serum HBsAg and ddPCR HBV-DNA as predictive parameters of HBsAg loss after nucleo(s)tide analogue (NA) treatment discontinuation in non-cirrhotic patients with chronic hepatitis B

Poster Presentation

Presenter: Anna Francesca Guerra

907

Exploring hepatitis B virus as an immunotherapeutic target for clinical trials of adoptively transferred T cells

Poster Presentation

Presenter: Ann Leen

915

Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings

Poster Presentation

Presenter: Victor de Lédighen

917

Two-year safety and efficacy of tenofovir alafenamide in chronic hepatitis B: a Hellenic multicenter ReAl-life CLInical Study (HERACLIS-TAF)

Poster Presentation

Presenter: George Papatheodoridis



930

Treatment of chronic hepatitis B in sub-saharan Africa: 5-year results of a pilot program in Ethiopia  
Poster Presentation  
Presenter: Asgeir Johannessen

961

Decrease in the burden of integrated hepatitis B virus DNA in chronic hepatitis B patients with minimally elevated alanine aminotransferase on tenofovir disoproxil fumarate as revealed by long-read DNA-sequencing  
Poster Presentation  
Presenter: David Pan

1091

Serum HBV RNA levels are associated with risk of hepatitis flare after stopping NA therapy in HBeAg-negative patients  
Poster Presentation  
Presenter: Kathy Jackson

1140

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naive patients with chronic hepatitis B  
Poster Presentation  
Presenter: Jihye Lim

1196

Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study  
Poster Presentation  
Presenter: Alessandro Loglio

1226

The orally available sodium/taurocholate co-transporting polypeptide inhibitor A2342 blocks hepatitis B and D entry in vitro  
Poster Presentation  
Presenter: Britta Bonn

1242

Comparative performance analysis between manual and automatic RNA extraction to quantify HDV RNA by RoboGene 2.0 kit in untreated and bulevirtide-treated HDV patients  
Poster Presentation  
Presenter: Sara Colonia Uceda Renteria

1318

Combination therapy in HBeAg-negative chronic hepatitis B patients with low-level viremia to nucleos(tide) analogues  
Poster Presentation  
Presenter: Shan Jean Damascene



1352

ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents covalently closed circular DNA formation by disruption of incoming capsids

Poster Presentation

Presenter: Kathryn M Booijink

1369

Real-world high adherence to hepatitis B antiviral treatment practice guidelines in Israel

Poster Presentation

Presenter: Yana Davidov

1382

Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort

Oral Presentation

Presenter: Helene Fontaine

1406

No detectable resistance to bulevirtide in participants with chronic hepatitis D (CHD) through 24 weeks of treatment

Poster Presentation

Presenter: Julius Hollnberger

1410

The HBV siRNA, ALG-125755, demonstrates a favourable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model

Poster Presentation

Presenter: Megan Fitzgerald

1456

Hepatitis delta management in the United States: an analysis of all-payer claims database

Poster Presentation

Presenter: Robert Wong

1461

Evaluation of the drug-drug interaction profile of vebicorvir, a first-generation hepatitis B core inhibitor: findings from phase 1 and phase 2a studies

Poster Presentation

Presenter: Katie Zomorodi

1473

Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities

Poster Presentation

Presenter: Michael Shen

1491



EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: final results of a 28-day phase 1b study in nuc-suppressed chronic hepatitis B patients

Poster Presentation

Presenter: Jordan Feld

1508

Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients

Poster Presentation

Presenter: Emily P. Thi

1509

Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB)

Poster Presentation

Presenter: Edward J Gane

1511

EDP-514, a potent pangenotypic class II hepatitis B virus core inhibitor, demonstrates significant HBV DNA and HBV RNA reductions in a phase 1b study in viremic, chronic hepatitis B patients

Poster Presentation

Presenter: Man-Fung Yuen

1519

Increased HBsAg reduction and relapse outcomes in HBeAg negative patients with chronic hepatitis B after nucleos(t)ide analogue withdrawal: 4.5 year follow up of the Toronto STOP Study

Poster Presentation

Presenter: Arif Sarowar

1530

Pharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liver

Poster Presentation

Presenter: Emily P. Thi

1537

Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B patients

Poster Presentation

Presenter: Sharie C Ganchua

1543

Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells

Poster Presentation

Presenter: Emily P. Thi

1555



Characterizing of hepatitis B virus serum RNA kinetics during TDF plus pegylated interferon alfa-2a with and without nucleic acid polymers

Poster Presentation

Presenter: Harel Dahari

1567

Early antiviral efficacy of tenofovir alafenamide fumarate in the initial treatment of chronic hepatitis B patients with normal ALT

Poster Presentation

Presenter: Xin Chi

1615

Viral and ALT kinetics after nucleos(t)ide analogue withdrawal among patients who remain off-therapy: results from a global, multi-ethnic cohort of chronic hepatitis B patients (RETRACT-B study)

Poster Presentation

Presenter: Grishma Hirode

1627

Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B

Poster Presentation

Presenter: Francois Gonzalez

1628

Incorporation of novel ASO chemistries significantly improves the potency and durability of HBV ASOs in the AAV-HBV mouse model

Poster Presentation

Presenter: Jin Hong

1662

Induction of pre-s antibodies in HBeAg negative chronic hepatitis B patients by therapeutic vaccination with the pre-s based vaccine VVX001 - interim analysis

Poster Presentation

Presenter: Petra Munda

1766

HEC121120, a novel allosteric modulator of HBV core protein demonstrates potent antiviral activities in vitro and in vivo

Poster Presentation

Presenter: qingying lai

1850

Evaluation of quantitative HBsAg levels in chronic hepatitis B - a targeted literature review

Poster Presentation

Presenter: Vera Gielen

1904



Lonafarnib combination with peginterferon Lambda diminished triphasic HDV kinetic pattern seen under Lambda monotherapy: the LIFT HDV study

Oral Presentation

Presenter: Harel Dahari

1920

Nucleoside/nucleotide analogues monotherapy is safe and efficient for the prevention of HBV flare-ups after liver transplantation in the long term

Poster Presentation

Presenter: Orly Sneh Arbib

1942

A new method to identify co-variation in hepatitis B virus whole genome sequences identifies networks of polymorphisms associated with drug resistance

Poster Presentation

Presenter: Sheila Lumley

2025

Baseline bile acid levels but not bile acid increases during bulevirtide treatment of hepatitis D are associated with HDV RNA decline

Poster Presentation

Presenter: Katja Deterding

2031

Low levels of qHBsAg and tenofovir therapy are associated with successful treatment withdrawal in HBeAg negative chronic hepatitis B: results from Spanish multicentric study

Poster Presentation

Presenter: Anna Pocerull

2043

Preliminary results of the effectiveness and safety of Tenofovir Alafenamide Fumarate prophylaxis in HBV-infected individuals, who received chemo/immunosuppressive therapy

Poster Presentation

Presenter: FEYZA GUNDUZ

2069

Real life efficacy, renal and lipid profile data of tenofovir alafenamide in switched chronic hepatitis B patients

Poster Presentation

Presenter: Fehmi Tabak

2072

Mathematical modeling of HDV RNA kinetics suggests high peginterferon Lambda efficacy in blocking viral production: insights from the LIMT-1 study

Poster Presentation

Presenter: Harel Dahari

2086





Heterologous prime-boost immunotherapy circumvents tolerance and induces broadly neutralizing antibodies that protects against hepatitis B and D co-infection and hepatitis D super-infection

Poster Presentation

Presenter: Lars Frelin

2091

Real-world data on treatment with bulevirtide in patients with chronic hepatitis B and D coinfection

Poster Presentation

Presenter: Toni Herta

2105

Higher rates of virological relapse after nucleos(t)ide analogue withdrawal in HBeAg-negative versus positive chronic hepatitis B patients: results from a global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B Study)

Poster Presentation

Presenter: Hannah S.J. Hirode

2161

Real life efficacy and tolerability of Tenofovir alafenamide fumarate in liver transplant recipients: a multicenter study

Poster Presentation

Presenter: Suna Yapali

2177

Impact of patient-related factors on the pharmacokinetics of Bulevirtide

Poster Presentation

Presenter: Renu Singh

2215

Reduction of liver stiffness in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study

Poster Presentation

Presenter: Heejin Cho

2275

Toll-like receptor 8 agonism activates monocytes and induces antiviral cytokine production by T-cells in HIV and chronic hepatitis B coinfection

Poster Presentation

Presenter: Lydia Tang

2291

Hepatocellular carcinoma incidence is reduced in cirrhotic chronic hepatitis B patients with HBsAg seroclearance comparing to those with viral suppression

Oral Presentation

Presenter: Rachel Wen-Juei Jeng

2524



Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switching to tenofovir alafenamide - an interim analysis

Poster Presentation

Presenter: Pin-Nan Cheng

2581

Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis

Poster Presentation

Presenter: Suna Yapali

## Viral hepatitis C: Clinical aspects except therapy

252

Active case management to connect hepatitis C notifications to care and treatment in Australia (CONNECT study), a randomised controlled trial

Poster Presentation

Presenter: Tafireyi Marukutira

589

Find out HCV patients: systematic study of 2013-2020 HCV files of a MDT viral hepatitis expert unit on the future of patients has made it possible to find out the lost ones and put them into treatment

Poster Presentation

Presenter: André-Jean Remy

751

Effectiveness of a central monitoring system for the continuum of care of hepatitis C in Brazil during COVID-19 pandemic

Poster Presentation

Presenter: Paulo Bittencourt

753

Retrieval of HCV patients lost to follow-up as a strategy as a strategy for hepatitis C microelimination: results of a brazilian multicentric study

Poster Presentation

Presenter: Paulo Bittencourt

834

Reorganizing and simplifying HCV diagnosis and treatment in special populations during COVID pandemic and beyond

Poster Presentation

Presenter: Paolo Scivetti

860

The health economic outcomes of trial ACTG5360/MINMON

Poster Presentation



Presenter: Benjamin Linas

905

Hepatitis C treatment during the COVID-19 pandemic has similar efficacy with less resource utilization: analysis from the British Columbia HCV network

Poster Presentation

Presenter: Shirley Jiang

928

ELIMINATE - interim results of an Austrian HCV macro-elimination project

Poster Presentation

Presenter: Caroline Schwarz

937

The Korean hepatitis C virus care cascade in a tertiary institution: current status and changes in testing, link to care, and treatment

Poster Presentation

Presenter: Jonggi Choi

966

Macroeconomic assessment of overall and per-patient healthcare costs of Hepatitis C-infected patients in an integrated health system in the era of direct-acting antiviral therapy

Poster Presentation

Presenter: David Kaplan

970

Awareness of chronic hepatitis B and C among men who have sex with men (MSM): epidemiological survey and on-site screening

Poster Presentation

Presenter: Marie Coessens

1063

Predictive factors for lost to follow-up pre and post-hepatitis C treatment: data from the British Columbia hepatitis C virus network

Poster Presentation

Presenter: Alnoor Ramji

1183

HCV screening in a tertiary French hospital : just do it !

Poster Presentation

Presenter: Si Nafa Si Ahmed

1258

Hepatitis C screening rates by age cohort 1945-1965 in a large community health system before, during and after the COVID pandemic

Poster Presentation

Presenter: David Bernstein



1396

Maximizing the potential of Cepheid, GeneXpert PCR rapid testing for hepatitis C through use of finger prick blood samples collected into EDTA capillary tubes

Poster Presentation

Presenter: Anam Choudhry

1446

Healthcare resource utilization in treatment-naïve patients with compensated cirrhosis receiving 8-weeks' glecaprevir/pibrentasvir stratified by drug use and socioeconomic status: a retrospective chart review

Poster Presentation

Presenter: Juan Isidro Jorquera

1649

Progress towards hepatitis C elimination: the feasibility and success of a nurse and harm reduction practitioner led model of care utilising rapid point of care HCV RNA testing at a medically supervised injecting room in Melbourne, Australia

Poster Presentation

Presenter: Michael Maclsaac

1804

Results of a ten year prospective observational study on acute hepatitis C in HCV-mono- and HIV/HCV-coinfected patients

Oral Presentation

Presenter: Christiana Graf

1814

Screening for hepatitis C in Denmark - the effect of a mobile outreach intervention

Poster Presentation

Presenter: Sandra Droese

1967

Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region

Poster Presentation

Presenter: Pietro Torre

2120

Treating children with HCV close to home through a virtual national multidisciplinary network

Poster Presentation

Presenter: Deirdre Kelly

2143

Association of sustained virologic response with measures of direct-acting antiviral adherence in patients with hepatitis C: data from the ASCEND and ANCHOR investigations

Type to be confirmed

Presenter: Sarah Kattakuzhy

2159



ATA haplotype of the interleukin-10 gene and low phase angle are associated with liver cirrhosis in chronic hepatitis C

Poster Presentation

Presenter: Nataly Lopes Viana

2184

Use of Glecaprevir/Pibrentasvir (G/P) for the treatment of HCV infection among fentanyl users: an interim analysis of the GRAND PLAN study

Poster Presentation

Presenter: Brian Conway

2242

Indigenous methodologies in practice through community engagement and telehealth outreach increase hepatitis C access to care in Alberta, Canada

Poster Presentation

Presenter: Kate Dunn

2329

Implication of metabolic associated fatty liver disease and sex differences in the risk of developing liver fibrosis in patients with Hepatitis C

Poster Presentation

Presenter: Martín Uriel Vázquez Medina

2358

Micro-eliminating hepatitis C in a network of 47 English Prisons through an industry, prison healthcare and patient organisation partnership

Poster Presentation

Presenter: Andrew Jones

2394

The 'Viennese epidemic' of acute HCV in the era of direct-acting antivirals

Poster Presentation

Presenter: David JM Bauer

2466

Approaches for a hepatitis C-free city: preliminary results

Poster Presentation

Presenter: Manuel Romero Gomez

2552

Success of a peer-led community based model of hepatitis C treatment support for marginalised populations

Poster Presentation

Presenter: Binta Sultan

2611

Impact of hepatitis C virus point-of-care (PoC) viral load assay compared to laboratory-based assays on uptake of testing and treatment, and turnaround times: a systematic review and meta-analysis



Poster Presentation

Presenter: Adam Trickey

2617

Diagnostic accuracy of point-of-care HCV viral load assays for HCV diagnosis: a systematic review and meta-analysis

Poster Presentation

Presenter: Weiming Tang

2622

Hepatitis-C virus viral load reflex testing following an initial positive HCV antibody test: a global systematic review and meta-analysis

Poster Presentation

Presenter: Weiming Tang

## Viral Hepatitis C: Post SVR and long term follow up

77

Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis

Poster Presentation

Presenter: Ian Lockart

371

Glycomics-based serum marker as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection

Poster Presentation

Presenter: Nicky Somers

397

Post-treatment elevated gamma-glutamyl transferase is the best predictor for future outcomes in HCV patients achieving sustained virological response - data from the German Hepatitis C-Registry (DHC-R)

Poster Presentation

Presenter: Stefan Mauss

506

The impact of liver function improvement after direct-acting antiviral therapy on the outcome in hepatitis C virus patients with decompensated cirrhosis

Poster Presentation

Presenter: Yuki Tahata

702

De-novo occurrence of portal vein thrombosis in patients with HCV-related cirrhosis after sustained virological response: medium to long term observations from the ongoing PITER cohort

Poster Presentation



Presenter: Loreta Kondili

835

Suboptimal follow-up, high re-infection, and drug-related death, among HCV-treated people who inject drugs in Tayside, Scotland

Poster Presentation

Presenter: Christopher Byrne

981

Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study

Poster Presentation

Presenter: Joanne Carson

1061

Five-years follow-up of cured HCV patients with or without cirrhosis under real-world interferon-free therapy

Poster Presentation

Presenter: Robert Flisiak

1074

Clearance of hepatitis C virus infection did not ameliorate the response to hepatitis B vaccine

Poster Presentation

Presenter: Ebada Said

1225

Reverse Inflammaging: biological age is accelerated in chronic HCV patients and decelerates after HCV cure

Poster Presentation

Presenter: Carlos Oltmanns

1283

Overall mortality in patients with chronic hepatitis C: major effects of social vulnerability, tobacco smoking, and history of unhealthy alcohol use (ANRS CO22 HEPATHER cohort)

Poster Presentation

Presenter: Carrieri Patrizia

1312

Is routine Ribavirin mandatory for genotype 3 hepatitis C compensated cirrhosis patients receiving Sofosbuvir/Velpatasvir? A meta-analysis

Poster Presentation

Presenter: Jing Hong Lebedel

1364

High frequency of hepatitis C virus reinfection following antiviral treatment in the North East of England

Poster Presentation

Presenter: Sumar Askar



1392

Incidence and risk factors of hepatitis C liver morbidity and mortality in the era of direct-acting antiviral therapies: a population-based linkage study

Poster Presentation

Presenter: Maryam Alavi

1674

Direct acting antiviral agents improve survival in patients with hepatitis C virus related hepatocellular carcinoma

Poster Presentation

Presenter: Hyun Young Woo

1853

Lack of Alpha-fetoprotein reduction after successful Hepatitis C treatment in patients with cirrhosis predicts the development of hepatocellular carcinoma during surveillance - a single unit real-world experience

Poster Presentation

Presenter: Aoife Alvain

1860

Patients with chronic HCV and decompensated cirrhosis are at risk for MELD purgatory

Poster Presentation

Presenter: Lisette Krassenburg

1877

The long-term effect of Hepatitis C eradication by direct-acting antivirals on patient's mood and quality of life as determined by the Beck's Depression Inventory and EQ5D Quality of Life questionnaires - a single unit study

Poster Presentation

Presenter: Aoife Alvain

1912

Assessing sustained virological response and reinfection from dried blood spots within an on-site hepatitis C diagnosis and treatment model of care in a harm reduction centre

Poster Presentation

Presenter: Anna Lens

1963

Hepatitis C virus (HCV)-specific T cell confer resistance to HCV re-infection after sustained virologic response in a non-cytolytic fashion among people who inject drugs: results from ANCHOR study

Poster Presentation

Presenter: Arshi Khanam

2038

Lack of fibrosis remodelling in chronic hepatitis C post SVR, as demonstrated by YKL-40, is predictive of hepatocellular carcinoma occurrence

Poster Presentation





Presenter: Maria Guerra Veloz

2039

HCV reinfection associated with IDU and cocaine use in a cohort of people with OUD: 4 Year follow-up data from the ANCHOR cohort

Poster Presentation

Presenter: Elana Rosenthal

2055

Noninvasive prediction of hepatocellular carcinoma development after oral antiviral therapy in patients with chronic hepatitis C: a multicenter study

Poster Presentation

Presenter: Yu Rim Lee

2136

Sustained low prevalence of HCV viremia among people who inject drugs following the treatment as prevention for hepatitis C (TraP HepC) nationwide elimination program in Iceland

Poster Presentation

Presenter: Magnús Gottfredsson

2209

Direct-acting antiviral treatment in Albanian patients with chronic hepatitis C and advanced liver fibrosis

Poster Presentation

Presenter: Liri Cuko

2214

Improved recurrence-free survival rates in patients with HCV-related hepatocellular carcinoma and sustained virological response to direct-acting antivirals

Poster Presentation

Presenter: Anca Trifan

2245

Long-term outcomes associated with task-shifting of HCV treatment by non-specialist providers: five year follow-up from the ASCEND cohort

Poster Presentation

Presenter: Sarah Kattakuzhy

2305

Risk stratification of hepatocellular carcinoma in cirrhotic patients after hepatitis C virus eradication: russian single - center experience

Poster Presentation

Presenter: Ekaterina Nabatchikova

2321

Distinct hepatocellular carcinoma risks in treated chronic hepatitis C patients with different definitions of advanced chronic liver disease

Poster Presentation



Presenter: Yen-Chun Liu

2323

Hepatocellular carcinoma risks of liver fibrosis changes after viral eradication in chronic hepatitis C patients

Poster Presentation

Presenter: Yen-Chun Liu

2363

Change in fibrosis and clinical progression three years after sustained virological response induced by direct antiviral agents in HIV/HCV subjects

Poster Presentation

Presenter: Maria Carnevali Frias

2517

FOCUS Project: preliminary results toward hepatitis C Virus screening and elimination in Almería, Spain

Poster Presentation

Presenter: Marta Casado

## Viral hepatitis C: Therapy and resistance

60

Dismal prognosis for cirrhotic HCV patients after initial DAA treatment failure, rescue therapy may be life-saving

Poster Presentation

Presenter: Johan Westin

425

Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool

Poster Presentation

Presenter: David Burger

555

Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset

Poster Presentation

Presenter: Alessandra Mangia

809

Sofosbuvir plus velpatisvir for 8 weeks in patients with acute hepatitis C: multicenter, single arm, phase 2 study (The HepNet acute HCV-V study)

Poster Presentation

Presenter: Benjamin Maasoumy



822

Full-length genome characterization of inherently resistant african HCV genotype 1, subtype 1I in patients failing DAA-based therapy

Poster Presentation

Presenter: Slim Fourati

828

Treating HCV in dual diagnosis acute psychiatric inpatients with substance use disorder

Poster Presentation

Presenter: vera dreizin

852

Eight-weeks of glecaprevir/pibrentasvir is well tolerated and yields high sustained virological response in HCV-infected treatment-naive patients with compensated cirrhosis: the CREST study

Poster Presentation

Presenter: Markus Cornberg

925

Glecaprevir/pibrentasvir and sofosbuvir for 16 weeks without ribavirin is safe and highly effective retreatment for patients who have failed an NS5A inhibitor containing antiviral regimen

Oral Presentation

Presenter: Edward J Gane

971

HCV-RNA viral load fingerstick assay as a simplified strategy for screening and linkage to care of people who use drugs attending 3 french addiction centers

Poster Presentation

Presenter: Denis Ouzan

1062

Pangenotypic and genotype-specific antivirals in the treatment of genotype 4 infected patients with HIV coinfection

Poster Presentation

Presenter: Dorota Zarębska-Michaluk

1194

Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure

Poster Presentation

Presenter: Julia Dietz

1228

Real-life effectiveness and safety of sofosbuvir/velpatasvir in difficult to treat hepatitis C patients

Poster Presentation

Presenter: Hyun Young Woo

1381

Polypharmacy and prevalence of multi drug-drug interactions in hepatitis C patients treated with pangenotypic direct acting antivirals: an analysis from three european countries



Type to be confirmed  
Presenter: Frank Tacke

1430  
Use of comedication in patients with hepatitis C and addiction or drug abuse treated with direct-acting antivirals: implication in drug-drug interactions  
Poster Presentation  
Presenter: Juan Turnes

1440  
Five years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-October 2021  
Poster Presentation  
Presenter: Tengiz Tsertsvadze

1551  
Simplifying mathematical-based response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients  
Poster Presentation  
Presenter: Harel Dahari

1565  
Epidemiology of hepatitis B virus infection among hepatitis C (HCV) infected patients treated within HCV elimination program in Georgia  
Poster Presentation  
Presenter: Maia Handanagic

1713  
Direct-acting antivirals and the risk of hepatitis B reactivation in hepatitis B and C coinfecting patients: a systematic review and meta-analysis  
Poster Presentation  
Presenter: JOO HYUN OH

1740  
Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA)  
Oral Presentation  
Presenter: Christiana Graf

1838  
Inhibition of high fitness viruses by different antiviral strategies when the infection has started  
Poster Presentation  
Presenter: Carlos García-Crespo

1862  
Treatment of hepatitis C in primary healthcare in the country of Georgia  
Poster Presentation  
Presenter: Tengiz Tsertsvadze



1957

Multicenter prospective study for the use of shortened pre-emptive therapy with Glecaprevir/Pibrentasvir (G/P) and Ezetimibe in hepatitis C (HCV) seronegative non-liver solid organ transplant recipients of HCV viremic grafts

Oral Presentation

Presenter: Bashar Aqel

1984

Optimal screening and linkage to care model to achieve hepatitis C elimination targets in Georgia

Poster Presentation

Presenter: Tengiz Tsertsvadze

2174

Establishing a protocol for management and DAA treatment of HCV during pregnancy: adherence to a co-located care protocol

Poster Presentation

Presenter: Tatyana Kushner

2190

Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial

Poster Presentation

Presenter: Brian Conway

2227

High Intensity Test and Treat (HITT): an overview of the initiative as part of the hepatitis C elimination programme in England

Oral Presentation

Presenter: Beatrice Emmanouil

2539

High efficacy and safety of pan-genotypic direct-acting antiviral regimens in adolescents and children: a global systematic review to inform new World Health Organization recommendations

Poster Presentation

Presenter: Giuseppe Indolfi

2606

Early vs. late treatment for hepatitis C virus discordant solid organ transplantation and direct acting antivirals: a meta-analysis

Poster Presentation

Presenter: Madison Gunn

# THE INTERNATIONAL LIVER CONGRESS<sup>TM</sup>

22-26  
JUNE  
2022  
LONDON

